NZ616779B2 - Modulation of apolipoprotein ciii (apociii) expression - Google Patents
Modulation of apolipoprotein ciii (apociii) expression Download PDFInfo
- Publication number
- NZ616779B2 NZ616779B2 NZ616779A NZ61677912A NZ616779B2 NZ 616779 B2 NZ616779 B2 NZ 616779B2 NZ 616779 A NZ616779 A NZ 616779A NZ 61677912 A NZ61677912 A NZ 61677912A NZ 616779 B2 NZ616779 B2 NZ 616779B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- apociii
- animal
- certain embodiments
- compound
- levels
- Prior art date
Links
- 108010056301 Apolipoprotein C-III Proteins 0.000 title claims abstract description 15
- 102000030703 Apolipoprotein C-III Human genes 0.000 title claims abstract description 8
- 230000014509 gene expression Effects 0.000 title claims description 42
- 230000000051 modifying Effects 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 303
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 82
- 230000001965 increased Effects 0.000 claims abstract description 70
- 208000008787 Cardiovascular Disease Diseases 0.000 claims abstract description 69
- 201000010099 disease Diseases 0.000 claims abstract description 58
- 230000001603 reducing Effects 0.000 claims abstract description 58
- 239000003814 drug Substances 0.000 claims abstract description 35
- 206010033645 Pancreatitis Diseases 0.000 claims abstract description 28
- 230000002730 additional Effects 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 229920000272 Oligonucleotide Polymers 0.000 claims description 222
- 150000003626 triacylglycerols Chemical class 0.000 claims description 200
- 150000007523 nucleic acids Chemical group 0.000 claims description 152
- 239000002777 nucleoside Substances 0.000 claims description 146
- 125000003835 nucleoside group Chemical group 0.000 claims description 93
- 235000000346 sugar Nutrition 0.000 claims description 91
- 239000003795 chemical substances by application Substances 0.000 claims description 65
- 230000000295 complement Effects 0.000 claims description 64
- 230000037250 Clearance Effects 0.000 claims description 50
- 230000035512 clearance Effects 0.000 claims description 50
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 42
- 230000000291 postprandial Effects 0.000 claims description 39
- 208000006575 Hypertriglyceridemia Diseases 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000011780 sodium chloride Substances 0.000 claims description 20
- 150000002500 ions Chemical class 0.000 claims description 16
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 15
- 229940104302 Cytosine Drugs 0.000 claims description 15
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 15
- 206010058108 Dyslipidaemia Diseases 0.000 claims description 15
- 206010061227 Lipid metabolism disease Diseases 0.000 claims description 15
- 238000007920 subcutaneous administration Methods 0.000 claims description 15
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 15
- 201000001320 atherosclerosis Diseases 0.000 claims description 13
- 206010062060 Hyperlipidaemia Diseases 0.000 claims description 12
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 12
- 229940035295 Ting Drugs 0.000 claims description 12
- 125000002619 bicyclic group Chemical group 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 12
- 230000002708 enhancing Effects 0.000 claims description 12
- 231100000862 numbness Toxicity 0.000 claims description 12
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 11
- 206010003119 Arrhythmia Diseases 0.000 claims description 11
- 206010002383 Angina pectoris Diseases 0.000 claims description 10
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims description 10
- 230000002068 genetic Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 238000007911 parenteral administration Methods 0.000 claims description 9
- 208000009576 Hypercholesterolemia Diseases 0.000 claims description 8
- 210000001015 Abdomen Anatomy 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 206010003658 Atrial fibrillation Diseases 0.000 claims description 6
- 206010008479 Chest pain Diseases 0.000 claims description 6
- 208000002173 Dizziness Diseases 0.000 claims description 6
- 210000003414 Extremities Anatomy 0.000 claims description 6
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 206010022562 Intermittent claudication Diseases 0.000 claims description 6
- 210000003141 Lower Extremity Anatomy 0.000 claims description 6
- 210000003205 Muscles Anatomy 0.000 claims description 6
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 206010042772 Syncope Diseases 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 230000035900 sweating Effects 0.000 claims description 6
- 230000002522 swelling Effects 0.000 claims description 6
- 206010002329 Aneurysm Diseases 0.000 claims description 5
- 206010028813 Nausea Diseases 0.000 claims description 5
- 206010033557 Palpitations Diseases 0.000 claims description 5
- 208000001871 Tachycardia Diseases 0.000 claims description 5
- 239000003529 anticholesteremic agent Substances 0.000 claims description 5
- 208000006218 Bradycardia Diseases 0.000 claims description 4
- 230000036471 bradycardia Effects 0.000 claims description 4
- 201000001084 cerebrovascular disease Diseases 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- 206010011703 Cyanosis Diseases 0.000 claims description 3
- 229940053207 Niacin Drugs 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 239000003524 antilipemic agent Substances 0.000 claims description 3
- GDLBFKVLRPITMI-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound ClC1=CC=C2NC(C)=NS(=O)(=O)C2=C1 GDLBFKVLRPITMI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004042 diazoxide Drugs 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 description 170
- 108020004707 nucleic acids Proteins 0.000 description 151
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 148
- 102000015779 HDL Lipoproteins Human genes 0.000 description 112
- 108060003412 GRP Proteins 0.000 description 111
- 210000002381 Plasma Anatomy 0.000 description 93
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 92
- 239000000074 antisense oligonucleotide Substances 0.000 description 92
- 230000000694 effects Effects 0.000 description 89
- 241000764238 Isis Species 0.000 description 83
- 241000699670 Mus sp. Species 0.000 description 80
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 80
- 229940107161 Cholesterol Drugs 0.000 description 73
- 235000012000 cholesterol Nutrition 0.000 description 65
- 239000002953 phosphate buffered saline Substances 0.000 description 63
- 150000002632 lipids Chemical class 0.000 description 42
- 239000000203 mixture Substances 0.000 description 40
- 125000003729 nucleotide group Chemical group 0.000 description 40
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 39
- 210000004185 Liver Anatomy 0.000 description 38
- 239000002773 nucleotide Substances 0.000 description 37
- 229920002477 rna polymer Polymers 0.000 description 36
- -1 Bicyclic nucleic acid Chemical class 0.000 description 35
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 239000003925 fat Substances 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 29
- 235000019197 fats Nutrition 0.000 description 28
- 108010007622 LDL Lipoproteins Proteins 0.000 description 27
- 102000007330 LDL Lipoproteins Human genes 0.000 description 27
- 239000007924 injection Substances 0.000 description 27
- 102000004895 Lipoproteins Human genes 0.000 description 26
- 108090001030 Lipoproteins Proteins 0.000 description 26
- 108020004999 Messenger RNA Proteins 0.000 description 26
- 229920002106 messenger RNA Polymers 0.000 description 26
- 210000004027 cells Anatomy 0.000 description 25
- 210000004369 Blood Anatomy 0.000 description 24
- 210000002966 Serum Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 238000002347 injection Methods 0.000 description 23
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 238000006722 reduction reaction Methods 0.000 description 22
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 21
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 21
- 235000005911 diet Nutrition 0.000 description 21
- 108010028554 LDL Cholesterol Proteins 0.000 description 19
- 241000699660 Mus musculus Species 0.000 description 19
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 19
- 239000002253 acid Substances 0.000 description 19
- 241000282693 Cercopithecidae Species 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 108090001061 Insulin Proteins 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 17
- 102100011688 LPL Human genes 0.000 description 17
- 230000000271 cardiovascular Effects 0.000 description 17
- 230000037213 diet Effects 0.000 description 17
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 16
- 230000003247 decreasing Effects 0.000 description 16
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- 210000000813 small intestine Anatomy 0.000 description 16
- 108010004103 Chylomicrons Proteins 0.000 description 15
- 206010012601 Diabetes mellitus Diseases 0.000 description 15
- 206010022489 Insulin resistance Diseases 0.000 description 15
- 241000282560 Macaca mulatta Species 0.000 description 15
- 208000008466 Metabolic Disease Diseases 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 229940079593 drugs Drugs 0.000 description 14
- 235000012054 meals Nutrition 0.000 description 14
- 238000003753 real-time PCR Methods 0.000 description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 14
- ONCCWDRMOZMNSM-FBCQKBJTSA-N 2-amino-6-[(4S,5R)-2,5-dihydroxy-2-oxo-1,3,2$l^{5}-dioxaphosphinane-4-carbonyl]-1H-pteridin-4-one Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 13
- 208000001145 Metabolic Syndrome Diseases 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000006011 modification reaction Methods 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 230000002829 reduced Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000001225 therapeutic Effects 0.000 description 13
- 210000001519 tissues Anatomy 0.000 description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 239000008177 pharmaceutical agent Substances 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 201000008739 coronary artery disease Diseases 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 102100017826 APOC3 Human genes 0.000 description 10
- 238000004166 bioassay Methods 0.000 description 10
- 230000001258 dyslipidemic Effects 0.000 description 10
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 239000007928 intraperitoneal injection Substances 0.000 description 10
- 239000002609 media Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000007929 subcutaneous injection Substances 0.000 description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 9
- 208000004981 Coronary Disease Diseases 0.000 description 9
- 102000033147 ERVK-25 Human genes 0.000 description 9
- 101700080605 NUC1 Proteins 0.000 description 9
- 229940035893 Uracil Drugs 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 235000013351 cheese Nutrition 0.000 description 9
- 235000020828 fasting Nutrition 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 101700006494 nucA Proteins 0.000 description 9
- 101700043375 sing Proteins 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 8
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 8
- 238000008214 LDL Cholesterol Methods 0.000 description 8
- 206010033647 Pancreatitis acute Diseases 0.000 description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
- 201000003229 acute pancreatitis Diseases 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 230000000968 intestinal Effects 0.000 description 8
- 230000002503 metabolic Effects 0.000 description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 229960000643 Adenine Drugs 0.000 description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 7
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 7
- 240000008415 Lactuca sativa Species 0.000 description 7
- 230000036740 Metabolism Effects 0.000 description 7
- 210000004080 Milk Anatomy 0.000 description 7
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 7
- 108091006028 chimera Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000002440 hepatic Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 230000000977 initiatory Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 230000035786 metabolism Effects 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 238000010369 molecular cloning Methods 0.000 description 7
- 235000015205 orange juice Nutrition 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 238000004450 types of analysis Methods 0.000 description 7
- 101700025839 APOE Proteins 0.000 description 6
- 102000007592 Apolipoproteins Human genes 0.000 description 6
- 108010071619 Apolipoproteins Proteins 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 108010046315 IDL Lipoproteins Proteins 0.000 description 6
- 229920002459 Intron Polymers 0.000 description 6
- 102000017055 Lipoprotein lipase Human genes 0.000 description 6
- 108010013563 Lipoprotein lipase Proteins 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 235000015197 apple juice Nutrition 0.000 description 6
- 125000004432 carbon atoms Chemical group C* 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000002354 daily Effects 0.000 description 6
- 230000001419 dependent Effects 0.000 description 6
- 201000010870 diseases of metabolism Diseases 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 235000012045 salad Nutrition 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 235000013311 vegetables Nutrition 0.000 description 6
- 206010000060 Abdominal distension Diseases 0.000 description 5
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 5
- 235000021068 Western diet Nutrition 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 235000015278 beef Nutrition 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 235000008429 bread Nutrition 0.000 description 5
- 235000012495 crackers Nutrition 0.000 description 5
- 210000004748 cultured cells Anatomy 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 125000002743 phosphorus functional group Chemical group 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrugs Drugs 0.000 description 5
- 230000004952 protein activity Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 201000011528 vascular disease Diseases 0.000 description 5
- 230000003442 weekly Effects 0.000 description 5
- 101700065507 APOB Proteins 0.000 description 4
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 4
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 4
- 229920001405 Coding region Polymers 0.000 description 4
- 108010072220 Cyclophilin A Proteins 0.000 description 4
- 240000002860 Daucus carota Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 4
- 108060004326 LDLR Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 102100012530 PPIA Human genes 0.000 description 4
- 229920000401 Three prime untranslated region Polymers 0.000 description 4
- 229940113082 Thymine Drugs 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 230000001668 ameliorated Effects 0.000 description 4
- 101700070309 apoeb Proteins 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000004429 atoms Chemical group 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 230000000875 corresponding Effects 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000000378 dietary Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 201000010238 heart disease Diseases 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 230000001771 impaired Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000020166 milkshake Nutrition 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 210000000056 organs Anatomy 0.000 description 4
- 230000003285 pharmacodynamic Effects 0.000 description 4
- 150000004713 phosphodiesters Chemical class 0.000 description 4
- 235000012830 plain croissants Nutrition 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 231100000486 side effect Toxicity 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000000700 tracer Substances 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 101700049216 APOC3 Proteins 0.000 description 3
- 210000000577 Adipose Tissue Anatomy 0.000 description 3
- 241000234282 Allium Species 0.000 description 3
- 210000001367 Arteries Anatomy 0.000 description 3
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 3
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 3
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 3
- 235000002767 Daucus carota Nutrition 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010014486 Elevated triglyceride Diseases 0.000 description 3
- 206010059183 Familial hypertriglyceridaemia Diseases 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 101700059151 HNF4A Proteins 0.000 description 3
- 208000000522 Hyperlipoproteinemia Type IV Diseases 0.000 description 3
- 101700072148 IAA2 Proteins 0.000 description 3
- 102000000853 LDL receptors Human genes 0.000 description 3
- 108010001831 LDL receptors Proteins 0.000 description 3
- 229920001320 Leader sequence (mRNA) Polymers 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 108091005503 Nucleic proteins Proteins 0.000 description 3
- 101710005767 POLR3C Proteins 0.000 description 3
- 240000005158 Phaseolus vulgaris Species 0.000 description 3
- 230000036823 Plasma Levels Effects 0.000 description 3
- 208000001280 Prediabetic State Diseases 0.000 description 3
- 208000008425 Protein Deficiency Diseases 0.000 description 3
- 240000003768 Solanum lycopersicum Species 0.000 description 3
- 229940104230 Thymidine Drugs 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 231100000494 adverse effect Toxicity 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000003111 delayed Effects 0.000 description 3
- 239000005549 deoxyribonucleoside Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000002243 furanoses Chemical class 0.000 description 3
- 235000014080 ginger ale Nutrition 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 235000002732 oignon Nutrition 0.000 description 3
- 125000004430 oxygen atoms Chemical group O* 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 235000013550 pizza Nutrition 0.000 description 3
- 229940096700 plain lipid modifying drugs Fibrates Drugs 0.000 description 3
- 201000009104 prediabetes syndrome Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000004141 reverse cholesterol transport Effects 0.000 description 3
- 239000002342 ribonucleoside Substances 0.000 description 3
- 101700086982 rnh Proteins 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 2,6-Diaminopurine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- ZFGOPJASRDDARH-ZQCBGZRTSA-N 3-[[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]p Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C(C1)[C@]2(C)CC[C@@H]1OC1CC2=CCC3C4CCC(C(C)CCCC(C)C)C4(C)CCC3C2(C)CC1 ZFGOPJASRDDARH-ZQCBGZRTSA-N 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- 102100007877 APOE Human genes 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N Acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 102000018616 Apolipoproteins B Human genes 0.000 description 2
- 108010027006 Apolipoproteins B Proteins 0.000 description 2
- 102000013918 Apolipoproteins E Human genes 0.000 description 2
- 108010025628 Apolipoproteins E Proteins 0.000 description 2
- 102000006410 Apoproteins Human genes 0.000 description 2
- 108010083590 Apoproteins Proteins 0.000 description 2
- 102100013894 BCL2 Human genes 0.000 description 2
- 108060000885 BCL2 Proteins 0.000 description 2
- 102100015655 BCL2L1 Human genes 0.000 description 2
- 101710032374 BCL2L1 Proteins 0.000 description 2
- 235000000318 Bindesalat Nutrition 0.000 description 2
- 244000106835 Bindesalat Species 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- 241000219198 Brassica Species 0.000 description 2
- 235000003351 Brassica cretica Nutrition 0.000 description 2
- 235000003343 Brassica rupestris Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108010068682 Cyclophilins Proteins 0.000 description 2
- 102000001493 Cyclophilins Human genes 0.000 description 2
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 description 2
- 101710003775 ERVK-10 Proteins 0.000 description 2
- 101710037030 ERVK-11 Proteins 0.000 description 2
- 101710009283 ERVK-18 Proteins 0.000 description 2
- 101710009286 ERVK-19 Proteins 0.000 description 2
- 101710035700 ERVK-25 Proteins 0.000 description 2
- 101710038044 ERVK-6 Proteins 0.000 description 2
- 101710014468 ERVK-7 Proteins 0.000 description 2
- 101710014482 ERVK-8 Proteins 0.000 description 2
- 210000002304 ESC Anatomy 0.000 description 2
- 206010014476 Elevated cholesterol Diseases 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 101710037135 GAPC2 Proteins 0.000 description 2
- 101710037116 GAPC3 Proteins 0.000 description 2
- 101710025049 GAPDG Proteins 0.000 description 2
- 101710008404 GAPDH Proteins 0.000 description 2
- 102100006425 GAPDH Human genes 0.000 description 2
- 101710010461 Gapdh1 Proteins 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 101710043924 HERVK_113 Proteins 0.000 description 2
- 210000003494 Hepatocytes Anatomy 0.000 description 2
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 2
- 208000001252 Hyperlipoproteinemias Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 101710025050 MK0970 Proteins 0.000 description 2
- 229950004994 Meglitinide Drugs 0.000 description 2
- 240000005561 Musa balbisiana Species 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 206010034203 Pectus carinatum Diseases 0.000 description 2
- 229960005095 Pioglitazone Drugs 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 206010036067 Polydipsia Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 229960002965 Pravastatin Drugs 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 240000005809 Prunus persica Species 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 101700058821 RARB Proteins 0.000 description 2
- 101710006375 RNASEH1 Proteins 0.000 description 2
- 101700078434 RT67 Proteins 0.000 description 2
- 229920001914 Ribonucleotide Polymers 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 229920000978 Start codon Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 240000008529 Triticum aestivum Species 0.000 description 2
- 206010060755 Type V hyperlipidaemia Diseases 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 210000003462 Veins Anatomy 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(E)-octadec-9-enoyl]oxypropyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 102000016679 alpha-Glucosidases Human genes 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- 235000015241 bacon Nutrition 0.000 description 2
- 235000012791 bagels Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 101710025091 cbbGC Proteins 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 229920002092 cellular RNA Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000005824 corn Nutrition 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 235000021158 dinner Nutrition 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 235000021022 fresh fruits Nutrition 0.000 description 2
- 101710025070 gapdh-2 Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000021331 green beans Nutrition 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 235000019137 high fructose diet Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 201000010252 hyperlipoproteinemia type III Diseases 0.000 description 2
- 201000001431 hyperuricemia Diseases 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 235000012459 muffins Nutrition 0.000 description 2
- 235000010460 mustard Nutrition 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 125000004437 phosphorous atoms Chemical group 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 108010038912 retinoid X receptors Proteins 0.000 description 2
- 102000034577 retinoid X receptors Human genes 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 229960000672 rosuvastatin Drugs 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- 230000000391 smoking Effects 0.000 description 2
- 230000000087 stabilizing Effects 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 231100000730 tolerability Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 235000021307 wheat Nutrition 0.000 description 2
- XUFXOAAUWZOOIT-WVJZLWNXSA-N (2S,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-WVJZLWNXSA-N 0.000 description 1
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1H-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
- FDZGOVDEFRJXFT-UHFFFAOYSA-N 2-(3-aminopropyl)-7H-purin-6-amine Chemical compound NCCCC1=NC(N)=C2NC=NC2=N1 FDZGOVDEFRJXFT-UHFFFAOYSA-N 0.000 description 1
- NXOLVMFMAFCDSR-UHFFFAOYSA-M 2-(chloromethyl)oxirane;prop-2-en-1-amine;N-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;chloride Chemical compound [Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C NXOLVMFMAFCDSR-UHFFFAOYSA-M 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- WKMPTBDYDNUJLF-UHFFFAOYSA-N 2-fluoroadenine Chemical compound NC1=NC(F)=NC2=C1N=CN2 WKMPTBDYDNUJLF-UHFFFAOYSA-N 0.000 description 1
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-imino-7-methyl-1,2,3,7-tetrahydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1H-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-Hydroxymethylcytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1H-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1H-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1H-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1H-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-Deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 1
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 102100007787 APOA1 Human genes 0.000 description 1
- 101700077954 APOA1 Proteins 0.000 description 1
- 102100001085 APOB Human genes 0.000 description 1
- 206010049460 Abasia Diseases 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229960001466 Acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N Acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N Acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- RZVHIXYEVGDQDX-UHFFFAOYSA-N Anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000018655 Apolipoproteins C Human genes 0.000 description 1
- 108010027070 Apolipoproteins C Proteins 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 229940096699 Bile acid sequestrants Drugs 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 1
- 229940077731 Carbohydrate nutrients Drugs 0.000 description 1
- 206010007515 Cardiac arrest Diseases 0.000 description 1
- 206010007625 Cardiogenic shock Diseases 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229960001761 Chlorpropamide Drugs 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 208000009863 Chronic Kidney Failure Diseases 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Clearol Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N Clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N Colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 102100005838 DHFR Human genes 0.000 description 1
- 235000002243 Daucus carota subsp sativus Nutrition 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Dichlothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 238000008787 Direct HDL Methods 0.000 description 1
- 101700057458 Drice Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101700008821 EXO Proteins 0.000 description 1
- 101700083023 EXRN Proteins 0.000 description 1
- 241000083551 Ena Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229960004580 GLIBENCLAMIDE Drugs 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N Glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 Glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N Glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 229940014653 Glyburide Drugs 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 206010019847 Hepatosplenomegaly Diseases 0.000 description 1
- 210000001624 Hip Anatomy 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010020937 Hypoaesthesia Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- 102000036849 Islet amyloid polypeptide Human genes 0.000 description 1
- 108010041872 Islet amyloid polypeptide Proteins 0.000 description 1
- 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 description 1
- 101700086454 LPA Proteins 0.000 description 1
- 102100001083 LPA Human genes 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- 102100011960 MIR7-3HG Human genes 0.000 description 1
- 101710008473 MIR7-3HG Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010025482 Malaise Diseases 0.000 description 1
- 229960003105 Metformin Drugs 0.000 description 1
- 108060004843 Mical Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 1
- 206010028640 Myopathy Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N N-(p-Tolylsulfonyl)-N'-butylcarbamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N Nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 Nateglinide Drugs 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229940099990 Ogen Drugs 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N Orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N Pathocidin Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 210000002824 Peroxisome Anatomy 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- RDOWQLZANAYVLL-UHFFFAOYSA-N Phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical compound C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 235000001560 Prosopis chilensis Nutrition 0.000 description 1
- 240000007909 Prosopis juliflora Species 0.000 description 1
- 235000014460 Prosopis juliflora var juliflora Nutrition 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 229920000320 RNA (poly(A)) Polymers 0.000 description 1
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 206010038444 Renal failure chronic Diseases 0.000 description 1
- 229920001785 Response element Polymers 0.000 description 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101710038979 SBXA1 Proteins 0.000 description 1
- 102100016749 SLC5A2 Human genes 0.000 description 1
- 101710040674 SLC5A2 Proteins 0.000 description 1
- 101700079296 SP1 Proteins 0.000 description 1
- 102100005391 SP1 Human genes 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 108020004459 Small Interfering RNA Proteins 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000003453 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 229940032147 Starch Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Stearin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 230000036201 Tissue concentration Effects 0.000 description 1
- 229960002277 Tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N Tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N Torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 Torcetrapib Drugs 0.000 description 1
- 210000004026 Tunica Intima Anatomy 0.000 description 1
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000291414 Vaccinium oxycoccus Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 240000005148 Vaccinium uliginosum Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 206010048211 Xanthelasma Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- HGMSJMJPXGGEBP-UHFFFAOYSA-N [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium Chemical compound C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 HGMSJMJPXGGEBP-UHFFFAOYSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 201000002936 artery disease Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 230000001174 ascending Effects 0.000 description 1
- 230000000923 atherogenic Effects 0.000 description 1
- 230000003143 atherosclerotic Effects 0.000 description 1
- 230000001746 atrial Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- BPYKTIZUTYGOLE-IFADSCNNSA-N bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000021219 chicken noodle soup Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N diguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035510 distribution Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 102000021670 drug binding proteins Human genes 0.000 description 1
- 108091011447 drug binding proteins Proteins 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000001376 familial combined hyperlipidemia Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012779 flatbread Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 230000003485 founder effect Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 201000002406 genetic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000000055 hyoplipidemic Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 238000000185 intracerebroventricular Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000003615 lipoprotein lipase activator Substances 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000021156 lunch Nutrition 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 235000013575 mashed potatoes Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical class CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 1
- 229920001239 microRNA Polymers 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021084 monounsaturated fats Nutrition 0.000 description 1
- 201000010770 muscular disease Diseases 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 230000003234 polygenic Effects 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000000630 rising Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000000580 secretagogue Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000001340 slower Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Inorganic materials [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical class CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000004962 sulfoxyl group Chemical group 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 101710032063 tcf7l1a Proteins 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002110 toxicologic Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108010002139 very low density lipoprotein triglyceride Proteins 0.000 description 1
- 230000035513 volume of distribution Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000005765 wild carrot Nutrition 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Abstract
Disclosed is a use of a compound targeting ApoCIII in the manufacture of a medicament for a) treating, preventing, delaying or ameliorating pancreatitis in an animal; b) increasing HDL levels and/or improving the ratio of TG to HDL in an animal thereby preventing, delaying or ameliorating a cardiovascular disease, disorder, condition or symptom thereof or onset of a cardiovascular disease, disorder, condition or symptom thereof in an animal; c) increasing HDL levels and/or improving the ratio of TG to HDL in an animal thereby reducing the risk of a cardiovascular disease, disorder, condition or symptom in an animal; and/or d) treating, preventing, delaying or ameliorating chylomicronemia, wherein the compound is capable of inhibiting apolipoprotein C-III. rdiovascular disease, disorder, condition or symptom thereof or onset of a cardiovascular disease, disorder, condition or symptom thereof in an animal; c) increasing HDL levels and/or improving the ratio of TG to HDL in an animal thereby reducing the risk of a cardiovascular disease, disorder, condition or symptom in an animal; and/or d) treating, preventing, delaying or ameliorating chylomicronemia, wherein the compound is capable of inhibiting apolipoprotein C-III.
Description
MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
Sequence Listing
The t application is being filed along with a Sequence Listing in electronic format.
The Sequence Listing is provided as a file entitled 30WOSEQ.TXT, created on April 27,
2012 which is 8 Kb in size. The information in the electronic format of the sequence listing is
incorporated herein by reference in its ty.
Field of the Invention
Provided herein are methods, compounds, and itions for reducing expression of
Apolipoprotein CIII (ApoCIII) mRNA and n, and increasing HDL or HDL ty in an
animal. Also, provided herein are methods, compounds, and compositions for an ApoCIII
inhibitor for reducing ApoCIII related diseases or conditions in an animal.
Background
Lipoproteins are globular, micelle-like particles that consist of a non-polar core of
acylglycerols and teryl esters surrounded by an amphiphilic coating of protein,
phospholipid and cholesterol. Lipoproteins have been classified into five broad categories on the
basis of their functional and physical properties: chylomicrons, very low density lipoproteins
(VLDL), intermediate density lipoproteins (IDL), low density lipoproteins (LDL), and high
density oteins (HDL). Chylomicrons transport dietary lipids from intestine to tissues.
VLDLs, IDLs and LDLs all transport triacylglycerols and cholesterol from the liver to tissues.
HDLs transport endogenous cholesterol from tissues to the liver
Lipoprotein particles undergo continuous metabolic processing and have variable
properties and compositions. Lipoprotein densities increase without increasing particle diameter
because the density of their outer gs is less than that of the inner core. The protein
components of lipoproteins are known as apolipoproteins. At least nine apolipoproteins are
distributed in significant amounts among the various human oteins.
oprotein C-III (ApoCIII) is a constituent ofHDL and of triglyceride (TG)-rich
lipoproteins. ed ApoCIII is associated with riglyceridemia. Accordingly, ApoCIIIhas
a role in hypertriglyceridemia, a risk factor for ry artery disease (Davidsson et al., J. Lipid
Res. 2005. 46: 1999-2006). ApoCIII slows clearance of triglyceride-rich lipoproteins by
WO 49495
inhibiting lipolysis, both through inhibition of lipoprotein lipase and by interfering with
lipoprotein binding to cell-surface glycosaminoglycan matrix (Shachter, Curr. Opin. l,
2001, 12, 297—304).
The gene encoding human apolipoprotein C-III (also called APOC3, APOC-III, ApoCIII,
and APO C-III) was cloned in 1984 by three research groups (Levy-Wilson et al, DNA, 1984, 3,
359-364; Protter et al, DNA, 1984, 3, 449-456; Sharpe et al, Nucleic Acids Res, 1984, 12, 3917-
3932). The coding sequence is interrupted by three s (Protter et al, DNA, 1984, 3, 449-
456). The human ApoCIII gene is located approximately 2.6 kb to the 3’ direction of the
apolipoprotein A-l gene and these two genes are convergently transcribed (Karathanasis, Proc.
Natl. Acad. Sci. U. S. A., 1985, 82, 6374-6378). Also cloned was a variant of human
apolipoprotein C-III with a Thr74 to Ala74 mutation from a patient with unusually high level of
serum apolipoprotein C-III. As the Thr74 is O-glycosylated, the Ala74 mutant therefore resulted
in increased levels of serum I g the carbohydrate moiety (Maeda et al, J. Lipid
Res, 1987, 28, 1405-1409). Other variants or polymorphisms that modulated Apo CIII
sion were later identif1ed. Some of the polymorphsims elevated ApoCIII. Elevated
ApoCIII levels were associated with elevated triglyceride (TG) levels and diseases such as
cardiovascular disease, metabolic syndrome, obesity and diabetes (Chan et al, lntJ Clin Pract,
2008, 62:799-809; Onat et at, Atherosclerosis, 2003, 168:81-89; Mendivil et al, ation,
2011, 124:2065-2072).
Five polymorphisms have been identified in the promoter region of the gene: C (at
position -641 of the gene) to A, G (at position -630 of the gene) to A, T (at position -625 of the
gene) to deletion, C (at position -482 of the gene) to T and T (at position -455 of the gene) to C.
All of these polymorphisms are in linkage disequilibrium with the SstI rphism in the 3’
untranslated region. The SstI polymorphic site distinguishes the S1 and S2 alleles and the S2
allele has been ated with elevated plasma triglyceride levels rman et al, Proc.
Natl. Acad. Sci. U. S. A., 1993, 90, 4562-4566). The ApoCIII promoter is downregulated by
insulin and this polymorphic site hes the insulin regulation. Thus the potential
overexpression of ApoCIII resulting from the loss of insulin regulation may be a contributing
factor to the development of hypertriglyceridemia associated with the S2 allele (Li et al, J. Clin.
Invest, 1995, 96, 2601-2605). The T (at position -455 of the gene) to C polymorphism has been
ated with an increased risk of coronary artery disease (Olivieri et al, J. LipidRes, 2002,
43, 1450-1457). Other polymorphisms in the human ApoCIII gene that have been associated with
elevated ApoCIII and/or triglyceride expression include: C (at position 1100) to T, C (at position
3175) to G, T (at position 3206) to G, C (at ons 323 8) to G, etc. (Tilly ei al, J. Lipid Res.,
2003, 44:430-436; Waterworth el al, Arterioscler Thromb Vasc Biol, 2000, 20:2663-2669;
Petersen el al., NEngl JMed, 2010, 362: 1082-1089).
In addition to insulin, other regulators of ApoCIII gene eXpression have been identified.
A response element for the nuclear orphan receptor rev-erb alpha has been located at positions -
23 to -18 of the gene, in the ApoCIII promoter region. Rev-erb alpha decreases ApoCIII
promoter activity (Raspe el al, J. Lipid Res., 2002, 43, 179). The I promoter
region from positions —86 to —74 of the gene is recognized by two nuclear s CIIIbl and
CIIIB2 (Ogami el al, J. Biol Chem, 1991, 266, 9640-9646). ApoCIII expression is also
upregulated by retinoids acting via the retinoid X receptor, and alterations in retinoid X receptor
abundance affects I transcription (Vu-Dac ei al, J. Clin. , 1998, 102, 625-632).
Specificity protein 1 (Sp1) and hepatocyte r factor-4 (HNF-4) have been shown to work
synergistically to transactivate the apolipoprotein C-III promoter via the HNF-4 binding site
(Kardassis el al, Biochemistry, 2002, 41, 1217-1228). HNF-4 also works in ction with
SMAD3-SMAD4 to transactivate the ApoCIII promoter (Kardassis ei al, J. Biol. Chem, 2000,
275, 41405-41414).
Transgenic and knockout mice have further defined the role of ApoCIII in sis.
OvereXpression of ApoCIII in transgenic mice leads to riglyceridemia and impaired
clearance of VLDL-triglycerides (de Silva ei al, J. Biol. Chem, 1994, 269, 2324-2335; Ito ei al,
Science, 1990, 249, 790-793). Knockout mice with a total absence of the ApoCIII protein
eXhibited significantly reduced plasma cholesterol and triglyceride levels compared with wild-
type mice and were protected from postprandial hypertriglyceridemia (Maeda ei al, J. Biol.
Chem, 1994, 269, 23610-23616).
Total plasma ApoCIII levels have been identified as a major determinant of serum
cerides, and epidemiological studies have demonstrated that ApoCIII and ApoB
oteins that have ApoCIII as a component independently predict coronary heart disease
(Sacks et al., Circulation. 2000. 102: 1886-1892; Lee et al., Arterioscler Thromb Vasc Biol. 2003.
23.‘ 8537 858). Studies also demonstrate that ApoCIII is a key determinant in the clearance of
triglyceride-rich oteins and its remnants in hypertriglyceridaemic states, including visceral
obesity, n resistance and the metabolic syndrome (Mauger et al., J. Lipid Res. 2006. 47:
1212-1218; Chan et al., Clin. Chem. 2002. 278-283; Ooi et al., Clin. Sci. 2008. 114: 611-624).
WO 49495
Hypertriglyceridemia is a common clinical trait associated with an increased risk of
cardiometabolic disease (Hegele et al. 2009, Hum Mol Genet, 18: 4189-4194; Hegele and Pollex
2009, Mol Cell Biochem, 326: 35-43) as well as of occurrence of acute pancreatitis in the most
severe forms (Toskes 1990, Gastroenterol Clin North Am, 19: 783-791; Gaudet et al. 2010,
Atherosclerosis Supplements, 11: 55-60; Catapano et al. 2011, Atherosclerosis, 2178: 81-844;
Tremblay et al. 2011, J Clin Lipidol, 5: 37-44). Examples of metabolic disease include, but
are not limited to, diabetes, lic syndrome/insulin resistance, and genetic disorders such as
familial chylomicronemia, familial combined hyperlipidemia and familial hypertriglyceridemia.
Hypertriglyceridemia is the consequence of increased production and/or reduced or
delayed lism of triglyceride ich lipoproteins: VLDL and, to a lesser extent,
chylomicrons (CM). Borderline high TGs (150-199 mg/dL) are commonly found in the l
population and are a common ent of the metabolic syndrome/insulin ance states.
The same is true for high TGs (200-499 mg/dL) except that as plasma TG levels se,
underlying genetic factors play an increasingly important etiologic role. Very high TGs (2500
mg/dL) are most often associated with elevated CM levels as well, and are accompanied by
increasing risk for acute pancreatitis. The risk of pancreatitis is considered clinically significant if
TG exceeds 880 mg/dL (>10 mmol) and the European Atherosclerosis Society/European Society
of Cardiology (EAS/ESC) 2011 guidelines state that actions to prevent acute pancreatitis are
mandatory (Catapano et al. 2011, Atherosclerosis, 2178: 81-844). According to the EAS/ESC
2011 guidelines, riglyceridemia is the cause of approximately 10% of all cases of
pancreatitis, and development of pancreatitis can occur at TG levels n 440-880 mg/dL.
Based on evidence from clinical studies trating that elevated TG levels are an independent
risk factor for atherosclerotic CVD, the guidelines from both the National Cholesterol Education
Program Adult ent Panel III (NCEP 2002, ation, 106: 3143-421) and the American
Diabetes Association (ADA 2008, Diabetes Care, 31: $12-$54.) recommend a target TG level of
less than 150 mg/dL to reduce cardiovascular risk.
ApoCIII-knockout mice had normal intestinal lipid absorption and hepatic VLDL
triacylglycerol secretion, but a rapid clearance of VLDL triacylglycerols and VLDL cholesteryl
esters from plasma that may explain the observed hypolipidaemia (Gerritsen et al., J. Lipid Res.
2005. 46: 1466-1473; Jong et al., J. Lipid Res. 2001. 42: 1578-1585). VLDL particles with
I have been cited to play a major role in identifying the high risk of coronary heart disease
in hypertriglyceridemia (Campos et al., J. Lipid Res. 2001. 42: 1239-1249). A genome-wide
association study found a naturally occurring ApoCIII null mutation in ter Amish people
demonstrated a favorable lipid profile and apparent cardioprotection, with no obvious detrimental
effects n el al., Science. 2008. 322: 1702-1705). The mutation carriers are observed to have
lower fasting and postprandial serum triglycerides and LDL-cholesterol, and higher levels of
HDL-cholesterol.
The HDL class of lipoproteins ses a heterogeneous and polydisperse population of
particles that are the most dense and smallest of size (Havel and Kane. In, The Metabolic &
Molecular Bases of Inherited Disease. 8th n. McGraw-Hill, New York, 2001 :2705—16).
HDL is a macromolecular compleX of lipids (cholesterol, cerides and olipids) and
proteins (apolipoproteins (apo) and enzymes). The surface ofHDL ns chiefly
apolipoproteins A, C and E. The function of some of these apoproteins is to direct HDL from the
peripheral tissues to the liver. Serum HDL levels can be affected by underlying genetic causes
(Weissglas-Volkov and Pajukanta, JLipidRes, 2010, 51 :2032-2057)
Epidemiological studies have indicated that increased levels ofHDL t t
cardiovascular disease or coronary heart disease (Gordon et al., Am. J. Med. 1977. 62: 707-714).
These effects of HDL-cholesterol are ndent of triglyceride and LDL-cholesterol
concentrations. In clinical practice, a low plasma HDL-cholesterol is more commonly ated
with other disorders that increase plasma triglycerides, for example, central obesity, insulin
resistance, type 2 diabetes mellitus and renal disease (chronic renal failure or nephrotic
proteinuria) (Kashyap. Am. J. Cardiol. 1998. 82: 42U-48U).
Currently, there are no known direct therapeutic agents that affect the function of
ApoCIII. The hypolipidemic effect of the fibrate class of drugs has been postulated to occur via a
mechanism where peroxisome proliferator activated or (PPAR) mediates the displacement
ofHNF-4 from the apolipoprotein C-III promoter, ing in transcriptional suppression of
apolipoprotein C-III (Hertz el al., J. Biol. Chem, 1995, 270, 13475). The statin class of
hypolipidemic drugs also lower triglyceride levels via an unknown mechanism, which results in
increases in lipoprotein lipase mRNA and a decrease in plasma levels of oprotein C-III
(Schoonjans el al., FEBS Lett, 1999, 452, 160-164). Consequently, there remains a long felt
need for additional agents capable of effectively inhibiting apolipoprotein C-III function.
Antisense technology is emerging as an effective means for reducing the expression of
certain gene products and may therefore prove to be uniquely useful in a number of therapeutic,
stic, and research applications for the modulation of ApoCIII.
We have previously disclosed compositions and method for inhibiting ApoCIII by
antisense compounds in US 20040208856 (US Patent 7,598,227), US 20060264395 (US Patent
7,750,141), and 783. In the present application, we disclose the cted result
that antisense inhibition of ApoCIII resulted in the elevation ofHDL levels and decrease in
postprandial ceride levels. This result will be useful, for example, to treat, prevent, delay,
decrease or ameliorate any one or more diseases, such as cardiovascular disease (e.g., coronary
heart disease or atherogenic es). For e, elevated postprandial (non-fasting)
triglyceride levels have been identified as a significant risk factor for cardiovascular diseases
(Bansal el al., JAA/IA, 2007, 9-16; Nordestgaard el al., , 2007, 298:299-308), Also,
in the present application, inhibition of ApoCIII expression unexpectedly results in increased
icron clearance and is ore important in the prevention of chylomicronemia (Chait et
al., 1992, Adv Intern Med. 1992, 37 :249-73), a dyslipidemic state caused by improper clearance
of chylomicron triglyceride. Severe forms of chylomicronemia can lead to pancreatitis, a life-
threatening condition. By inhibiting intestinal ApoCIII, inhibition of lipoprotein lipase would be
reduced, and icron triglyceride clearance would be enhanced, thereby preventing
pancreatitis.
y of the Invention
Provided herein are methods of increasing HDL levels by stering to an animal a
compound targeting ApoCIII.
Certain embodiments provide a method of preventing, treating, ameliorating, delaying the
onset of or ng the risk of a cardiovascular disease, disorder or condition in an animal
comprising administering a compound targeting ApoCIII to the animal. The compound
administered to the animal prevents, treats, rates, delays the onset of, or reduces the risk
of, the cardiovascular disease, disorder or condition by increasing HDL levels in the animal.
Certain embodiments provide a method of reducing the risk for a cardiovascular disease
in an animal comprising administering to the animal a therapeutically effective amount of a
compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides,
wherein the modified ucleotide is complementary to an ApoCIII nucleic acid. In certain
embodiments, the ApoCIII c acid is as shown in SEQ ID NO: 1 or SEQ ID NO: 2. In
certain embodiments, the compound comprises a modified oligonucleotide consisting of 12 to 30
linked nucleosides, and having a nucleobase sequence comprising at least 8 contiguous
nucleobases of ISIS 304801 (SEQ ID NO: 3). In further embodiments, the compound
administered to the animal reduces the risk for a cardiovascular disease, by increasing HDL
levels.
Certain embodiments provide a method of preventing, ng, ameliorating or reducing
at least one symptom of a cardiovascular disease in an animal, sing administering to the
animal a therapeutically effective amount of a compound comprising a d oligonucleotide
consisting of 12 to 30 linked nucleosides, wherein the modified oligonucleotide is
complementary to an ApoCIII nucleic acid. In certain embodiments, the ApoCIII nucleic acid is
as shown in SEQ ID NO: 1 or SEQ ID NO: 2. In certain embodiments, the nd comprises
a modified oligonucleotide ting of 12 to 30 linked nucleosides, and having a nucleobase
sequence comprising at least 8 uous nucleobases of ISIS 304801 (SEQ ID NO: 3). In
further embodiments, the compound administered to the animal ts, treats, ameliorates or
reduces at least one symptom of the cardiovascular disease in the animal, by increasing HDL
levels in the animal.
n embodiments provide a method of raising HDL levels in an animal by
administering to the animal a compound consisting of ISIS 304801 (SEQ ID NO: 3) to raise the
HDL levels in the animal.
Certain embodiments e a method of preventing, treating, rating or reducing
at least one symptom of a cardiovascular disease in an animal by administering to the animal a
2O compound ting of ISIS 304801 (SEQ ID NO: 3) to prevent, treat, ameliorate or reduce at
least one symptom of the cardiovascular disease in the animal, by increasing HDL levels in the
animal.
Certain ments provide a method of raising HDL levels in an animal by
administering to the animal a modified oligonucleotide, having the sequence of SEQ ID NO: 3
(ISIS 304801) wherein the modified oligonucleotide comprises: a gap segment consisting of 10
linked deoxynucleosides; a 5’ wing segment consisting of 5 linked nucleosides; a 3’ wing
segment consisting 5 linked nucleosides, wherein the gap segment is positioned immediately
adjacent to and between the 5’ wing segment and the 3’ wing segment and wherein each
nucleoside of each wing segment comprises a 2’-O-methyoxyethyl sugar, wherein each cytosine
is a 5’-methylcytosine, and wherein each internucleoside linkage is a phosphorothioate e,
wherein the modified oligonucleotide raises the HDL levels in the animal.
Certain embodiments provide a method of preventing, treating, ameliorating or reducing
at least one symptom of a cardiovascular disease in an animal by stering to the animal a
modified oligonucleotide, having the sequence of ISIS 304801 (SEQ ID NO: 3) wherein the
modified oligonucleotide comprises: a gap segment consisting of 10 linked deoxynucleosides; a
’ wing segment consisting of 5 linked nucleosides; a 3’ wing segment ting 5 linked
nucleosides; n the gap segment is positioned immediately nt to and between the 5’
wing segment and the 3’ wing segment and wherein each nucleoside of each wing segment
comprises a 2’-O-methyoxyethyl sugar, wherein each cytosine is a 5’-methylcytosine, and
wherein each internucleoside linkage is a phosphorothioate e, wherein the modified
oligonucleotide prevents, treats, ameliorates or reduces at least one symptom in the animal with
the vascular e by raising the HDL levels in the animal.
n embodiments provide a method of g HDL levels in an animal by
administering to the animal a compound comprising a modified oligonucleotide consisting of 12
to 30 linked nucleosides, wherein the modified oligonucleotide is mentary to an ApoCIII
nucleic acid, as shown in SEQ ID NO: 1 or SEQ ID NO: 2, to raise the HDL levels in the animal.
Certain ments provide a method of preventing, treating, ameliorating or reducing
at least one m of a cardiovascular disease in an animal by administering to the animal a
compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides,
wherein the modified oligonucleotide is complementary to an ApoCIII nucleic acid, as shown in
2O SEQ ID NO: 1 or SEQ ID NO: 2, to preventing, treating, ameliorating or reducing at least one
symptom of the cardiovascular disease in the animal, by raising the HDL levels of the animal.
Certain embodiments provide a method of decreasing CETP levels by administering a
compound targeting ApoCIII to an animal. In certain embodiments, the compound comprises a
modified oligonucleotide ting of 12 to 30 linked nucleosides, and having a nucleobase
sequence complementary to an ApoCIII nucleic acid. In certain embodiments, the nucleobase
sequence comprises at least 8 contiguous nucleobases of ISIS 304801 (SEQ ID NO: 3). In certain
embodiments, the compound consists of the bases of ISIS 304801 (SEQ ID NO: 3).
Certain embodiments provide a method of increasing ApoAl, PONl, fat clearance,
icron triglyceride clearance, post prandial triglyceride clearance or HDL by administering
a nd targeting ApoCIII to an . In certain embodiments, the compound comprises a
modified oligonucleotide consisting of 12 to 30 linked nucleosides, and having a nucleobase
sequence complementary to an ApoCIII nucleic acid. In certain embodiments, the nucleobase
WO 49495
sequence comprises at least 8 contiguous nucleobases of ISIS 304801 (SEQ ID NO: 3). In certain
embodiments, the compound ts of the nucleobases of ISIS 304801 (SEQ ID NO: 3).
Certain embodiments provide a method of ting, delaying or rating
pancreatitis comprising: (a) selecting an animal with, or at risk of, pancreatitis, and (b)
administering a compound targeting ApoCIII to the animal, wherein the pancreatitis is prevented,
delayed or ameliorated.
Certain ments provide a method of preventing, delaying or ameliorating
pancreatitis sing: (a) selecting an animal with, or at risk of, pancreatiis, and (b)
administering a compound targeting ApoCIII to the animal, thereby increasing chylomicron
clearance, wherein the pancreatitis is prevented, delayed or ameliorated.
In n embodiments, the animal has, or is at risk for, hypertriglyceridemia. In certain
embodiments, the riglyceridemia is Fredrickson Type II, IV or V. In certain embodiments,
the animal has a genetic defect leading to hypertriglyceridemia. In certain ments, the
genetic defect is a heterozygous LPL deficiency or an ApoCIII polymorphism. In certain
embodiments, the animal has a ceride level 2 500 mg/dL and a heterozygous LPL
deficiency.
In certain embodiments, the animal has a ceride level n 100-200 mg/dL, 100-
300 mg/dL, 100-400 mg/dL, 100-500 mg/dL, 0 mg/dL, 300-500 mg/dL, 400-500 mg/dL,
500-1000 mg/dL, 600-1000 mg/dL, 700-1000 mg/dL, 800-1000 mg/dL, 900-1000 mg/dL, 500-
1500 mg/dL, 1000-1500 mg/dL, 100-2000 mg/dL, 150-2000 mg/dL, 200-2000 mg/dL, 300-2000
mg/dL, 400-2000 mg/dL, 500-2000 mg/dL, 600-2000 mg/dL, 700-2000 mg/dL, 800-2000 mg/dL7
900-2000 mg/dL, 1000-2000 mg/dL, 1100-2000 mg/dL, 1200-2000 mg/dL, 1300-2000 mg/dL,
1400-2000 mg/dL, or 1500-2000 mg/dL.
In certain embodiments, increased chylomicron clearance enhances clearance of
postprandial triglycerides and/or decreases postprandial triglycerides.
Certain embodiments provide a use of a compound targeted to ApoCIII for preventing,
treating, ameliorating or reducing at least one symptom of a cardiovascular disease, by increasing
HDL levels.
Certain embodiments provide a use of a compound targeted to ApoCIII for increasing
HDL levels in an .
Certain embodiments provide a use of a compound targeted to ApoCIII for the
preparation of a medicament for increasing HDL levels in an animal.
Certain embodiments e a use of a compound targeted to ApoCIII for the
preparation of a medicament for ing the ratio of TG to HDL.
Detailed Description of the Invention
It is to be understood that both the foregoing l description and the following
detailed description are exemplary and explanatory only and are not restrictive of the invention,
as claimed. Herein, the use of the singular includes the plural unless specifically stated
otherwise. As used herein, the use of “or” means r” unless stated otherwise. Furthermore,
the use of the term “including” as well as other forms, such as “includes” and “included”, is not
limiting. Also, terms such as “element” or “component” encompass both elements and
components comprising one unit and elements and components that comprise more than one
subunit, unless specifically stated otherwise.
The section headings used herein are for organizational purposes only and are not to be
construed as ng the subject matter described. All documents, or portions of documents,
cited in this application, including, but not limited to, s, patent ations, articles, books,
and treatises, are hereby expressly incorporated by reference for the portions of the document
discussed herein, as well as in their entirety.
Definitions
Unless specific definitions are provided, the lature utilized in connection with,
and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and
medicinal and pharmaceutical chemistry described herein are those well known and commonly
used in the art. Standard techniques may be used for chemical synthesis, and chemical analysis.
Where permitted, all patents, ations, published applications and other publications,
GENBANK Accession Numbers and associated sequence information obtainable through
databases such as National Center for Biotechnology Information (NCBI) and other data ed
to throughout in the disclosure herein are orated by reference for the portions of the
document discussed herein, as well as in their ty.
Unless ise indicated, the following terms have the following meanings:
“2’-O-methoxyethyl” (also 2’-MOE, 2’-O(CH2)2-OCH3 and 2’-O-(2-methoxyethyl))
refers to an O-methoxy-ethyl modification of the 2’ position of a fiirosyl ring. A 2
yethyl modified sugar is a modified sugar.
“2’-O-methoxyethyl tide” means a nucleotide comprising a 2’-O-methoxyethyl
modified sugar moiety.
“3’ target site” refers to the nucleotide of a target nucleic acid which is complementary to
the 3’-most nucleotide of a particular antisense compound.
“5’ target site” refers to the nucleotide of a target nucleic acid which is complementary to
the 5’-most nucleotide of a particular antisense compound.
“5-methylcytosine” means a cytosine modified with a methyl group attached to the 5’
position. A 5-methylcytosine is a modified nucleobase.
“About” means within ::10% of a value. For example, if it is stated, “a marker may be
increased by about 50%”, it is implied that the marker may be increased between 45%-5 5%.
“Active ceutical agent” means the nce or substances in a pharmaceutical
composition that provide a eutic benefit when administered to an dual. For example,
in n embodiments an antisense oligonucleotide ed to ApoCIII is an active
pharmaceutical agent.
“Active target region” or “target ” means a region to which one or more active
antisense compounds is targeted. “Active antisense compounds” means antisense compounds that
reduce target nucleic acid levels or protein levels.
“Administered concomitantly” refers to the co-administration of two agents in any
manner in which the pharmacological effects of both are manifest in the patient at the same time.
Concomitant administration does not require that both agents be administered in a single
pharmaceutical composition, in the same dosage form, or by the same route of administration.
The s of both agents need not manifest themselves at the same time. The effects need only
be overlapping for a period of time and need not be coextensive.
“Administering” means providing a pharmaceutical agent to an individual, and includes,
but is not limited to administering by a medical professional and self-administering.
” means an active substance that can provide a therapeutic benefit when
administered to an animal. “First Agent” means a therapeutic compound of the invention. For
example, a first agent can be an nse oligonucleotide targeting ApoCIII. “Second agent”
means a second therapeutic nd of the invention (e. g. a second antisense oligonucleotide
targeting ApoCIII) and/or a non-ApoCIII therapeutic compound.
“Amelioration” refers to a ing of at least one indicator, sign, or symptom of an
associated e, disorder, or condition. The severity of indicators may be determined by
subjective or objective es, which are known to those skilled in the art.
l” refers to a human or non-human animal, including, but not limited to, mice,
rats, rabbits, dogs, cats, pigs, and non-human primates, including, but not limited to, monkeys
and chimpanzees.
“Antisense activity” means any detectable or measurable activity attributable to the
hybridization of an antisense compound to its target nucleic acid. In certain embodiments,
antisense activity is a se in the amount or expression of a target nucleic acid or protein
d by such target nucleic acid.
ense compound” means an oligomeric compound that is capable of undergoing
hybridization to a target nucleic acid through hydrogen bonding. As used herein, the term
“antisense compound” asses pharmaceutically acceptable derivatives of the compounds
described herein.
“Antisense inhibition” means the reduction of target nucleic acid levels or target n
levels in the presence of an antisense compound complementary to a target nucleic acid
compared to target nucleic acid levels or target protein levels in the absence of the antisense
compound.
“Antisense oligonucleotide” means a single-stranded oligonucleotide having a nucleobase
sequence that permits hybridization to a ponding region or segment of a target nucleic acid.
As used , the term “antisense oligonucleotide” encompasses pharmaceutically acceptable
derivatives of the compounds described herein.
“ApoCIII” means any nucleic acid or protein sequence encoding ApoCIII. For example,
in n embodiments, an ApoCIII includes a DNA sequence encoding ApoCIII, a RNA
sequence transcribed from DNA encoding ApoCIII (including genomic DNA comprising introns
and , a mRNA sequence encoding ApoCIII, or a peptide ce encoding ApoCIII.
“ApoCIII mRNA” means a mRNA encoding an ApoCIII protein.
“ApoCIII protein” means any protein sequence encoding ApoCIII.
“Atherosclerosis” means a hardening of the arteries affecting large and medium-sized
arteries and is characterized by the presence of fatty deposits. The fatty deposits are called
"atheromas" or es,” which consist mainly of cholesterol and other fats, m and scar
tissue, and damage the lining of arteries.
“Bicyclic sugar” means a filrosyl ring modified by the bridging of two non-geminal ring
atoms. A bicyclic sugar is a modified sugar.
“Bicyclic nucleic acid” or “BNA” refers to a nucleoside or nucleotide n the
furanose n of the nucleoside or nucleotide includes a bridge connecting two carbon atoms
on the furanose ring, thereby forming a bicyclic ring system.
“Cap structure” or “terminal cap moiety” means chemical modifications, which have been
incorporated at either terminus of an antisense compound.
“Cardiovascular disease” or “cardiovascular disorder” refers to a group of conditions
related to the heart, blood vessels, or the circulation. Examples of cardiovascular diseases
include, but are not limited to, aneurysm, angina, arrhythmia, atherosclerosis, ovascular
disease e), coronary heart disease, hypertension, dyslipidemia, hyperlipidemia,
hypertriglyceridemia and hypercholesterolemia.
“Chemically distinct region” refers to a region of an antisense compound that is in some
way chemically different than another region of the same antisense compound. For example, a
region having 2’-O-methoxyethyl tides is chemically distinct from a region having
nucleotides without 2’-O-methoxyethyl ations.
“Chimeric antisense nd” means an antisense compound that has at least two
chemically ct regions.
“Cholesterol” is a sterol molecule found in the cell membranes of all animal tissues.
Cholesterol must be transported in an animal’s blood plasma by lipoproteins including very low
y lipoprotein (VLDL), intermediate density lipoprotein (IDL), low density lipoprotein
(LDL), and high density lipoprotein (HDL). “Plasma cholesterol” refers to the sum of all
lipoproteins (VDL, IDL, LDL, HDL) esterified and/or non-estrified cholesterol present in the
plasma or serum.
“Cholesterol absorption inhibitor” means an agent that inhibits the absorption of
exogenous cholesterol obtained from diet.
“Co-administration” means administration of two or more agents to an individual. The
two or more agents can be in a single pharmaceutical composition, or can be in separate
pharmaceutical compositions. Each of the two or more agents can be administered through the
same or different routes of administration. Co-administration asses parallel or tial
administration.
“Complementarity” means the capacity for pairing between nucleobases of a first nucleic
acid and a second nucleic acid. In certain embodiments, mentarity between the first and
second nucleic acid can be between two DNA strands, between two RNA strands, or between a
DNA and an RNA strand. In certain embodiments, some of the nucleobases on one strand are
matched to a complementary hydrogen bonding base on the other strand. In n embodiments,
all of the nucleobases on one strand are matched to a complementary hydrogen bonding base on
the other strand. In certain embodiments, a first nucleic acid is an antisense compound and a
second nucleic acid is a target nucleic acid. In certain such embodiments, an antisense
oligonucleotide is a first nucleic acid and a target nucleic acid is a second nucleic acid.
“Contiguous nucleobases” means bases immediately adjacent to each other.
“Constrained ethyl” or “cEt” refers to a bicyclic nucleoside having a fiiranosyl sugar that
ses a methyl(methyleneoxy) (4’-CH(CH3)-O-2’) bridge n the 4’ and the 2’ carbon
atoms.
-reactive” means an oligomeric compound ing one nucleic acid sequence can
hybridize to a different c acid sequence. For example, in some instances an antisense
oligonucleotide targeting human ApoCIII can cross-react with a murine ApoCIII. Whether an
oligomeric compound cross-reacts with a nucleic acid sequence other than its designated target
depends on the degree of complementarity the compound has with the non-target nucleic acid
sequence. The higher the complementarity between the oligomeric compound and the non-target
c acid, the more likely the oligomeric compound will cross-react with the nucleic acid.
“Cure” means a method that restores health or a ibed treatment for an illness.
ary heart disease (CHD)” means a narrowing of the small blood vessels that supply
blood and oxygen to the heart, which is often a result of atherosclerosis.
“Deoxyribonucleotide” means a nucleotide having a hydrogen at the 2’ on of the
sugar portion of the nucleotide. Deoxyribonucleotides may be modified with any of a variety of
sub stituents.
“Diabetes mellitus” or “diabetes” is a syndrome characterized by disordered metabolism
and abnormally high blood sugar (hyperglycemia) resulting from insufficient levels of insulin or
reduced insulin sensitivity. The characteristic symptoms are excessive urine production (polyuria)
due to high blood glucose levels, excessive thirst and increased fluid intake (polydipsia)
attempting to compensate for increased urination, blurred vision due to high blood glucose effects
on the eye's , unexplained weight loss, and lethargy.
tic dyslipidemia” or “type 2 diabetes with dyslipidemia” means a condition
characterized by Type 2 es, reduced HDL-C, elevated triglycerides, and elevated small,
dense LDL particles.
“Diluent” means an ingredient in a composition that lacks pharmacological activity, but is
pharmaceutically necessary or desirable. For e, the diluent in an injected composition
may be a liquid, e. g. saline solution.
“Dyslipidemia” refers to a disorder of lipid and/or lipoprotein metabolism, including lipid
and/or lipoprotein overproduction or deficiency. idemias may be manifested by elevation of
lipids such as icron, cholesterol and triglycerides as well as lipoproteins such as low-
density lipoprotein (LDL) cholesterol. An example of a dyslipidemia is chylomicronemia.
“Dosage unit” means a form in which a pharmaceutical agent is provided, e. g. pill, tablet,
or other dosage unit known in the art. In certain embodiments, a dosage unit is a vial containing
lized antisense oligonucleotide. In certain embodiments, a dosage unit is a vial containing
tituted antisense oligonucleotide.
“Dose” means a specified quantity of a pharmaceutical agent provided in a single
administration, or in a specified time period. In certain embodiments, a dose can be stered
in one, two, or more boluses, tablets, or injections. For example, in certain embodiments where
subcutaneous administration is desired, the desired dose requires a volume not easily
accommodated by a single injection, therefore, two or more injections can be used to e the
2O desired dose. In certain embodiments, the pharmaceutical agent is administered by infusion over
an extended period of time or uously. Doses can be stated as the amount of pharmaceutical
agent per hour, day, week, or month. Doses can also be stated as mg/kg or g/kg.
“Effective amount” or “therapeutically effective amount” means the amount of active
pharmaceutical agent sufficient to effectuate a desired physiological e in an individual in
need of the agent. The effective amount can vary among individuals depending on the health and
physical condition of the individual to be treated, the taxonomic group of the individuals to be
treated, the formulation of the composition, assessment of the individual’s medical condition, and
other relevant factors.
The “Fredrickson” system is used to classify primary ic) causes of dislipidemia into
several subgroups or types. Dislipidemia types that may be amenable to therapy with the
compounds disclosed herein e, but are not limited to, Fredrickson Type II, IV and V.
“Fredrickson Type 1” exists in several forms: Type 1a is a lipoprotein lipase deficiency
due to a deficiency ofLPL or altered apoC-II; Type 1b is a al apoprotein CII ncy, a
condition caused by a lack of lipoprotein lipase activator; and Type 1c is a chylomicronemia due
to circulating inhibitor of lipoprotein lipase. Type I is a rare disorder that usually presents in
childhood. It is characterized by severe elevations in icrons and extremely elevated TG
levels (always reaching well above 1000 mg/dL and not uently rising as high as 10,000
mg/dL or more) with episodes of abdominal pain, recurrent acute pancreatitis, eruptive cutaneous
xanthomata, and hepatosplenomegaly. Patients rarely p atherosclerosis, s because
their plasma lipoprotein particles are too large to enter into the arterial intima (Nordestgaard et
al., J Lipid Res, 1988, 29:1491-1500; Nordestgaard et al., Arteriosclerosis, 1988, 8:421-428).
Type I is usually caused by mutations of either the LPL gene, or of the gene's or apoC-II,
resulting in the inability of affected individuals to produce filnctionally active LPL. Patients are
either homozygous for such mutations or compound heterozygous. The prevalence is
approximately 1 in 1,000,000 in the general population and much higher in South Africa and
Eastern Quebec as a result of a founder effect. Patients respond minimally, or not at all, to TG-
lowering drugs (Tremblay et al., J Clin Lipidol, 2011, 5:37-44; Brisson et al., Pharmacogenet
Genom, 2010, 20:742-747) and hence restriction of dietary fat to 20 grams/day or less is used to
manage the symptoms of this rare disorder.
“Fredrickson Type II” is the most common form of primary hyperlipidemia. It is further
classified into Type 11a and Type IIb, depending mainly on whether there is elevation in VLDL in
addition to LDL cholesterol (LDL-C). Type IIa (familial holesterolemia) may be sporadic
(due to dietary factors), polygenic, or truly al as a result of a mutation in either the LDL
receptor gene on chromosome 19 (0.2% of the population) or the apolipoprotein B (apoB) gene
(0.2%). The familial form is characterized by tendon xanthoma, xanthelasma and premature
cardiovascular disease. The incidence of this disease is about 1 in 500 for heterozygotes, and 1 in
1,000,000 for homozygotes. Type IIb (also known as familial combined hyperlipoproteinemia) is
a mixed hyperlipidemia (high cholesterol and TG levels), caused by elevations in LDL-C and in
VLDL. The high VLDL levels are due to overproduction of substrates, including TG, acetyl
CoA, and an increase in B-100 sis. They may also be caused by the decreased clearance of
LDL. ence in the tion is about 10%.
“Fredrickson Type III” (also known as dysbetalipoproteinemia) is a remnant l
disease, or broad-beta disease (Fern el al., J Clin Pathol, 2008, 61:1174-118). It is due to
cholesterol-rich VLDL (B-VLDL). Typically, patients with this condition have elevated plasma
cholesterol and TG levels because of impaired clearance of chylomicron and VLDL ts
(e. g. IDL). The impaired nce is due to a defect in apolipoprotein E (apoE). Normally
functioning apoE contained on the remnants would enable binding to the LDL or and
removal from the circulation. lation of the remnants in affected individuals can result in
xanthomatosis and premature coronary and/or peripheral ar disease. The most common
cause for Type III is the presence of apoE E2/E2 genotype. Its prevalence has been estimated to
be approximately 1 in 10,000.
“Fredrickson Type IV” (also known as familial hypertriglyceridemia) is an autosomal
dominant condition occurring in approximately 1% of the tion. TG levels are elevated as a
result of excess hepatic production of VLDL or heterozygous LPL deficiency, but are almost
always less than 1000 mg/dL. Serum cholesterol levels are usually within normal limits. The
disorder is geneous and the phenotype strongly influenced by environmental factors,
ularly carbohydrate and ethanol consumption.
“Fredrickson Type V” has high VLDL and chylomicrons. It is characterized by carriers of
loss-of-fiinction LPL gene ts associated with LPL activity of at least 20% (i.e. partial LPL
deficiency as compared to Fredrickson Type I). These ts present with lactescent plasma and
severe hypertriglyceridemia because of chylomicrons and VLDL. TG levels are invariably
r than 1000 mg/dL and total cholesterol levels are always elevated. The LDL-C level is
usually low. It is also associated with increased risk for acute pancreatitis, glucose intolerance
and hyperuricemia. Symptoms generally present in adulthood (> 35years) and, gh the
prevalence is relatively rare, it is much more common than homozygous or compound
heterozygous LPL deficient ts.
“Fully complementary” or “100% complementary” means each nucleobase of a
nucleobase sequence of a first nucleic acid has a complementary nucleobase in a second
nucleobase sequence of a second nucleic acid. In certain embodiments, a first nucleic acid is an
antisense compound and a second nucleic acid is a target nucleic acid.
“Gapmer” means a chimeric nse compound in which an internal region having a
plurality of nucleosides that support RNase H cleavage is positioned n external regions
having one or more nucleosides, wherein the nucleosides comprising the internal region are
chemically distinct from the nucleoside or nucleosides comprising the external regions. The
internal region may be referred to as a “gap” or “gap segment” and the external regions may be
referred to as “wings” or “wing segments.”
“Gap-widened” means a chimeric nse compound having a gap segment of 12 or
more contiguous 2’-deoxyribonucleosides positioned between and immediately adjacent to 5’ and
3’ wing segments having from one to siX nucleosides.
“Glucose” is a monosaccharide used by cells as a source of energy and inflammatory
intermediate. a glucose” refers to glucose present in the plasma.
“High density lipoprotein-C (HDL-C)” means terol associated with high density
lipoprotein particles. Concentration C in serum (or plasma) is typically quantified in
mg/dL or nmol/L. “HDL-C” and “plasma HDL-C” mean HDL-C in serum and plasma,
tively.
“HMG—CoA reductase inhibitor” means an agent that acts through the tion of the
enzyme HlVlG—CoA reductase, such as atorvastatin, rosuvastatin, fluvastatin, lovastatin,
pravastatin, and simvastatin.
“Hybridization” means the annealing of complementary c acid molecules. In
certain embodiments, complementary c acid molecules include an antisense compound and
a target nucleic acid.
“Hypercholesterolemia” means a condition characterized by elevated cholesterol or
circulating (plasma) cholesterol, LDL-cholesterol and VLDL-cholesterol, as per the guidelines of
2O the Expert Panel Report of the National Cholesterol Educational Program (NCEP) of Detection,
Evaluation of Treatment of high cholesterol in adults (see, Arch. Int. Med. (1988) 148, 36-39).
“Hyperlipidemia” or “hyperlipemia” is a condition terized by elevated serum lipids
or circulating (plasma) lipids. This condition manifests an abnormally high concentration of fats.
The lipid fractions in the circulating blood are cholesterol, low density lipoproteins, very low
density lipoproteins, icrons and triglycerides. The Fredrickson classification of
hyperlipidemias is based on the pattern of TG and cholesterol-rich lipoprotein les, as
measured by electrophoresis or ultracentrifugation and is commonly used to terize y
causes of hyperlipidemias such as hypertriglyceridemia (Fredrickson and Lee, Circulation, 1965,
31:321-327; ckson et al., New Eng J Med, 1967, 276 (1): 34—42).
“Hypertriglyceridemia” means a condition characterized by elevated triglyceride levels.
Its etiology includes primary (i.e. genetic causes) and secondary (other underlying causes such as
diabetes, metabolic syndrome/insulin resistance, obesity, physical vity, cigarette smoking,
excess alcohol and a diet very high in carbohydrates) factors or, most often, a combination of
both (Yuan er a]. CMAJ, 2007, 176: l 1 13-1 120).
ifying” or “selecting an animal with metabolic or cardiovascular disease” means
identifying or selecting a subject prone to or having been diagnosed with a metabolic disease, a
cardiovascular disease, or a metabolic syndrome; or, identifying or selecting a subject having any
symptom of a lic disease, cardiovascular disease, or metabolic syndrome including, but
not limited to, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia,
ension increased insulin resistance, decreased n sensitivity, above normal body
weight, and/or above normal body fat content or any combination thereof Such identif1cation
can be accomplished by any , ing but not limited to, standard clinical tests or
assessments, such as measuring serum or circulating (plasma) cholesterol, measuring serum or
circulating (plasma) blood-glucose, measuring serum or ating (plasma) triglycerides,
ing blood-pressure, measuring body fat content, measuring body weight, and the like.
“Improved cardiovascular outcome” means a reduction in the occurrence of adverse
cardiovascular events, or the risk thereof Examples of adverse cardiovascular events include,
without limitation, death, reinfarction, stroke, cardiogenic shock, ary edema, cardiac
arrest, and atrial dysrhythmia.
“Immediately adjacent” means there are no intervening ts between the
immediately adjacent elements, for e, between regions, segments, nucleotides and/or
sides.
asing HDL” or “raising HDL” means increasing the level ofHDL in an animal after
administration of at least one compound of the invention, compared to the HDL level in an
animal not administered any compound.
“Individual” or “subject” or “animal” means a human or non-human animal selected for
ent or therapy.
“Induce”, “inhibit”, “potentiate77 (Lelevate77 (L 77 (L
7 7 increase”, “decrease reduce” or the like
denote quantitative differences between two states. For example, “an amount effective to inhibit
the activity or expression of ApoCIII” means that the level of activity or expression of ApoCIII in
a treated sample will differ from the level of ApoCIII activity or expression in an untreated
sample. Such terms are applied to, for example, levels of expression, and levels of activity.
“Inhibiting the expression or activity” refers to a reduction or blockade of the expression
or activity of a RNA or protein and does not necessarily indicate a total elimination of expression
or activity.
“Insulin resistance” is defined as the condition in which normal amounts of insulin are
inadequate to produce a normal insulin response from fat, muscle and liver cells. Insulin resistance
in fat cells results in hydrolysis of stored cerides, which es free fatty acids in the blood
plasma. Insulin resistance in muscle reduces glucose uptake whereas insulin resistance in liver
reduces glucose storage, with both effects serving to elevate blood glucose. High plasma levels of
insulin and glucose due to insulin resistance often leads to metabolic syndrome and type 2
diabetes.
“Insulin sensitivity” is a measure of how effectively an individual processes glucose. An
individual having high n sensitivity ively processes glucose whereas an individual
with low insulin sensitivity does not effectively process glucose.
“Internucleoside e” refers to the al bond between nucleosides.
“Intravenous administration” means administration into a vein.
“Linked nucleosides” means adjacent nucleosides which are bonded together.
“Lipid-lowering” means a reduction in one or more lipids in a subject. “Lipid-raising”
means an increase in a lipid (e.g., HDL) in a subject. Lipid-lowering or raising can occur
with one or more doses over time.
“Lipid-lowering therapy” or “lipid lowering agent” means a eutic regimen provided
to a subject to reduce one or more lipids in a subject. In certain embodiments, a lipid-lowering
therapy is provided to reduce one or more of CETP, ApoB, total cholesterol, LDL-C, VLDL-C,
IDL-C, L-C, triglycerides, small dense LDL particles, and Lp(a) in a t. Examples
of lipid-lowering therapy include statins, fibrates, MTP inhibitors.
“Lipoprotein”, such as VLDL, LDL and HDL, refers to a group of ns found in the
serum, plasma and lymph and are important for lipid transport. The chemical composition of each
lipoprotein differs in that the HDL has a higher tion of protein versus lipid, s the
VLDL has a lower proportion of protein versus lipid.
“Low density lipoprotein-cholesterol (LDL-C)” means cholesterol carried in low density
lipoprotein particles. Concentration ofLDL-C in serum (or plasma) is typically fied in
mg/dL or nmol/L. “Serum LDL-C” and “plasma LDL-C” mean LDL-C in the serum and plasma,
respectively.
“Major risk factors” refers to factors that contribute to a high risk for a particular disease
or condition. In certain embodiments, major risk s for ry heart disease include,
without limitation, cigarette smoking, hypertension, low HDL-C, family history of coronary heart
disease, age, and other factors disclosed herein.
“Metabolic disorder” or “metabolic e” refers to a ion characterized by an
alteration or disturbance in metabolic fiinction. “Metabolic” and “metabolism” are terms well
known in the art and generally include the whole range of mical processes that occur
within a living organism. Metabolic disorders include, but are not limited to, lycemia,
prediabetes, diabetes (type 1 and type 2), y, insulin resistance, metabolic syndrome and
dyslipidemia due to type 2 diabetes.
“Metabolic syndrome” means a condition characterized by a clustering of lipid and non-
lipid cardiovascular risk factors of metabolic origin. In certain embodiments, metabolic syndrome
is identified by the presence of any 3 of the following factors: waist circumference of greater than
102 cm in men or greater than 88 cm in women; serum triglyceride of at least 150 mg/dL; HDL-
C less than 40 mg/dL in men or less than 50 mg/dL in women; blood re of at least 130/85
mmHg; and fasting e of at least 110 mg/dL. These determinants can be readily measured in
clinical practice (JAMA, 2001, 285: 2486-2497).
“Mismatch” or omplementary base” refers to the case when a nucleobase of
a first nucleic acid is not capable of pairing with the corresponding nucleobase of a second or
target nucleic acid.
“Mixed dyslipidemia” means a condition characterized by elevated cholesterol and
elevated cerides.
“Modified internucleoside linkage” refers to a substitution or any change from a naturally
occurring internucleoside bond. For example, a phosphorothioate linkage is a modified
internucleoside linkage.
“Modified nucleobase” refers to any nucleobase other than adenine, cytosine, guanine,
thymidine, or uracil. For e, 5-methylcytosine is a modified nucleobase. An “unmodified
base” means the purine bases adenine (A) and guanine (G), and the pyrimidine bases
thymine (T), cytosine (C), and uracil (U).
“Modified nucleoside” means a nucleoside having at least one modified sugar moiety,
and/or modified nucleobase.
“Modified nucleotide” means a nucleotide having at least one modified sugar moiety,
modified internucleoside linkage and/or modified nucleobase.
“Modified oligonucleotide” means an oligonucleotide comprising at least one modified
tide.
“Modified sugar” refers to a substitution or change from a natural sugar. For example, a
ethoxyethyl modified sugar is a modified sugar.
“Motif’ means the n of chemically ct regions in an antisense compound.
“Naturally occurring internucleoside linkage” means a 3' to 5' phosphodiester linkage.
“Natural sugar moiety” means a sugar found in DNA (2’-H) or RNA (2’-OH).
“Nucleic acid” refers to molecules composed of monomeric nucleotides. A nucleic acid
includes ribonucleic acids (RNA), deoxyribonucleic acids (DNA), single-stranded nucleic acids
(ssDNA), double-stranded nucleic acids (dsDNA), small ering ribonucleic acids (siRNA),
and microRNAs ). A nucleic acid may also comprise a combination of these elements in
a single molecule.
“Nucleobase” means a cyclic moiety capable of pairing with a base of another
nucleic acid.
“Nucleobase complementarity” refers to a nucleobase that is capable of base pairing with
another nucleobase. For example, in DNA, adenine (A) is complementary to thymine (T). For
example, in RNA, adenine (A) is complementary to uracil (U). In certain embodiments,
mentary base refers to a nucleobase of an antisense compound that is capable of
base pairing with a nucleobase of its target nucleic acid. For example, if a base at a certain
on of an antisense compound is capable of hydrogen bonding with a nucleobase at a certain
position of a target nucleic acid, then the oligonucleotide and the target c acid are
considered to be mentary at that nucleobase pair.
“Nucleobase sequence” means the order of contiguous nucleobases independent of any
sugar, linkage, or nucleobase modification.
“Nucleoside” means a nucleobase linked to a sugar.
“Nucleoside mimetic” includes those ures used to replace the sugar or the sugar and
the base, and not necessarily the linkage at one or more positions of an oligomeric compound; for
example nucleoside mimetics haVing morpholino, cyclohexenyl, cyclohexyl, tetrahydropyranyl,
bicyclo or tricyclo sugar mimetics such as non-filranose sugar units.
“Nucleotide” means a nucleoside having a phosphate group covalently linked to the sugar
portion of the nucleoside.
“Nucleotide mimetic” includes those structures used to e the nucleoside and the
linkage at one or more positions of an oligomeric compound such as for example peptide nucleic
acids or morpholinos (morpholinos linked by -N(H)-C(=O)-O- or other non-phosphodiester
linkage).
“Oligomeric compound” or “oligomer” means a polymer of linked ric subunits
which is capable of izing to a region of a nucleic acid molecule. In certain embodiments,
oligomeric compounds are oligonucleosides. In certain embodiments, oligomeric nds are
oligonucleotides. In certain embodiments, oligomeric compounds are antisense compounds. In
certain ments, oligomeric compounds are antisense oligonucleotides. In certain
embodiments, oligomeric compounds are chimeric oligonucleotides.
“Oligonucleotide” means a polymer of linked nucleosides each of which can be modified
or unmodified, independent from one r.
“Parenteral administration” means stration through injection or infiision. Parenteral
administration includes subcutaneous administration, intravenous administration, intramuscular
administration, intraarterial administration, intraperitoneal administration, or ranial
administration, e. g. intrathecal or intracerebroventricular administration. Administration can be
continuous, chronic, short or intermittent.
“Peptide” means a le formed by linking at least two amino acids by amide bonds.
Peptide refers to ptides and proteins.
“Pharmaceutical agent” means a substance that provides a therapeutic benefit when
administered to an individual. For example, in certain embodiments, an antisense oligonucleotide
targeted to ApoCIII is pharmaceutical agent.
“Pharmaceutical composition” or sition” means a mixture of substances suitable
for administering to an individual. For example, a pharmaceutical composition may comprise
one or more active agents and a pharmaceutical carrier, such as a sterile aqueous solution.
“Pharmaceutically able carrier” means a medium or diluent that does not interfere
with the structure of the compound. Certain of such rs enable pharmaceutical compositions
to be formulated as, for example, tablets, pills, dragees, es, s, gels, syrups, slurries,
suspension and lozenges for the oral ingestion by a subject. Certain of such carriers enable
WO 49495
pharmaceutical compositions to be formulated for injection, infusion or topical administration.
For example, a pharmaceutically acceptable carrier can be a sterile aqueous solution.
“Pharmaceutically acceptable derivative” or “salts” encompasses derivatives of the
compounds described herein such as solvates, hydrates, esters, prodrugs, polymorphs, isomers,
isotopically labelled variants, pharmaceutically acceptable salts and other derivatives known in
the art.
“Pharmaceutically acceptable salts” means physiologically and ceutically
acceptable salts of antisense compounds, i.e., salts that retain the desired biological activity of the
parent nd and do not impart undesired toxicological effects thereto. The term
“pharmaceutically acceptable salt” or “salt” includes a salt prepared from pharmaceutically
acceptable non-toxic acids or bases, including inorganic or organic acids and bases.
“Pharmaceutically acceptable salts” of the compounds bed herein may be ed by
methods well-known in the art. For a review of pharmaceutically acceptable salts, see Stahl and
h, Handbook of Pharmaceutical Salts: Properties, Selection and Use -VCH,
Weinheim, Germany, 2002). Sodium salts of antisense oligonucleotides are useful and are well
accepted for eutic administration to humans. Accordingly, in one embodiment the
compounds described herein are in the form of a sodium salt.
“Phosphorothioate linkage” means a linkage between sides where the
phosphodiester bond is d by replacing one of the non-bridging oxygen atoms with a sulfur
2O atom. A phosphorothioate linkage is a modified ucleoside e.
“Portion” means a defined number of contiguous (i.e. linked) nucleobases of a nucleic
acid. In certain embodiments, a portion is a defined number of contiguous nucleobases of a
target nucleic acid. In certain embodiments, a portion is a defined number of contiguous
nucleobases of an antisense compound.
“Prevent” refers to delaying or forestalling the onset or development of a disease,
disorder, or condition for a period of time from minutes to itely. Prevent also means
reducing risk of developing a disease, disorder, or condition.
“Prodrug” means a therapeutic agent that is prepared in an inactive form that is converted
to an active form (i.e., a drug) within the body or cells f by the action of endogenous
enzymes or other chemicals or conditions.
“Raise” means to increase in amount. For example, to raise plasma HDL levels means to
increase the amount ofHDL in the plasma.
“Ratio of TG to HDL” means the TG levels relative to HDL . The occurrence of
high TG and/or low HDL has been linked to cardiovascular disease nce, outcomes and
mortality. ving the ratio of TG to HDL” means to se TG and/or raise HDL levels.
“Reduce” means to bring down to a r extent, size, amount, or number. For example,
to reduce plasma triglyceride levels means to bring down the amount of triglyceride in the
plasma.
“Region” or “target ” is defined as a portion of the target nucleic acid having at
least one identifiable structure, fiinction, or characteristic. For example, a target region may
encompass a 3’ UTR, a 5’ UTR, an exon, an intron, an exon/intron junction, a coding region, a
translation tion , translation termination region, or other defined nucleic acid region.
The structurally defined regions for ApoCIII can be obtained by accession number from sequence
databases such as NCBI and such information is incorporated herein by reference. In certain
embodiments, a target region may encompass the sequence from a 5’ target site of one target
segment within the target region to a 3’ target site of another target segment within the target
region.
“Ribonucleotide” means a nucleotide having a hydroxy at the 2’ position of the sugar
portion of the tide. Ribonucleotides can be modified with any of a variety of substituents.
“Second agent” or “second therapeutic agent” means an agent that can be used in
combination with a “first agent”. A second therapeutic agent can include, but is not limited to, an
siRNA or antisense oligonucleotide including antisense oligonucleotides targeting ApoCIII. A
second agent can also include anti-ApoCIII antibodies, ApoCIII peptide inhibitors, cholesterol
lowering agents, lipid ng agents, glucose lowering agents and anti-inflammatory agents.
“Segments” are defined as smaller, sub-portions of regions within a nucleic acid. For
example, a “target t” means the sequence of nucleotides of a target nucleic acid to which
one or more antisense compounds is targeted. “5’ target site” refers to the 5’-most tide of a
target segment. “3’ target site” refers to the t nucleotide of a target segment.
“Shortened” or “truncated” versions of antisense oligonucleotides or target nucleic acids
taught herein have one, two or more nucleosides d.
“Side effects” means physiological responses attributable to a treatment other than the
desired effects. In certain embodiments, side effects include ion site reactions, liver
function test abnormalities, renal function abnormalities, liver toxicity, renal toxicity, central
nervous system abnormalities, myopathies, and malaise. For example, increased
aminotransferase levels in serum may indicate liver toxicity or liver function abnormality. For
example, increased bilirubin may indicate liver toxicity or liver function abnormality.
“Single-stranded oligonucleotide” means an oligonucleotide which is not hybridized to a
complementary strand.
“Specifically hybridizable” refers to an antisense compound having a ient degree of
complementarity to a target nucleic acid to induce a desired effect, while exhibiting minimal or
no effects on non-target nucleic acids under conditions in which specific binding is d, i.e.
under physiological conditions in the case of in vivo assays and therapeutic treatments.
“Statin” means an agent that inhibits the activity of HlVlG—CoA reductase.
“Subcutaneous administration” means administration just below the skin.
“Subject” means a human or non-human animal ed for treatment or therapy.
“Symptom of cardiovascular disease or disorder” means a phenomenon that arises from
and accompanies the vascular disease or disorder and serves as an indication of it. For
example, angina; chest pain; shortness of breath; ations; ss; dizziness; nausea;
sweating; tachycardia; bradycardia; arrhythmia; atrial fibrillation; swelling in the lower
extremities; is; fatigue; fainting; numbness of the face; numbness of the limbs;
claudication or cramping of muscles; bloating of the abdomen; or fever are ms of
cardiovascular disease or disorder.
“Targeting” or “targeted” means the process of design and selection of an antisense
compound that will specif1cally hybridize to a target nucleic acid and induce a desired effect.
“Target c acid,” “target RNA,” and “target RNA transcript” all refer to a nucleic
acid capable of being targeted by antisense compounds.
“Therapeutic lifestyle ” means dietary and lifestyle changes intended to lower
fat/adipose tissue mass and/or cholesterol. Such change can reduce the risk of developing heart
disease, and may includes recommendations for dietary intake of total daily calories, total fat,
saturated fat, polyunsaturated fat, monounsaturated fat, ydrate, protein, cholesterol,
insoluble fiber, as well as recommendations for physical activity.
“Treat” refers to administering a compound of the invention to effect an alteration or
improvement of a disease, disorder, or condition.
“Triglyceride” or “TG” means a lipid or neutral fat consisting of ol ed with
three fatty acid molecules.
“Type 2 diabetes,” (also known as “type 2 diabetes mellitus”, tes mellitus, type 2”,
“non-insulin-dependent diabetes (NIDDM)”, “obesity d diabetes”, or “adult-onset
diabetes”) is a metabolic disorder that is primarily characterized by insulin resistance, relative
insulin deficiency, and hyperglycemia.
“Unmodified tide” means a nucleotide composed of naturally occurring
nucleobases, sugar moieties, and internucleoside linkages. In certain ments, an
unmodified nucleotide is an RNA tide (i.e. B-D-ribonucleosides) or a DNA nucleotide (i.e.
oxyribonucleoside).
“Wing segment” means one or a ity of nucleosides modified to impart to an
oligonucleotide properties such as enhanced inhibitory activity, increased binding affinity for a
target nucleic acid, or resistance to degradation by in vivo nucleases.
Certain Embodiments
Certain embodiments provide a method of reducing ApoCIII levels in an animal by
administering a compound to the animal targeting I, thereby decreasing ApoCIII levels. In
certain embodiments, ApoCIII levels are d in the liver or small intestine.
Certain embodiments provide a method of increasing HDL levels and/or improving the
ratio of TG to HDL in an animal by administering a compound to the animal wherein the
compound targets ApoCIII and increases HDL levels and/or improves the ratio of TG to HDL.
2O Certain ments provide a method of preventing, delaying or ameliorating a
cardiovascular disease, disorder, condition, or symptom thereof, in an animal comprising
administering a compound targeting ApoCIII to the animal, wherein the compound administered
to the animal prevents, treats or ameliorates the cardiovascular disease, disorder, condition or
m in the animal by increasing HDL levels in the animal and/or ing the ratio of TG
to HDL.
Certain ments provide a method of preventing, delaying or ameliorating a
pancreatitis in an animal comprising administering a compound targeting ApoCIII to the animal,
wherein the compound administered to the animal prevents, treats or ameliorates the atitis
in the animal by increasing HDL levels in the animal and/or improving the ratio of TG to HDL.
In certain embodiments, the pancreatitis is acute pancreatitis.
Certain embodiments provide a method of preventing, treating, ameliorating, ng the
onset, or reducing the risk of, a cardiovascular disease, disorder or condition in an animal,
comprising of administering to the animal a nd that targets ApoCIII, wherein the
compound prevents, treats, ameliorates, delays the onset, or reduces of the risk of the
cardiovascular disease, er or ion in the animal by increasing HDL levels in the
animal and/or improving the ratio of TG to HDL.
Certain embodiments provide a method of decreasing CETP levels by administering a
compound targeting ApoCIII to an .
Certain embodiments provide a method of increasing ApoAl, PONl, fat clearance,
chylomicron ceride clearance and/or HDL by administering a compound targeting ApoCIII
to an animal. Certain embodiments provide a method for improving the ratio of TG to HDL.
In certain embodiments, the ApoCIII nucleic acid is any of the sequences set forth in
GERBANK Accession No. NM_000040.1 (incorporated herein as SEQ ID NO: 1), and
GERBANK ion No. NT_O33899.8 truncated from nucleotides 20262640 to 20266603
porated herein as SEQ ID NO: 2).
In certain embodiments, the compound targeting ApoCIII is a d oligonucleotide.
In further embodiments, the modified oligonucleotide has a base sequence comprising at
least 8 contiguous nucleobases of ISIS 304801 (SEQ ID NO: 3). In certain embodiments, the
modified ucleotide is at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or
at least 100% complementary to SEQ ID NO: 1 or SEQ ID NO: 2.
In certain embodiments, the modified oligonucleotide consists of a single-stranded
modified oligonucleotide.
In certain embodiments, the modified oligonucleotide consists of 12-30 linked
nucleosides.
In certain embodiments, the modified oligonucleotide consists of 20 linked nucleosides.
In certain embodiments, the compound comprises at least one modified internucleoside
linkage. In certain embodiments, the internucleoside linkage is a phosphorothioate
internucleoside linkage.
In n embodiments, the compound comprises at least one nucleoside comprising a
modified sugar. In certain ments, the at least one modified sugar is a ic sugar. In
certain embodiments, the at least one d sugar comprises a 2’-O-methoxyethyl.
In certain embodiments, the compound comprises at least one nucleoside comprising a
modified nucleobase. In certain embodiments, the modified nucleobase is a 5-methylcytosine.
In certain embodiments, the compound comprising modified oligonucleotide comprises:
(i) a gap segment consisting of linked deoxynucleosides; (ii) a 5’ wing segment consisting of
linked nucleosides, (iii) a 3’ wing segment consisting of linked nucleosides, n the gap
segment is positioned immediately adjacent to and between the 5’ wing segment and the 3’ wing
segment and wherein each nucleoside of each wing segment comprises a modified sugar.
In certain embodiments, the compound comprising modified oligonucleotide comprises:
(i) a gap segment consisting of 8-12 linked deoxynucleosides; (ii) a 5’ wing segment ting
of l-5 linked nucleosides, (iii) a 3’ wing segment consisting of l-5 linked nucleosides, wherein
the gap segment is positioned ately adjacent to and between the 5’ wing segment and the
3’ wing segment, wherein each nucleoside of each wing segment comprises a ethoxyethyl
sugar, wherein each cytosine is a 5’-methylcytosine, and wherein each internucleoside linkage is
a phosphorothioate linkage.
In certain embodiments, the compound comprising modified oligonucleotide comprises:
(i) a gap segment consisting often linked ucleosides; (ii) a 5’ wing segment consisting of
five linked nucleosides, (iii) a 3’ wing segment consisting of five linked nucleosides, wherein the
gap segment is oned immediately adjacent to and between the 5’ wing segment and the 3’
wing segment, wherein each side of each wing segment comprises a 2’-O-methoxyethyl
sugar, wherein each ne is a 5’-methylcytosine, and wherein each internucleoside e is
a orothioate linkage.
In n embodiments, the modified oligonucleotide has a nucleobase sequence
comprising at least 8 contiguous bases of a nucleobase sequence of ISIS 304801 (SEQ ID
NO: 3).
Certain embodiments provide a method of reducing the risk of a cardiovascular disease in
an animal by administering to the animal a eutically effective amount of a compound
sing a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the
modified oligonucleotide is complementary to an ApoCIII nucleic acid and wherein the modified
oligonucleotide increases HDL levels and/or improves the ratio of TG to HDL. In certain
embodiments, the ApoCIII c acid is either SEQ ID NO: 1 or SEQ ID NO: 2. In certain
embodiments, the modified oligonucleotide is at least 80%, at least 85%, at least 90%, at least
95%, at least 98% or at least 100% complementary to SEQ ID NO: 1 or SEQ ID NO: 2. In r
embodiments the modified nucleotide comprises at least 8 contiguous nucleobases of the
nucleobase sequence of ISIS 304801 (SEQ ID NO: 3).
2012/035694
Certain embodiments e a method of preventing, treating, ameliorating, or reducing
at least one m of a cardiovascular disease in an animal, comprising administering to the
animal a therapeutically effective amount of a nd sing a modified oligonucleotide
consisting of 12 to 30 linked nucleosides and is complementary to an ApoCIII nucleic acid. In
certain embodiments, the ApoCIII nucleic acid is either SEQ ID NO: 1 or SEQ ID NO: 2. In
certain embodiments, the modified oligonucleotide is at least 80%, at least 85%, at least 90%, at
least 95%, at least 98% or at least 100% mentary to SEQ ID NO: 1 or SEQ ID NO: 2. In
further embodiments, the compound administered to the animal prevents, treats, ameliorates or
reduces at least one m of the vascular disease by increasing HDL levels and/or
improving the ratio of TG to HDL. In further embodiments, the modified oligonucleotide
comprises at least 8 contiguous nucleobases of ISIS 304801 (SEQ ID NO: 3).
In further embodiments, symptoms of a vascular disease include, but are not d
to, angina; chest pain; ess of breath; palpitations; weakness; dizziness; nausea; sweating;
tachycardia; ardia; arrhythmia; atrial fibrillation; swelling in the lower extremities;
is; fatigue; fainting; numbness of the face; numbness of the limbs; claudication or
cramping of muscles; bloating of the abdomen; or fever.
Certain embodiments provide a method of raising HDL levels and/or improving the ratio
of TG to HDL in an animal by administering to the animal a compound consisting of the
nucleobase sequence of ISIS 304801 (SEQ ID NO: 3). Further embodiments provide a method of
preventing, treating, ameliorating or reducing at least one symptom of a cardiovascular disease in
an animal by administering to the animal a compound consisting of the nucleobase sequence of
ISIS 304801 (SEQ ID NO: 3), thereby increasing the HDL levels and/or improving the ratio of
TG to HDL in the animal.
Certain embodiments provide a method of raising HDL levels and/or improving the ratio
of TG to HDL in an animal by administering to the animal a modified oligonucleotide having the
sequence of ISIS 304801, wherein the modified oligonucleotide comprises: (i) a gap segment
consisting often linked deoxynucleosides; (ii) a 5’ wing segment consisting of five linked
nucleosides; (iii) a 3’ wing segment consisting of five linked nucleosides, wherein the gap
t is positioned immediately adjacent to and between the 5’ wing segment and the 3’ wing
segment, wherein each nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar,
wherein each cytosine is a 5’-methylcytosine, and wherein each ucleoside linkage is a
phosphorothioate linkage.
Certain embodiments provide a method of preventing, treating, ameliorating, or ng
at least one symptom of a cardiovascular e in an animal by administering to the animal a
modified oligonucleotide having the sequence of ISIS 304801 (SEQ ID NO: 3), n the
modified oligonucleotide of the compound comprises: (i) a gap segment consisting often linked
deoxynucleosides; (ii) a 5’ wing segment consisting of five linked nucleosides; (iii) a 3’ wing
segment consisting of five linked nucleosides, wherein the gap segment is positioned
immediately adjacent to and between the 5’ wing segment and the 3’ wing segment, wherein each
nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar, n each ne is
a 5’-methylcytosine, and wherein each internucleoside linkage is a phosphorothioate linkage.
Certain embodiments provide a method of raising the HDL levels and/or improving the
ratio of TG to HDL in an animal by administering to the animal a compound comprising a
modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the modified
oligonucleotide is complementary to an ApoCIII nucleic acid. In certain embodiments, the
ApoCIII nucleic acid is either SEQ ID NO: 1 or SEQ ID NO: 2. In certain embodiments, the
modified oligonucleotide is at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or
at least 100% complementary to SEQ ID NO: 1 or SEQ ID NO: 2.
Certain embodiments provide a method of preventing, treating, ameliorating or reducing
at least one symptom of a cardiovascular disease in an animal by administering to the animal a
compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides,
n the modified ucleotide is complementary to an ApoCIII nucleic acid, and raises
the HDL levels in the animal. In certain ments, the ApoCIII nucleic acid is either SEQ ID
NO: 1 or SEQ ID NO: 2. In certain embodiments, the modified ucleotide is at least 80%, at
least 85%, at least 90%, at least 95%, at least 98% or at least 100% complementary to SEQ ID
NO: 1 or SEQ ID NO: 2.
Certain embodiments provide a method of decreasing CETP levels by administering a
compound ing ApoCIII to an animal. In certain embodiments, the compound comprises a
d oligonucleotide consisting of 12 to 30 linked sides, wherein the modified
oligonucleotide is complementary to an ApoCIII nucleic acid. In certain embodiments, the
ApoCIII nucleic acid is either SEQ ID NO: 1 or SEQ ID NO: 2. In certain embodiments, the
modified oligonucleotide is at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or
at least 100% complementary to SEQ ID NO: 1 or SEQ ID NO: 2. In certain embodiments, the
compound comprises a modified oligonucleotide ting of 12 to 30 linked nucleosides and
has a nucleobase sequence comprising at least 8 contiguous nucleobases of ISIS 304801 (SEQ ID
NO: 3). In certain embodiments, the compound consists of the nucleobases of ISIS 304801 (SEQ
ID NO: 3).
Certain embodiments provide a method of increasing ApoAl, PONl, fat clearance,
chylomicron triglyceride clearance and/or HDL by administering a compound targeting I
to an animal. In certain ments, the compound ses a modified oligonucleotide
consisting of 12 to 30 linked nucleosides, wherein the d oligonucleotide is
complementary to an ApoCIII nucleic acid. In certain embodiments, the ApoCIII nucleic acid is
either SEQ ID NO: 1 or SEQ ID NO: 2. In certain embodiments, the modified oligonucleotide is
at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 100%
complementary to SEQ ID NO: 1 or SEQ ID NO: 2. In certain embodiments, the compound
comprises a modified oligonucleotide ting of 12 to 30 linked nucleosides and has a
nucleobase sequence sing at least 8 contiguous nucleobases of ISIS 304801 (SEQ ID NO:
3). In certain embodiments, the compound consists of the nucleobases of ISIS 304801 (SEQ ID
NO: 3).
In certain embodiments, the animal is human.
In certain embodiments, the cardiovascular disease is aneurysm, angina, arrhythmia,
atherosclerosis, cerebrovascular disease, coronary heart disease, hypertension, dyslipidemia,
hyperlipidemia, hypertriglyceridemia or hypercholesterolemia. In certain embodiments, the
dyslipidemia is chylomicronemia.
In certain embodiments, the animal is at risk for pancreatitis. In certain ments,
reducing ApoCIII levels in the liver and/or small intestine prevents pancreatitis. In certain
embodiments, raising HDL levels and/or improving the ratio of TG to HDL prevents pancreatitis.
In certain embodiments, reducing ApoCIII levels in the liver and/or small intestine
e clearance of postprandial triglyceride. In certain embodiments, raising HDL levels
and/or ing the ratio of TG to HDL enhance clearance of andial triglyceride. In
certain embodiments, reducing ApoCIII levels in the liver and/or small intestine lowers
andial triglyceride. In certain ments, g HDL levels and/or improving the ratio
of TG to HDL lowers postprandial triglyceride.
In certain embodiments, reducing ApoCIII levels in the liver and/or small intestine
improves the ratio ofHDL to TG.
In certain ments, the nd is parenterally administered. In r
embodiments, the parenteral administration is subcutaneous.
In certain embodiments, the compound is co-administered with a second agent. In certain
embodiments, the second agent is a e-lowering agent. In certain embodiments, the second
agent is an LDL, TG or cholesterol lowering agent.
In certain ments, the compound and the second agent are administered
concomitantly or sequentially.
In certain embodiments, the compound is a salt form. In further embodiments, the
compound further comprises of a pharmaceutically acceptable carrier or diluent.
Certain embodiments provide use of a compound targeted to ApoCIII in the preparation
of a medicament for decreasing I levels in an animal. Certain embodiments provide use of
a compound targeted to ApoCIII for decreasing ApoCIII levels in an . In certain
embodiments, ApoCIII levels are decreased in the liver or small intestine. Certain embodiments
e use of a compound targeted to ApoCIII in the preparation of a medicament for for
preventing, treating, ameliorating or reducing at least one symptom of a cardiovascular e by
increasing HDL levels and/or improving the ratio of TG to HDL. Certain embodiments provide
use of a compound targeted to ApoCIII for preventing, treating, ameliorating or reducing at least
one symptom of a cardiovascular e by increasing HDL levels and/or improving the ratio of
TG to HDL. Certain embodiments provide a use of a compound ed to ApoCIII for
increasing HDL levels and/or improving the ratio of TG to HDL in an animal. Certain
embodiments provide a use of a compound targeted to ApoCIII for the preparation of a
ment for sing HDL levels and/or improving the ratio of TG to HDL in an animal. In
certain embodiments, the compound is at least 80%, at least 85%, at least 90%, at least 95%, at
least 98% or at least 100% complementary to an ApoCIII nucleic acid sequence. In certain
embodiments, the ApoCIII c acid is either SEQ ID NO: 1 or SEQ ID NO: 2. In certain
embodiments, the compound is a modified oligonucleotide. In certain embodiments, the modified
oligonucleotide has a nucleobase sequence comprising at least 8 nucleobases of ISIS 304801
(SEQ ID NO: 3). In certain embodiments, the modified oligonucleotide has the nucleobase
ce of ISIS 304801 (SEQ ID NO: 3).Certain embodiments provide use of a compound
targeted to ApoCIII in the preparation of a medicament for treating an animal with pancreatitis or
at risk for pancreatitis. Certain ments provide use of a compound targeted to ApoCIII for
treating an animal with pancreatitis or at risk for pancreatitis. Certain embodiments provide use
of a compound targeted to ApoCIII in the preparation of a medicament for reducing ApoCIII
levels in the liver and/or small intestine. Certain embodiments provide use of a compound
targeted to ApoCIII for reducing I levels in the liver and/or small intestine. Certain
embodiments provide use of a compound targeted to ApoCIII in the preparation of a medicament
for preventing atitis. Certain embodiments provide use of a nd targeted to ApoCIII
for preventing pancreatitis.
Certain embodiments provide use of a compound targeted to ApoCIII in the preparation
of a medicament for reducing ApoCIII levels in the liver and/or small intestine in an animal with
hypertriglyceridemia. Certain embodiments provide use of a compound targeted to ApoCIII for
reducing ApoCIII levels in the liver and/or small intestine in an animal with
hypertriglyceridemia. Certain embodiments provide use of a compound targeted to ApoCIII in
the ation of a ment for enhancing clearance of postprandial triglyceride. Certain
embodiments provide use of a compound targeted to ApoCIII for enhancing clearance of
postprandial triglyceride. Certain embodiments provide use of a compound targeted to ApoCIII
in the preparation of a medicament for lowering postprandial triglyceride. Certain embodiments
provide use of a compound targeted to ApoCIII for ng andial triglyceride.
Antisense Compounds
Oligomeric compounds include, but are not limited to, oligonucleotides, oligonucleosides,
2O oligonucleotide analogs, oligonucleotide mimetics, antisense compounds, antisense
oligonucleotides, and siRNAs. An oligomeric nd may be “antisense” to a target nucleic
acid, meaning that is capable of undergoing hybridization to a target nucleic acid through
hydrogen bonding.
In certain embodiments, an antisense compound has a nucleobase ce that, when
n in the 5’ to 3’ direction, comprises the reverse complement of the target segment of a
target nucleic acid to which it is targeted. In certain such embodiments, an antisense
ucleotide has a nucleobase sequence that, when written in the 5’ to 3’ direction, comprises
the reverse complement of the target segment of a target nucleic acid to which it is ed.
In n embodiments, an antisense compound ed to an ApoCIII nucleic acid is 12
to 30 nucleotides in length. In other words, antisense compounds are from 12 to 30 linked
nucleobases. In other embodiments, the antisense compound comprises a modified
ucleotide consisting of 8 to 80, 10 to 80, 12 to 50, 15 to 30, 18 to 24, 19 to 22, or 20 linked
nucleobases. In certain such embodiments, the antisense compound comprises a modified
oligonucleotide consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52,
53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78,
79, or 80 linked nucleobases in length, or a range defined by any two of the above values. In
some embodiments, the antisense compound is an nse oligonucleotide.
In certain embodiments, the antisense nd comprises a shortened or truncated
modified oligonucleotide. The shortened or truncated modified oligonucleotide can have one or
more nucleosides d from the 5’ end (5’ truncation), one or more nucleosides deleted from
the 3’ end (3’ truncation) or one or more nucleosides deleted from the central portion.
Alternatively, the deleted nucleosides may be sed throughout the modified oligonucleotide,
for example, in an antisense compound having one nucleoside deleted from the 5’ end and one
nucleoside deleted from the 3’ end.
When a single additional side is present in a lengthened oligonucleotide, the
additional nucleoside may be located at the central portion, 5’ or 3’ end of the oligonucleotide.
When two or more additional nucleosides are present, the added nucleosides may be adjacent to
each other, for example, in an ucleotide having two nucleosides added to the central
portion, to the 5’ end (5’ addition), or alternatively to the 3’ end (3’ addition), of the
oligonucleotide. Alternatively, the added nucleosides may be dispersed hout the nse
compound, for example, in an oligonucleotide having one nucleoside added to the 5’ end and one
subunit added to the 3’ end.
It is possible to increase or decrease the length of an antisense nd, such as an
nse oligonucleotide, and/or introduce mismatch bases without eliminating activity. For
example, in Woolf et al. (Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992), a series of antisense
ucleotides 13-25 nucleobases in length were tested for their ability to induce cleavage of a
target RNA in an oocyte injection model. Antisense oligonucleotides 25 nucleobases in length
with 8 or 11 mismatch bases near the ends of the antisense oligonucleotides were able to direct
specific cleavage of the target mRNA, albeit to a lesser extent than the antisense oligonucleotides
that contained no mismatches. Similarly, target specific cleavage was achieved using 13
nucleobase antisense oligonucleotides, including those with 1 or 3 mismatches.
Gautschi et al (J. Natl. Cancer Inst. 93:463-471, March 2001) demonstrated the ability of
an ucleotide having 100% complementarity to the bcl-2 mRNA and having 3 mismatches
to the bcl-XL mRNA to reduce the expression of both bcl-2 and bCl-XL in vitro and in vivo.
Furthermore, this oligonucleotide trated potent anti-tumor activity in viva.
Maher and Dolnick (Nuc. Acid. Res. l6:334l-3358,l988) tested a series oftandem 14
nucleobase antisense oligonucleotides, and 28 and 42 nucleobase antisense oligonucleotides
comprised of the sequence of two or three of the tandem antisense ucleotides, respectively,
for their ability to arrest ation of human DHFR in a rabbit reticulocyte assay. Each of the
three 14 base antisense oligonucleotides alone was able to inhibit translation, albeit at a
more modest level than the 28 or 42 nucleobase antisense oligonucleotides.
Antisense CompoundMotifs
In certain embodiments, antisense compounds targeted to an ApoCIII nucleic acid have
chemically modified subunits arranged in patterns, or motifs, to confer to the antisense
compounds properties such as ed inhibitory activity, sed binding affinity for a target
nucleic acid, or resistance to degradation by in vivo nucleases.
Chimeric antisense compounds typically contain at least one region modified so as to
confer increased resistance to nuclease degradation, increased cellular uptake, increased binding
affinity for the target nucleic acid, and/or increased inhibitory activity. A second region of a
chimeric nse compound may optionally serve as a substrate for the ar endonuclease
RNase H, which cleaves the RNA strand of an RNA: DNA dupleX.
2O Antisense compounds having a gapmer motif are considered chimeric antisense
compounds. In a gapmer an internal region having a plurality of tides that supports RNase
H cleavage is positioned between al regions having a plurality of nucleotides that are
chemically ct from the sides of the internal region. In the case of an antisense
oligonucleotide having a gapmer motif, the gap segment generally serves as the substrate for
endonuclease cleavage, while the wing ts comprise modified nucleosides. In certain
embodiments, the regions of a gapmer are differentiated by the types of sugar moieties
comprising each distinct region. The types of sugar es that are used to differentiate the
regions of a gapmer may in some embodiments include B-D-ribonucleosides, [3-D-
deoxyribonucleosides, 2'—modified nucleosides (such 2’-modified nucleosides may include 2’-
MOE, and 2’-O-CH3, among ), and bicyclic sugar modified nucleosides (such bicyclic
sugar modified sides may include those having a 4’-(CH2)n-O-2’ bridge, where n=1 or
n=2). Preferably, each distinct region comprises uniform sugar moieties. The wing-gap-wing
motif is ntly described as “X-Y-Z”, where “X” represents the length of the 5’ wing region,
“Y” represents the length of the gap region, and “Z” represents the length of the 3’ wing region.
As used herein, a gapmer described as “X-Y-Z” has a configuration such that the gap segment is
positioned immediately adjacent to each of the 5’ wing segment and the 3’ wing segment. Thus,
no intervening nucleotides exist n the 5’ wing segment and gap segment, or the gap
segment and the 3’ wing segment. Any of the antisense compounds described herein can have a
gapmer motif. In some embodiments, X and Z are the same; in other embodiments they are
different. In a preferred embodiment, Y is between 8 and 15 nucleotides. X, Y or Z can be any of
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,
30 or more nucleotides. Thus, gapmers include, but are not limited to, for example , 44,
412—3, 4—124, 314—3, 213—5, 22, 11, 310—3, 210—2, 11,22, 66, 55, 11,
22, 2132, 12, 23, 3102, 12 or 22.
In certain embodiments, the antisense compound as a “wingmer” motif, haVing a wing-
gap or ng configuration, i.e. an X-Y or Y-Z configuration as described above for the
gapmer configuration. Thus, wingmer configurations include, but are not limited to, for example
-10,8-4,4-12,12-4,3-14,16-2,18-1,10-3,2-10,1-10,8-2,2-13 or 5—13.
In certain embodiments, antisense compounds targeted to an I nucleic acid possess
a 55 gapmer motif
In certain embodiments, an antisense compound targeted to an ApoCIII nucleic acid has a
gap-widened motif
Target Nucleic Acids, Target Regions and Nucleotide Sequences
Nucleotide sequences that encode I include, without limitation, the following:
GERBANK Accession No. NM_000040.1 (incorporated herein as SEQ ID NO: 1), and
K Accession No. NT_O33899.8 truncated from nucleotides 20262640 to 20266603
(incorporated herein as SEQ ID NO: 2).
It is understood that the sequence set forth in each SEQ ID NO in the es ned
herein is independent of any modification to a sugar moiety, an internucleoside linkage, or a
nucleobase. As such, nse nds defined by a SEQ ID NO may se,
independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a
nucleobase. Antisense compounds described by Isis Number (Isis No) indicate a combination of
nucleobase sequence and motif
2012/035694
In certain embodiments, a target region is a structurally defined region of the target
nucleic acid. For example, a target region may encompass a 3’ UTR, a 5’ UTR, an exon, an
intron, an ntron junction, a coding region, a translation initiation region, translation
ation region, or other defined nucleic acid region. The structurally defined regions for
I can be obtained by accession number from sequence databases such as NCBI and such
information is incorporated herein by reference. In certain embodiments, a target region may
encompass the ce from a 5’ target site of one target segment within the target region to a
3’ target site of another target segment within the target region.
In certain embodiments, a “target segment” is a smaller, sub-portion of a target region
within a nucleic acid. For example, a target t can be the sequence of nucleotides of a
target nucleic acid to which one or more antisense compounds are targeted. “5’ target site” refers
to the 5’-most nucleotide of a target segment. “3’ target site” refers to the 3’-most nucleotide of a
target segment.
A target region may contain one or more target segments. Multiple target segments within
a target region may be overlapping. Alternatively, they may be non-overlapping. In certain
embodiments, target segments within a target region are separated by no more than about 300
nucleotides. In certain ments, target segments within a target region are separated by a
number of nucleotides that is, is about, is no more than, is no more than about, 250, 200, 150,
100, 90, 80, 70, 60, 50, 40, 30, 20, or 10 nucleotides on the target nucleic acid, or is a range
defined by any two of the preceding values. In certain embodiments, target ts within a
target region are separated by no more than, or no more than about, 5 nucleotides on the target
nucleic acid. In certain embodiments, target segments are contiguous. Contemplated are target
regions defined by a range haVing a starting nucleic acid that is any of the 5’ target sites or 3’
target sites listed, herein.
Targeting includes determination of at least one target segment to which an nse
compound hybridizes, such that a desired effect occurs. In certain embodiments, the desired
effect is a reduction in mRNA target nucleic acid levels. In certain embodiments, the desired
effect is reduction of levels of n encoded by the target nucleic acid or a phenotypic change
associated with the target nucleic acid.
le target segments may be found within a 5’ UTR, a coding region, a 3’ UTR, an
intron, an exon, or an exon/intron junction. Target segments containing a start codon or a stop
codon are also suitable target segments. A suitable target segment may specifically exclude a
certain structurally defined region such as the start codon or stop codon.
The ination of suitable target segments may include a comparison of the sequence
of a target nucleic acid to other sequences throughout the genome. For example, the BLAST
algorithm may be used to identify regions of rity amongst different nucleic acids. This
comparison can prevent the selection of antisense compound sequences that may hybridize in a
non-specific manner to sequences other than a selected target nucleic acid (i.e., non-target or off-
target sequences).
There can be variation in activity (e.g., as defined by percent reduction of target nucleic
acid levels) of the antisense compounds within an active target region. In certain embodiments,
ions in ApoCIII mRNA levels are indicative of inhibition of ApoCIII expression.
Reductions in levels of an ApoCIII n can be indicative of inhibition of target mRNA
sion. Further, phenotypic changes can be indicative of inhibition of I expression.
For example, an increase in HDL levels, decrease in LDL levels, or se in triglyceride
levels, are among phenotypic changes that may be assayed for inhibition of ApoCIII expression.
Other phenotypic indications, e. g., symptoms associated with a cardiovascular disease, may also
be assessed; for example, angina; chest pain; ess of breath; palpitations; weakness;
dizziness; ; sweating; ardia; bradycardia; arrhythmia; atrial fibrillation; swelling in
the lower extremities; cyanosis; fatigue; fainting; numbness of the face; numbness of the limbs;
claudication or cramping of s; bloating of the abdomen; or fever.
Hybridization
In some embodiments, hybridization occurs between an antisense compound disclosed
herein and an ApoCIII c acid. The most common mechanism of hybridization involves
hydrogen bonding (e.g., Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding)
between complementary nucleobases of the nucleic acid molecules.
ization can occur under g conditions. Stringent conditions are sequence-
dependent and are determined by the nature and ition of the nucleic acid molecules to be
hybridized.
Methods of determining whether a ce is specifically hybridizable to a target nucleic
acid are well known in the art (Sambrooke and Russell, Molecular Cloning: A Laboratory
Manual, 3rd Ed, 2001). In certain ments, the antisense compounds ed herein are
specifically izable with an ApoCIII nucleic acid.
Complementarity
An antisense compound and a target nucleic acid are complementary to each other when a
sufficient number of nucleobases of the antisense compound can hydrogen bond with the
corresponding bases of the target nucleic acid, such that a desired effect will occur (e.g.,
antisense inhibition of a target nucleic acid, such as an ApoCIII nucleic acid).
An antisense compound may hybridize over one or more segments of an ApoCIII nucleic
acid such that intervening or adjacent segments are not involved in the hybridization event (e.g., a
loop structure, mismatch or hairpin structure).
In certain embodiments, the antisense compounds provided herein, or a specified portion
thereof, are, or are at least, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to an ApoCIII nucleic acid, a target
region, target segment, or specified portion thereof. Percent complementarity of an antisense
compound with a target nucleic acid can be determined using routine s.
For e, an antisense compound in which 18 of 20 nucleobases of the antisense
compound are complementary to a target region, and would therefore specifically ize,
would represent 90 percent complementarity. In this example, the ing mplementary
nucleobases may be clustered or interspersed with mentary nucleobases and need not be
contiguous to each other or to complementary nucleobases. As such, an antisense compound
which is 18 nucleobases in length having 4 (four) mplementary nucleobases which are
flanked by two regions of complete complementarity with the target nucleic acid would have
77.8% overall complementarity with the target nucleic acid and would thus fall within the scope
of the present invention. Percent complementarity of an antisense compound with a region of a
target nucleic acid can be determined routinely using BLAST ms (basic local alignment
search tools) and PowerBLAST programs known in the art (Altschul et al., J. Mol. Biol, 1990,
215, 403 410; Zhang and , Genome Res, 1997, 7, 649 656). Percent homology, sequence
identity or complementarity, can be determined by, for example, the Gap program (Wisconsin
Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research
Park, Madison Wis), using default settings, which uses the algorithm of Smith and Waterman
(Adv. Appl. Math., 1981, 2, 482-489).
In certain embodiments, the antisense compounds provided herein, or specified portions
thereof, are fillly complementary (i.e. 100% complementary) to a target c acid, or specified
portion thereof. For example, an antisense compound may be fully complementary to an
ApoCIII c acid, or a target region, or a target segment or target sequence thereof. As used
, “fully complementary” means each nucleobase of an antisense nd is capable of
precise base pairing with the ponding nucleobases of a target nucleic acid. For example, a
nucleobase antisense compound is fully complementary to a target sequence that is 400
nucleobases long, so long as there is a corresponding 20 nucleobase portion of the target nucleic
acid that is fillly complementary to the antisense compound. Fully complementary can also be
used in nce to a specified portion of the first and /or the second nucleic acid. For example, a
nucleobase portion of a 30 nucleobase antisense compound can be “fiilly complementary” to a
target sequence that is 400 nucleobases long. The 20 nucleobase portion of the 30 nucleobase
oligonucleotide is fully complementary to the target sequence if the target sequence has a
corresponding 20 nucleobase portion n each nucleobase is complementary to the 20
base portion of the antisense compound. At the same time, the entire 30 nucleobase
antisense compound may or may not be fully complementary to the target sequence, depending
on whether the remaining 10 nucleobases of the antisense compound are also complementary to
the target sequence.
The location of a non-complementary nucleobase(s) can be at the 5’ end or 3’ end of the
2O antisense compound. Alternatively, the non-complementary base(s) can be at an internal
position of the antisense compound. When two or more non-complementary nucleobases are
present, they can be contiguous (i.e. linked) or non-contiguous. In one embodiment, a non-
complementary nucleobase is located in the wing segment of a gapmer antisense ucleotide.
In certain embodiments, antisense compounds that are, or are up to, 12, 13, 14, 15, 16, 17,
18, 19, or 20 nucleobases in length comprise no more than 4, no more than 3, no more than 2, or
no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as an
ApoCIII nucleic acid, or specified portion thereof
In certain embodiments, nse compounds that are, or are up to, 12, 13, 14, 15, 16, 17,
18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length comprise no more than
6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non-
complementary nucleobase(s) relative to a target nucleic acid, such as an I c acid, or
specified portion thereof
The antisense compounds provided herein also e those which are complementary to
a portion of a target nucleic acid. As used herein, “portion” refers to a defined number of
contiguous (i.e. linked) nucleobases within a region or segment of a target nucleic acid. A
“portion” can also refer to a defined number of contiguous nucleobases of an antisense
compound. In certain embodiments, the antisense compounds are complementary to at least an 8
base portion of a target segment. In certain embodiments, the antisense compounds are
complementary to at least a 10 base n of a target t. In certain embodiments,
the antisense compounds are complementary to at least a 12 nucleobase portion of a target
segment. In certain embodiments, the antisense compounds are complementary to at least a 15
nucleobase portion of a target segment. Also contemplated are antisense compounds that are
complementary to at least a 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleobase
portion of a target segment, or a range defined by any two of these values.
Identity
The antisense nds provided herein may also have a defined percent identity to a
particular nucleotide sequence, SEQ ID NO, or ce of a compound represented by a
specific Isis number, or portion thereof. As used herein, an antisense compound is identical to the
sequence disclosed herein if it has the same nucleobase pairing ability. For example, a RNA
which contains uracil in place of thymidine in a disclosed DNA sequence would be considered
identical to the DNA sequence since both uracil and thymidine pair with adenine. Shortened and
lengthened versions of the antisense compounds described herein as well as nds having
non-identical bases ve to the antisense nds provided herein also are contemplated.
The non-identical bases may be adjacent to each other or dispersed throughout the antisense
compound. Percent identity of an antisense compound is calculated according to the number of
bases that have identical base g relative to the sequence to which it is being ed.
In certain embodiments, the nse compounds, or portions thereof, are at least 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to one or more of the
antisense compounds or SEQ ID NOs, or a portion thereof, disclosed herein.
Modifications
A nucleoside is a base-sugar combination. The nucleobase (also known as base) portion
of the nucleoside is normally a heterocyclic base . Nucleotides are nucleosides that further
e a phosphate group covalently linked to the sugar portion of the nucleoside. For those
nucleosides that include a pentofiiranosyl sugar, the phosphate group can be linked to the 2', 3' or
' hydroxyl moiety of the sugar. Oligonucleotides are formed through the nt linkage of
adjacent nucleosides to one another, to form a linear polymeric oligonucleotide. Within the
oligonucleotide structure, the ate groups are commonly ed to as forming the
internucleoside linkages of the oligonucleotide.
Modifications to antisense compounds encompass substitutions or changes to
internucleoside es, sugar moieties, or nucleobases. Modified antisense compounds are
often preferred over native forms because of desirable ties such as, for example, enhanced
cellular , enhanced affinity for nucleic acid target, increased stability in the presence of
nucleases, or increased inhibitory activity.
Chemically modified nucleosides can also be employed to increase the binding affinity of
a ned or truncated antisense oligonucleotide for its target nucleic acid. Consequently,
comparable results can often be obtained with shorter antisense compounds that have such
chemically modified nucleosides.
Modified Inlernucleosz'de Linkages
The naturally ing internucleoside linkage ofRNA and DNA is a 3' to 5'
phosphodiester linkage. Antisense compounds having one or more modified, i.e. turally
occurring, internucleoside linkages are often selected over nse compounds having naturally
occurring internucleoside linkages because of desirable properties such as, for example, ed
cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence
of nucleases.
Oligonucleotides having modified internucleoside linkages e internucleoside
linkages that retain a phosphorus atom as well as internucleoside es that do not have a
phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are
not limited to, phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidate, and
phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-
ning linkages are well known.
In certain embodiments, antisense nds targeted to an ApoCIII nucleic acid
comprise one or more modified internucleoside linkages. In certain ments, the modified
internucleoside linkages are phosphorothioate linkages. In certain embodiments, each
internucleoside linkage of an antisense compound is a orothioate internucleoside linkage.
Modified Sugar Moielies
Antisense nds of the invention can optionally contain one or more nucleosides
wherein the sugar group has been modified. Such sugar modified nucleosides may impart
enhanced nuclease stability, increased g affinity, or some other beneficial biological
property to the antisense compounds. In certain embodiments, nucleosides comprise ally
modified ribofiiranose ring moieties. es of chemically modified ribofiiranose rings
include without limitation, addition of substitutent groups (including 5' and 2' substituent groups,
bridging of non-geminal ring atoms to form bicyclic nucleic acids (BNA), replacement of the
ribosyl ring oxygen atom with S, N(R), or C(R1)(R2) (R, R1 and R2 are each independently H, C1-
C12 alkyl or a protecting group) and combinations thereof. Examples of chemically modified
sugars include 2'—F-5'—methyl substituted nucleoside (see PCT International Application WC
2008/101 157 Published on 8/21/08 for other disclosed 5',2'-bis substituted nucleosides) or
replacement of the ribosyl ring oxygen atom with S with further tution at the 2'—position
(see published US. Patent Application US2005-0130923, published on June 16, 2005) or
alternatively stitution of a BNA (see PCT International Application WC 2007/134181
hed on 11/22/07 wherein LNA is tuted with for example a 5'-methyl or a 5'-vinyl
group).
Examples of nucleosides having modified sugar moieties include without limitation
nucleosides comprising 5'-vinyl, 5'-methyl (R or S), 4'—S, 2'-F, 3, 2’-OCH2CH3, 2’-
OCH2CH2F and 2'—O(CH2)2OCH3 substituent groups. The substituent at the 2’ position can also
be ed from allyl, amino, azido, thio, O-allyl, O-Cl-Clo alkyl, OCF3, OCHzF, 2SCH3,
O(CH2)2-O-N(Rm)(Rn), O-CH2-C(=O)-N(Rm)(Rn), and O-CH2-C(=0)-N(R1)-(CH2)2-N(Rm)(Rn),
where each R1, RIn and RH is, independently, H or substituted or unsubstituted C1-C10 alkyl.
As used herein, lic nucleosides” refer to modified nucleosides comprising a
bicyclic sugar moiety. Examples of bicyclic nucleosides include without limitation nucleosides
comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments,
antisense nds provided herein include one or more bicyclic nucleosides comprising a 4’
to 2’ bridge. Examples of such 4’ to 2’ bridged bicyclic nucleosides, include but are not d
to one of the formulae: 4'—(CH2)—O-2' (LNA); 4'—(CH2)-S-2'; 4'—(CH2)2-O-2' (ENA); CH3)-
O-2' and 4'—CH(CH20CH3)-O-2' (and analogs thereof see US. Patent 845, issued on July
, 2008); 4'—C(CH3)(CH3)-O-2' (and analogs thereof see published International Application
WO/2009/006478, published January 8, 2009); 4'-CH2-N(OCH3)-2' (and analogs thereof see
published International Application WO/2008/150729, published er 11, 2008); 4'-CH2-O-
N(CH3)-2' (see published US. Patent Application US2004-0171570, published September 2,
2004 ); 4'-CH2-N(R)-O-2', wherein R is H, C1-C12 alkyl, or a protecting group (see US. Patent
7,427,672, issued on September 23, 2008); 4'-CH2-C(H)(CH3)-2' (see padhyaya el al., J.
Org. Chem, 2009, 74, 118-134); and 4'-CH2-C(=CH2)-2' (and analogs thereof see published
International Application WC 2008/154401, published on December 8, 2008).
Further reports related to bicyclic nucleosides can also be found in published literature
(see for example: Singh el al., Chem. Commun, 1998, 4, 455-456; Koshkin el 61]., edron,
1998, 54, 3607-3630; tedt el 61]., Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 638;
Kumar el al., . Med. Chem. Left, 1998, 8, 2219-2222; Singh el al., J. Org. Chem, 1998,
63, 10039; SriVastava el al., J. Am. Chem. Soc., 2007, 129(26) 8362-8379; Elayadi el 61].,
Curr. Opinion Invest. Drugs, 2001, 2, 558-561; Braasch el 61]., Chem. Biol, 2001, 8, l-7; and
Drum el 61]., Curr. Opinion Mol. Ther., 2001, 3, 239-243; US. Patent Nos. 6,268,490; 6,525,191;
6,670,461; 6,770,748; 6,794,499; 7,034,133; 7,053,207; 7,399,845; 7,547,684; and 7,696,345;
US. Patent Publication No. US2008-00396l8; US2009-001228l; US. Patent Serial Nos.
60/989,574; 61/026,995; 61/026,998; 61/056,564; 61/086,231; 61/097,787; and 61/099,844;
hed PCT International applications ; WC 2004/1063 56; WO
2005/021570; ; ; ; and WO 06478.
Each of the foregoing bicyclic nucleosides can be prepared haVing one or more stereochemical
sugar configurations including for example bofuranose and B-D-ribofuranose (see PCT
international application 98/00393, published on March 25, 1999 as W0 99/14226).
In certain embodiments, bicyclic sugar moieties ofBNA nucleosides include, but are not
limited to, nds haVing at least one bridge between the 4' and the 2’ position of the
pentofilranosyl sugar moiety n such bridges independently ses 1 or from 2 to 4
linked groups independently selected from -[C(Ra)(Rb)]n-, -C(Ra)=C(Rb)-, -C(Ra)=N-, -C(=O)-,
-C(= a): -C(=S)-a , -Si(Ra)2-, -S(=0)x-. and -N(Ra)-;
wherein:
X is 0, l, or 2;
n is l, 2, 3, or 4;
each Ra and Rb is, independently, H, a protecting group, hydroxyl, C1-C12 alkyl,
substituted C1-C12 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted
C2-C12 alkynyl, C5-C20 aryl, substituted C5-C20 aryl, heterocycle radical, substituted heterocycle
radical, heteroaryl, substituted heteroaryl, C5-C7 alicyclic radical, substituted C5-C7 alicyclic
radical, halogen, OJ1, NJ1J2, SJ1, N3, COOJ1, acyl (C(=O)—H), substituted acyl, CN, sulfonyl
(S(=O)2-J1), or sulfoxyl (S(=O)-J1); and
each J1 and J2 is, ndently, H, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl,
substituted C2-C12 alkenyl, C2-C12 alkynyl, tuted C2-C12 alkynyl, C5-C20 aryl, substituted
C5-C20 aryl, acyl (C(=O)-H), substituted acyl, a heterocycle radical, a substituted cycle
radical, C1-C12 aminoalkyl, substituted C1-C12 lkyl or a protecting group.
In certain embodiments, the bridge of a bicyclic sugar moiety is -[C(Ra)(Rb)]n-,
-[C(Ra)(Rb)]n-O-, -C(RaRb)-N(R)-O- or —C(RaRb)-O-N(R)-. In certain embodiments, the bridge is
4'—CH2-2', 4'—(CH2)2-2', 4'—(CH2)3-2', -O-2', 4'—(CH2)2-O-2', 4'-CH2-O-N(R)-2' and 4'—CH2-
N(R)—O-2'— wherein each R is, independently, H, a protecting group or C1-C12 alkyl.
In certain ments, bicyclic nucleosides are further defined by isomeric
configuration. For example, a nucleoside comprising a 4’-2’ methylene-oxy bridge, may be in
the d-L configuration or in the [3-D ration. Previously, d-L-methyleneoxy (4’-CH2-O-2’)
BNA's have been incorporated into antisense oligonucleotides that showed antisense actiVity
(Frieden el al., Nucleic Acids Research, 2003, 21 , 63 65-63 72).
In certain embodiments, bicyclic nucleosides include, but are not limited to, (A) d-L-
methyleneoxy (4’-CH2-O-2’) BNA BNA
, (B) thyleneoxy (4’-CH2-O-2’) , (C)
ethyleneoxy (4’-(CH2)2-O-2’) BNA , (D) xy (4’-CH2-O-N(R)-2’) BNA, (E) oxyamino
(4’-CH2-N(R)-O-2’) BNA, and (F) methyl(methyleneoxy) (4’-CH(CH3)-O-2’) BNA, (G)
methylene-thio (4’-CH2-S-2’) BNA, (H) methylene-amino (4’-CH2-N(R)-2’) BNA, (1) methyl
carbocyclic (4’-CH2-CH(CH3)-2’) BNA, and (J) propylene carbocyclic H2)3-2’) BNA as
depicted below.
(A) (B) (C)
E O BX
H3C \o
E O BX E O BX E O BX E O BX
(G) (H)R (D
wherein BX is the base moiety and R is independently H, a protecting group or C1-C12 alkyl.
In certain embodiments, bicyclic nucleosides are provided having Formula I:
wherein:
BX is a heterocyclic base moiety;
-Qa-Qb-Qc- is -CH2-N(Rc)-CH2-, -C(=O)-N(Rc)-CH2-, -N(RC)-, -CH2-N(Rc)-O- or -
N(Rc)'O'CH2;
RC is C1-C12 alkyl or an amino protecting group; and
Ta and Tb are each, independently H, a hydroxyl protecting group, a conjugate group, a
reactive phosphorus group, a phosphorus moiety or a covalent attachment to a support medium.
In certain ments, bicyclic sides are provided having Formula II:
2012/035694
wherein:
BX is a cyclic base moiety;
Ta and Tb are each, independently H, a hydroxyl protecting group, a conjugate group, a
reactive phosphorus group, a phosphorus moiety or a covalent attachment to a support medium;
Za is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, tuted C1-C6 alkyl, substituted C2-C6
alkenyl, substituted C2-C6 alkynyl, acyl, substituted acyl, substituted amide, thiol or substituted
thio.
In one embodiment, each of the substituted groups is, independently, mono or poly
tuted with substituent groups independently selected from halogen, oxo, yl, OJC,
NJch, SIC, N3, OC(=X)JC, and NJeC(=X)NJch, wherein each Jc, Id and I6 is, independently, H, C1-
C6 alkyl, or substituted C1-C6 alkyl and X is O or NJC.
In certain embodiments, bicyclic nucleosides are provided having Formula III:
o BX
o \0
I III
Tb
wherein:
BX is a heterocyclic base moiety;
Ta and Tb are each, independently H, a hydroxyl protecting group, a conjugate group, a
reactive phosphorus group, a orus moiety or a covalent attachment to a support medium;
Zb is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, substituted C1-C6 alkyl, substituted C2-C6
l, substituted C2-C6 alkynyl or substituted acyl (C(=O)-).
In certain embodiments, bicyclic nucleosides are provided having Formula IV:
qa qb
Ta_0 BX
O/Tb
1?] IV
wherein:
BX is a heterocyclic base moiety;
Ta and Tb are each, independently H, a hydroxyl protecting group, a conjugate group, a
ve phosphorus group, a phosphorus moiety or a covalent attachment to a support medium;
Rdis C1-C6 alkyl, substituted C1-C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6
alkynyl or substituted C2-C6 alkynyl,
each qa, qb, qc and qd is, independently, H, halogen, C1-C6 alkyl, substituted C1-C6 alkyl,
C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 l or substituted C2-C6 alkynyl, C1-C6
alkoxyl, substituted C1-C6 alkoxyl, acyl, substituted acyl, C1-C6 lkyl or substituted C1-C6
aminoalkyl;
In certain embodiments, bicyclic sides are provided having Formula V:
Ta—O BX
O—Tb
wherein:
BX is a heterocyclic base moiety;
Ta and Tb are each, ndently H, a hydroxyl protecting group, a conjugate group, a
reactive phosphorus group, a orus moiety or a covalent attachment to a support medium;
qa, qb, qe and qf are each, independently, hydrogen, halogen, C1-C12 alkyl, substituted C1-
C12 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl,
C1-C12 alkoxy, substituted C1-C12 , OJj, SJj, SOJj, SOZJj, NJij, N3, CN, C(=O)OJ-,
C(=O)NJij, C(=O)Jj, O-C(=O)NJij, N(H)C(=NH)NJij, N(H)C(=O)NJij orN(H)C(=S)NJij;
or qe and qf together are =C(qg)(qh);
qg and qh are each, independently, H, halogen, C1-C12 alkyl or substituted C1-C12 alkyl.
The synthesis and preparation of the methyleneoxy (4’-CH2-O-2’) BNA monomers
adenine, cytosine, guanine, 5-methyl-cytosine, thymine and uracil, along with their
oligomerization, and c acid recognition properties have been described (Koshkin el al.,
edron, 1998, 54, 3607-3630). BNAs and preparation thereof are also described in WO
98/39352 and WO 99/14226.
Analogs of methyleneoxy 2-O-2’) BNA and 2'—thio-BNAs, have also been
prepared (Kumar el al., Bioorg. Med. Chem. Left, 1998, 8, 222). Preparation of locked
nucleoside analogs comprising oligodeoxyribonucleotide duplexes as substrates for nucleic acid
polymerases has also been described (Wengel el al., W0 99/14226 ). Furthermore, synthesis of
2'—amino-BNA, a novel comformationally restricted high-affinity oligonucleotide analog has been
described in the art (Singh el al., J. Org. Chem., 1998, 63, 1003 5-10039). In addition, 2'-amino-
and 2'—methylamino-BNA's have been prepared and the thermal stability of their duplexes with
complementary RNA and DNA s has been previously reported.
In certain embodiments, bicyclic sides are provided having Formula VI:
Ta_0 BX
O‘Tb
(lj VI
wherein:
BX is a heterocyclic base moiety;
Ta and Tb are each, independently H, a hydroxyl protecting group, a conjugate group, a
reactive orus group, a phosphorus moiety or a nt attachment to a support medium;
each qi, qj, qk and q1 is, independently, H, halogen, C1-C12 alkyl, substituted C1-C12 alkyl,
C2-C12 alkenyl, tuted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, C1-C12
alkoxyl, substituted C1-C12 alkoxyl, OJj, SJj, SOJj, SOZJj, NJij, N3, CN, C(=O)OJj, C(=O)NJij,
C(=O)Jj, O-C(=O)NJij, N(H)C(=NH)NJij, N(H)C(=O)NJij C(=S)NJij; and
qi and qJ- or ql and qk together are =C(qg)(qh), wherein qg and qh are each, independently,
H, halogen, C1-C12 alkyl or substituted C1-C12 alkyl.
One carbocyclic bicyclic nucleoside having a 2)3-2' bridge and the alkenyl analog
bridge CH-CH2-2' have been described (Freier el al., Nucleic Acids Research, 1997,
(22), 4429-4443 and Albaek el al., J. Org. Chem, 2006, 71, 7731-7740). The synthesis and
preparation of carbocyclic bicyclic sides along with their oligomerization and biochemical
studies have also been described (Srivastava el al., J. Am. Chem. Soc, 2007, 129(26), 8362-
8379)
As used herein, “4’-2’ bicyclic nucleoside” or “4’ to 2’ bicyclic nucleoside” refers to a
bicyclic nucleoside comprising a furanose ring comprising a bridge connecting two carbon atoms
of the se ring connects the 2’ carbon atom and the 4’ carbon atom of the sugar ring.
As used herein, “monocylic nucleosides” refer to nucleosides comprising modified sugar
moieties that are not bicyclic sugar moieties. In certain embodiments, the sugar moiety, or sugar
moiety analogue, of a nucleoside may be modified or substituted at any position.
As used herein, “2’-modified sugar” means a syl sugar modified at the 2’ position.
In certain embodiments, such modifications include substituents selected from: a halide,
including, but not d to substituted and unsubstituted alkoxy, substituted and unsubstituted
kyl, substituted and unsubstituted amino alkyl, substituted and unsubstituted alkyl,
substituted and unsubstituted allyl, and substituted and unsubstituted alkynyl. In certain
embodiments, 2’ modifications are ed from substituents including, but not limited to:
O[(CH2)nO]mCH3, O(CH2)nNH2, O(CH2)nCH3, O(CH2)nF, O(CH2)nONH2, =O)N(H)CH3,
and O(CH2)nON[(CH2)nCH3]2, where n and m are from 1 to about 10. Other 2'— substituent
groups can also be selected from: C1-C12 alkyl, substituted alkyl, alkenyl, alkynyl, alkaryl,
aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, F, CF3, OCF3, SOCH3, SOzCH3,
ONOz, N02, N3, NHz, cycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino,
substituted silyl, an RNA cleaving group, a er group, an intercalator, a group for improving
pharmacokinetic properties, or a group for ing the pharmacodynamic properties of an
antisense compound, and other substituents having similar properties. In certain embodiments,
modifed nucleosides comprise a 2’-MOE side chain (Baker el al., J. Biol. Chem, 1997, 272,
11944-12000). Such 2'-MOE substitution have been described as having improved binding
affinity compared to unmodified nucleosides and to other modified nucleosides, such as 2’- 0-
methyl, O-propyl, and O-aminopropyl. ucleotides having the 2'-MOE substituent also
have been shown to be antisense inhibitors of gene expression with promising features for in vivo
use (Martin, Helv. Chim. Acta, 1995, 78, 486-504; Altmann el al., , 1996, 50, 168-176;
Altmann el al., Biochem. Soc. Trams, 1996, 24, 630-637; and n el al., Nucleosides
Nucleotides, 1997, 16, 917-926).
As used herein, a “modified tetrahydropyran nucleoside” or “modified THP nucleoside”
means a nucleoside having a six-membered tetrahydropyran ” substituted in for the
pentofilranosyl residue in normal nucleosides (a sugar surrogate). Modified THP nucleosides
include, but are not limited to, what is ed to in the art as heXitol nucleic acid (HNA), anitol
nucleic acid (ANA), manitol nucleic acid (MNA) (see Leumann, Bioorg. Med. Chem, 2002, 10,
841-854), fiuoro HNA (F-HNA) or those compounds having Formula VII:
(11 C12
Ta_O (13
C17 C14
(16 BX
Tb/ R1 R2 (15
wherein independently for each of said at least one ydropyran nucleoside analog of Formula
VII:
BX is a heterocyclic base moiety;
Ta and Tb are each, independently, an internucleoside linking group linking the
tetrahydropyran nucleoside analog to the antisense compound or one of Ta and Tb is an
internucleoside linking group linking the tetrahydropyran nucleoside analog to the nse
compound and the other of Ta and Tb is H, a hydroxyl protecting group, a linked conjugate group
or a 5' or 3'-terminal group;
q1, q2, q3, q4, q5, q6 and q7 are each independently, H, C1-C6 alkyl, substituted C1-C6 alkyl,
C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl or substituted C2-C6 alkynyl; and each of
R1 and R2 is selected from en, hydroxyl, halogen, ituted or unsubstituted alkoxy,
NJ1J2, SJ1, N3, OC(=X)J1, OC(=X)NJ1J2, NJ3C(=X)NJ1J2 and CN, wherein X is O, S or NJ1 and
each J1, J2 and J3 is, independently, H or C1-C6 alkyl.
In n embodiments, the d THP nucleosides of Formula VII are provided
wherein q1, q2, q3, q4, q5, q6 and q7 are each H. In certain embodiments, at least one of q1, q2, q3,
q4, q5, q6 and q7 is other than H. In n embodiments, at least one of q1, q2, q3, q4, q5, q6 and q7
is methyl. In certain embodiments, THP nucleosides of Formula VII are provided wherein one of
R1 and R2 is fluoro. In certain embodiments, R1 is fluoro and R2 is H; R1 is methoxy and R2 is H,
and R1 is methoxyethoxy and R2 is H.
As used , “2’-modif1ed” or “2’-substituted” refers to a nucleoside comprising a
sugar comprising a substituent at the 2’ position other than H or OH. 2’-modif1ed nucleosides,
include, but are not d to, bicyclic nucleosides n the bridge connecting two carbon
atoms of the sugar ring connects the 2’ carbon and another carbon of the sugar ring; and
sides with non-bridging 2’substituents, such as allyl, amino, azido, thio, O-allyl, O-Cl-Clo
alkyl, -OCF3, O-(CH2)2-O-CH3, 2'-O(CH2)2SCH3, O-(CH2)2-O-N(Rm)(Rn), or O-CH2-C(=O)-
N(Rm)(Rn), where each RIn and RH is, independently, H or substituted or unsubstituted C1-C10
alkyl. 2’-modifed nucleosides may r comprise other modifications, for example at other
positions of the sugar and/or at the nucleobase.
As used , “2’-F” refers to a nucleoside comprising a sugar comprising a fluoro
group at the 2’ position.
As used herein, “2’-OMe” or “2’-OCH3” or “2’-O-methyl” each refers to a nucleoside
comprising a sugar comprising an -OCH3 group at the 2’ position of the sugar ring.
As used herein, “MOE” or “2’-MOE” or “2’-OCH2CH2OCH3” or “2’-O-methoxyethyl”
each refers to a nucleoside comprising a sugar comprising a -OCH2CH2OCH3 group at the 2’
position of the sugar ring.
As used herein, "oligonucleotide" refers to a nd comprising a plurality of linked
2O nucleosides. In certain embodiments, one or more of the plurality of nucleosides is modified. In
certain embodiments, an oligonucleotide comprises one or more ribonucleosides (RNA) and/or
deoxyribonucleosides (DNA).
Many other o and tricyclo sugar surrogate ring systems are also known in the art
that can be used to modify nucleosides for incorporation into antisense compounds (see for
example reView article: Leumann, Bioorg. Med. Chem, 2002, 10, 841-854).
Such ring systems can o s additional substitutions to enhance actiVity.
Methods for the preparations of modified sugars are well known to those skilled in the
art.
In nucleotides haVing modified sugar moieties, the nucleobase moieties (natural,
modified or a combination f) are maintained for hybridization with an appropriate c
acid target.
In certain embodiments, nse compounds comprise one or more sides having
modified sugar moieties. In certain embodiments, the d sugar moiety is 2’-MOE. In
certain embodiments, the 2’-MOE modified nucleosides are arranged in a gapmer motif. In
n embodiments, the modified sugar moiety is a bicyclic nucleoside having a (4’-CH(CH3)-
0-2’) bridging group. In certain embodiments, the (4’-CH(CH3)-O-2’) modified nucleosides are
arranged throughout the wings of a gapmer motif. In certain embodiments, the modified sugar
moiety is a cEt. In certain embodiments, the cEt modified tides are arranged throughout
the wings of a gapmer motif.
Modified Nucleobases
Nucleobase (or base) modifications or substitutions are structurally guishable from,
yet fiinctionally interchangeable with, naturally occurring or synthetic unmodified nucleobases.
Both l and modified nucleobases are capable of participating in hydrogen bonding. Such
nucleobase modifications may impart se stability, binding affinity or some other beneficial
biological property to antisense nds. Modified nucleobases include synthetic and natural
nucleobases such as, for example, 5-methylcytosine (5-me-C). Certain nucleobase substitutions,
including 5-methylcytosine substitutions, are ularly useful for increasing the binding
affinity of an antisense compound for a target c acid. For example, 5-methylcytosine
substitutions have been shown to increase nucleic acid dupleX stability by 0.6-1 .2°C (Sanghvi,
Y.S., Crooke, ST. and Lebleu, B., eds., Antisense Research andApplications, CRC Press, Boca
Raton, 1993, pp. 276-278).
onal modified nucleobases include 5-hydroxymethyl cytosine, xanthine,
hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-
propyl and other alkyl derivatives of e and guanine, uracil, 2-thiothymine and 2-
thiocytosine, 5-halouracil and cytosine, 5-propynyl (-CEC-CH3) uracil and cytosine and other
alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil
(pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-
substituted es and guanines, 5-halo particularly 5-bromo, 5-trifiuoromethyl and other S-
tuted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-
adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-
deazaguanine and 3-deazaadenine.
Heterocyclic base moieties may include those in which the purine or pyrimidine base is
replaced with other heterocycles, for e 7-deaza-adenine, 7-deazaguanosine, 2-
yridine and 2-pyridone. Nucleobases that are particularly useful for increasing the binding
affinity of nse compounds include 5-substituted pyrimidines, 6-azapyrimidines and N—2, N-
6 and 0-6 substituted purines, including 2 aminopropyladenine, 5-propynyluracil and 5-
propynylcytosine.
In certain embodiments, antisense compounds ed to an ApoCIII nucleic acid
comprise one or more modified bases. In certain ments, gap-widened antisense
oligonucleotides targeted to an ApoCIII nucleic acid comprise one or more modified nucleobases.
In certain embodiments, the modified base is 5-methylcytosine. In certain embodiments,
each cytosine is a 5-methylcytosine.
Compositions andMethodsfor Formulating Pharmaceutical Compositions
Antisense oligonucleotides may be d with pharmaceutically acceptable active or
inert substance for the preparation of pharmaceutical compositions or formulations.
Compositions and methods for the formulation of pharmaceutical compositions are dependent
upon a number of criteria, including, but not limited to, route of administration, extent of e,
or dose to be administered.
Antisense compound targeted to an ApoCIII c acid can be utilized in
pharmaceutical compositions by combining the antisense compound with a suitable
pharmaceutically acceptable diluent or r.
In certain embodiments, the “pharmaceutical carrier” or “excipient” is a
pharmaceutically able solvent, suspending agent or any other pharmacologically inert
vehicle for delivering one or more nucleic acids to an animal. The ent can be liquid or solid
and can be selected, with the planned manner of administration in mind, so as to provide for the
desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a
given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited
to, binding agents (e.g., pregelatinized maize starch, nylpyrrolidone or hydroxypropyl
methylcellulose, etc); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin,
gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc);
ants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic
stearates, hydrogenated vegetable oils, corn , polyethylene glycols, sodium benzoate,
WO 49495
sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents
(e.g., sodium lauryl sulphate, etc.).
Pharmaceutically acceptable organic or inorganic excipients, which do not deleteriously
react with nucleic acids, suitable for eral or non-parenteral stration can also be used
to formulate the itions of the present invention. Suitable pharmaceutically acceptable
carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols,
n, lactose, e, magnesium stearate, talc, silicic acid, viscous paraffin,
hydroxymethylcellulose, polyvinylpyrrolidone and the like.
A pharmaceutically acceptable diluent includes phosphate-buffered saline (PBS). PBS is a
diluent suitable for use in itions to be delivered parenterally. Accordingly, in one
embodiment, employed in the methods described herein is a pharmaceutical composition
comprising an antisense compound targeted to an ApoCIII nucleic acid and a pharmaceutically
acceptable diluent. In certain embodiments, the pharmaceutically acceptable diluent is PBS. In
certain embodiments, the antisense compound is an antisense oligonucleotide.
ceutical compositions comprising antisense compounds encompass any
pharmaceutically acceptable salts, esters, or salts of such , or an ucleotide which,
upon administration to an animal, including a human, is capable of providing (directly or
indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the
disclosure is also drawn to pharmaceutically able salts of antisense compounds, prodrugs,
pharmaceutically able salts of such prodrugs, and other bioequivalents. Suitable
pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.
A prodrug can e the incorporation of additional nucleosides at one or both ends of
an antisense compound which are cleaved by endogenous nucleases within the body, to form the
active antisense compound.
ConjugatedAntisense Compounds
nse compounds may be covalently linked to one or more moieties or conjugates
which enhance the activity, cellular distribution or cellular uptake of the resulting antisense
oligonucleotides. Typical conjugate groups include cholesterol moieties and lipid moieties.
Additional conjugate groups include carbohydrates, phospholipids, biotin, phenazine, ,
phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes.
Antisense compounds can also be modified to have one or more stabilizing groups that
are generally attached to one or both termini of antisense compounds to enhance properties such
as, for example, nuclease stability. Included in stabilizing groups are cap ures. These
terminal modifications protect the antisense compound from exonuclease ation, and can
help in delivery and/or localization within a cell. The cap can be present at the 5'—terminus (5'-
cap), or at the 3'—terminus (3'—cap), or can be present on both i. Cap structures are well
known in the art and include, for example, inverted deoxy abasic caps. Further 3' and 5'-
izing groups that can be used to cap one or both ends of an antisense compound to impart
nuclease stability include those disclosed in WO 03/004602 published on January 16, 2003.
Cell Culture andAntisense nds Treatment
The effects of antisense compounds on the level, activity or expression of ApoCIII
nucleic acids or proteins can be tested in vitro in a variety of cell types. Cell types used for such
analyses are ble from commercial vendors (e. g. American Type Culture Collection,
Manassus, VA; Zen-Bio, Inc., Research Triangle Park, NC; Clonetics Corporation, Walkersville,
MD) and cells are cultured according to the vendor’s ctions using cially available
reagents (e. g. Invitrogen Life logies, Carlsbad, CA). Illustrative cell types include, but are
not limited to, HepG2 cells, Hep3B cells, Huh7 (hepatocellular carcinoma) cells, primary
hepatocytes, A549 cells, GM04281 fibroblasts and LLC-MK2 cells.
In Vitro Testing ofAntl'sense ucleotides
Described herein are methods for treatment of cells with antisense oligonucleotides,
which can be modified appropriately for treatment with other antisense compounds.
In general, cells are treated with antisense oligonucleotides when the cells reach
approximately 60-80% confluence in culture.
One t commonly used to introduce antisense oligonucleotides into cultured cells
es the cationic lipid transfection reagent LIPOFECTIN® (Invitrogen, Carlsbad, CA).
Antisense oligonucleotides are mixed with LIPOFECTIN® in OPTI-MEM® l (Invitrogen,
Carlsbad, CA) to achieve the desired final concentration of antisense oligonucleotide and a
CTIN® concentration that typically ranges 2 to 12 ug/mL per 100 nM antisense
oligonucleotide.
Another reagent used to introduce antisense oligonucleotides into ed cells includes
LIPOFECTAMINE 2000® (Invitrogen, Carlsbad, CA). Antisense oligonucleotide is mixed with
LIPOFECTAMINE 2000® in EM® 1 reduced serum medium (Invitrogen, Carlsbad,
CA) to achieve the desired concentration of nse ucleotide and a CTAMINE®
concentration that lly ranges 2 to 12 ug/mL per 100 nM antisense oligonucleotide.
Another reagent used to introduce antisense oligonucleotides into cultured cells includes
Cytofectin® (Invitrogen, Carlsbad, CA). Antisense oligonucleotide is mixed with Cytofectin® in
OPTI-MEM® 1 reduced serum medium (Invitrogen, Carlsbad, CA) to achieve the desired
concentration of antisense oligonucleotide and a Cytofectin® concentration that typically ranges
2 to 12 ug/mL per 100 nM antisense oligonucleotide.
Another reagent used to introduce antisense oligonucleotides into cultured cells includes
OligofectamineTM (Invitrogen Life Technologies, Carlsbad, CA). Antisense oligonucleotide is
mixed with OligofectamineTM in Opti-MEMTM-l reduced serum medium (Invitrogen Life
Technologies, Carlsbad, CA) to achieve the desired concentration of oligonucleotide with an
OligofectamineTM to oligonucleotide ratio of approximately 0.2 to 0.8 uL per 100 nM.
Another reagent used to introduce antisense oligonucleotides into cultured cells includes
FuGENE 6 (Roche stics Corp., Indianapolis, IN). Antisense oligomeric compound was
mixed with FuGENE 6 in 1 mL of serum-free RPMI to achieve the desired concentration of
oligonucleotide with a FuGENE 6 to oligomeric compound ratio of l to 4 uL ofFuGENE 6 per
2O 100 nM.
Another technique used to introduce antisense oligonucleotides into cultured cells
includes electroporation (Sambrooke and Russell in Molecular Cloning. A Laboratory Manual.
Third Edition. Cold Spring Harbor Laboratory Press, Cold Spring , New York. 2001).
Cells are treated with antisense ucleotides by routine methods. Cells are typically
harvested 16-24 hours after antisense oligonucleotide treatment, at which time RNA or protein
levels of target nucleic acids are measured by methods known in the art and bed herein
(Sambrooke and l in Molecular Cloning. A Laboratory Manual. Third Edition. Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 2001). In l, when
ents are performed in multiple replicates, the data are presented as the average of the
ate treatments.
The concentration of antisense oligonucleotide used varies from cell line to cell line.
Methods to determine the optimal nse oligonucleotide concentration for a particular cell
line are well known in the art (Sambrooke and Russell in Molecular Cloning. A Laboratory
Manual. Third Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
2001). Antisense oligonucleotides are typically used at concentrations ranging from 1 nM to 300
nM when transfected with LIPOFECTAMINE2000® (Invitrogen, ad, CA), ctin®
(Invitrogen, ad, CA) or CytofectinTM (Genlantis, San Diego, CA). Antisense
oligonucleotides are used at higher concentrations ranging from 625 to 20,000 nM when
transfected using electroporation.
RNA ion
RNA analysis can be performed on total cellular RNA or )+ mRNA. Methods of
RNA isolation are well known in the art (Sambrooke and Russell in Molecular Cloning. A
Laboratory Manual. Third Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
New York. 2001). RNA is prepared using methods well known in the art, for example, using the
® Reagent (Invitrogen, Carlsbad, CA) according to the cturer’s recommended
protocols.
is ofInhibition of Target Levels or Expression
Inhibition of levels or expression of an ApoCIII nucleic acid can be assayed in a variety
ofways known in the art (Sambrooke and Russell in Molecular Cloning. A Laboratory Manual.
Third Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 2001). For
example, target nucleic acid levels can be quantitated by, e.g., Northern blot analysis, competitive
polymerase chain on (PCR), or quantitative real-time PCR. RNA analysis can be performed
on total cellular RNA or poly(A)+ mRNA. Methods ofRNA ion are well known in the art.
Northern blot analysis is also routine in the art. tative real-time PCR can be conveniently
accomplished using the cially available ABI PRISM® 7600, 7700, or 7900 Sequence
Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to
manufacturer’ s instructions.
Quantitative Real-Time PCR Analysis of Target RNA Levels
Quantitation of target RNA levels may be accomplished by quantitative real-time PCR
using the ABI PRISM® 7600, 7700, or 7900 Sequence Detection System (PE-Applied
2012/035694
Biosystems, Foster City, CA) ing to manufacturer’s instructions. Methods of quantitative
real-time PCR are well known in the art.
Prior to real-time PCR, the isolated RNA is ted to a reverse transcriptase (RT)
reaction, which produces complementary DNA (cDNA) that is then used as the substrate for the
real-time PCR amplification. The RT and real-time PCR reactions are med sequentially in
the same sample well. RT and real-time PCR reagents are obtained from ogen (Carlsbad,
CA). RT and real-time-PCR reactions are d out by methods well known to those skilled in
the art.
Gene (or RNA) target quantities obtained by real time PCR can be normalized using
either the expression level of a gene whose expression is constant, such as cyclophilin A, or by
quantifying total RNA using RIBOGREEN® (Invitrogen, Inc. Carlsbad, CA). Cyclophilin A
expression is quantified by real time PCR, by being run simultaneously with the target,
multiplexing, or separately. Total RNA is fied using RIBOGREEN® RNA quantification
reagent (Invitrogen, Inc. Carlsbad, CA). Methods ofRNA quantification by RIBOGREEN® are
taught in Jones, L.J., et al, (Analytical Biochemistry, 1998, 265, 368-374). A CYTOFLUOR®
4000 instrument (PE Applied Biosystems, Foster City, CA) is used to measure RIBOGREEN®
fluorescence.
Probes and primers are designed to hybridize to an ApoCIII nucleic acid. Methods for
designing ime PCR probes and primers are well known in the art, and may include the use
of software such as PRIMER EXPRESS® Software (Applied Biosystems, Foster City, CA).
Gene target quantities obtained by RT, real-time PCR can use either the expression level
of GAPDH or Cyclophilin A, genes whose expression are constant, or by quantifying total RNA
using RiboGreenTM (Molecular Probes, Inc. , OR). GAPDH or Cyclophilin A expression
can be quantified by RT, real-time PCR, by being run simultaneously with the target,
lexing, or separately. Total RNA was quantified using RiboGreenTM RNA quantification
t (Molecular Probes, Inc. , OR).
Analysis ofProtein Levels
Antisense inhibition of ApoCIII nucleic acids can be assessed by measuring ApoCIII
protein levels. Protein levels of ApoCIII can be evaluated or quantitated in a variety of ways well
known in the art, such as immunoprecipitation, Western blot analysis oblotting), enzyme-
linked immunosorbent assay (ELISA), quantitative protein assays, protein activity assays (for
example, caspase activity assays), immunohistochemistry, immunocytochemistry or
fluorescence-activated cell sorting (FACS) (Sambrooke and Russell in Molecular Cloning. A
Laboratory Manual. Third Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
New York. 2001). Antibodies directed to a target can be identified and obtained from a variety of
sources, such as the MSRS catalog of dies (Aerie Corporation, Birmingham, MI), or can be
prepared via conventional monoclonal or polyclonal antibody generation methods well known in
the art. Antibodies useful for the ion of human and mouse ApoCIII are commercially
available.
In vivo testing ofantisense compounds
Antisense compounds, for e, antisense oligonucleotides, are tested in animals to
assess their y to inhibit expression of ApoCIII and produce phenotypic changes. Testing
can be performed in normal animals, or in experimental disease . For administration to
animals, antisense oligonucleotides are formulated in a pharmaceutically acceptable diluent, such
as ate-buffered saline. stration includes parenteral routes of administration.
Calculation of antisense oligonucleotide dosage and dosing frequency depends upon factors such
as route of administration and animal body weight. Following a period of treatment with
antisense oligonucleotides, RNA is ed from tissue and changes in I nucleic acid
expression are measured. Changes in ApoCIII protein levels are also ed.
Certain Indications
In certain embodiments, provided herein are methods of treating an dual comprising
stering one or more pharmaceutical compositions as described herein. In certain
embodiments, the individual has a cardiovascular disease or a metabolic disorder.
In certain embodiments, the cardiovascular disease is aneurysm, angina, arrhythmia,
atherosclerosis, cerebrovascular disease, coronary heart disease, hypertension, dyslipidemia,
ipidemia, hypertriglyceridemia, holesterolemia, stroke and the like. In certain
embodiments, the dyslipidemia is chylomicronemia.
As shown in the es below, compounds targeted to ApoCIII as described herein
have been shown to modulate physiological markers or phenotypes of a cardiovascular e.
In certain of the experiments, the compounds increased HDL levels, and decreased LDL and
triglyceride levels compared to untreated animals. In certain embodiments, the increase in HDL
levels and decrease in LDL and triglyceride levels was associated with an inhibition of ApoCIII
by the compounds.
In certain embodiments, physiological markers of a cardiovascular disease may be
quantifiable. For example, HDL levels may be ed and quantified by, for example, standard
lipid tests. For such markers, in certain embodiments, the marker may be increased by about 5,
, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%, or a range defined by
any two of these values.
Also, provided herein are methods for preventing, treating or ameliorating a symptom
associated with a cardiovascular disease in a subject in need thereof. In certain embodiments,
ed is a method for reducing the rate of onset of a symptom associated with a cardiovascular
disease. In certain embodiments, provided is a method for reducing the severity of a symptom
associated with a cardiovascular disease. In such embodiments, the methods comprise
administering to an individual in need thereof a therapeutically effective amount of a compound
targeted to an I nucleic acid.
Cardiovascular diseases are characterized by numerous physical symptoms. Any
symptom known to one of skill in the art to be associated with a vascular disease can be
prevented, treated, ameliorated or otherwise modulated as set forth above in the s
described above. In certain ments, the symptom may be any of, but not limited to, angina,
chest pain, shortness of breath, palpitations, weakness, dizziness, nausea, sweating, tachycardia,
ardia, hmia, atrial fibrillation, swelling in the lower extremities, cyanosis, fatigue,
fainting, numbness of the face, numbness of the limbs, claudication or cramping of s,
bloating of the abdomen or fever.
In certain ments, the m is . In certain embodiments, the symptom is
chest pain. In certain embodiments, the symptom is shortness of breath. In certain embodiments,
the symptom is palpitations. In certain embodiments, the m is weakness. In certain
embodiments, the symptom is dizziness. In certain embodiments, the symptom is nausea. In
certain embodiments, the symptom is sweating. In certain embodiments, the symptom is
tachycardia. In certain embodiments, the symptom is bradycardia. In certain embodiments, the
symptom is arrhythmia. In certain embodiments, the symptom is atrial fibrillation. In certain
embodiments, the symptom is swelling in the lower extremities. In certain embodiments, the
symptom is is. In certain ments, the symptom is fatigue. In certain embodiments,
the symptom is fainting. In n embodiments, the m is numbness of the face. In certain
2012/035694
embodiments, the symptom is numbness of the limbs. In certain embodiments, the symptom is
claudication or cramping of muscles. In certain embodiments, the symptom is bloating of the
abdomen. In certain embodiments, the symptom is impaired short-term fever.
In certain embodiments, the metabolic disorders include, but are not limited to,
hyperglycemia, prediabetes, diabetes (type I and type II), obesity, insulin resistance, metabolic
syndrome and diabetic dyslipidemia.
In n embodiments, nds targeted to ApoCIII as described herein modulate
physiological markers or ypes of a metabolic er. In certain embodiments,
physiological markers of a lic disorder may be quantifiable. For example, glucose levels
or insulin resistance can be measured and quantified by standard tests known in the art. For such
markers, in certain embodiments, the marker may be decreased by about 5, 10, 15, 20, 25, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%, or a range defined by any two ofthese
values. In another e, insulin ivity or HDL levels can be measured and quantified by
standard tests known in the art. For such markers, in certain embodiments, the marker may be
increase by about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%,
or a range defined by any two of these values.
Also, provided herein are methods for preventing, treating or ameliorating a symptom
associated with a metabolic disorder in a subject in need thereof. In certain embodiments,
provided is a method for reducing the rate of onset of a symptom associated with a metabolic
disorder. In certain embodiments, ed is a method for ng the severity of a symptom
associated with a metabolic disorder. In such embodiments, the methods comprise administering
to an individual in need thereof a therapeutically effective amount of a compound targeted to an
ApoCIII nucleic acid.
lic disorders are characterized by numerous physical symptoms. Any symptom
known to one of skill in the art to be associated with a metabolic disorder can be prevented,
d, ameliorated or otherwise modulated as set forth above in the methods described above. In
certain embodiments, the m may be any of, but not limited to, excessive urine production
(polyuria), excessive thirst and increased fluid intake (polydipsia), blurred vision, unexplained
weight loss and lethargy.
In n embodiments, provided are methods of treating an individual comprising
administering a eutically effective amount of one or more pharmaceutical compositions as
described . In certain embodiments, the individual has a cardiovascular disease. In certain
embodiments, administration of a therapeutically effective amount of an antisense compound
targeted to an ApoCIII nucleic acid is accompanied by monitoring of ApoCIII levels or markers
of cardiovascular disease, diabetes or other e process associated with the expression of
ApoCIII, to determine an individual’s response to administration of the antisense compound. An
individual’s response to stration of the antisense compound is used by a physician to
determine the amount and duration of therapeutic intervention.
In certain embodiments, stration of an antisense compound ed to an ApoCIII
nucleic acid results in reduction of ApoCIII expression by at least about 15, 20, 25, 30, 35, 40,
45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%, or a range defined by any two ofthese values. In
certain embodiments, ApoCIII expression is reduced to S 50 mg/L, 3 60 mg/L, 3 70 mg/L, 3 80
mg/L, S 90 mg/L, S 100 mg/L, S 110 mg/L, S 120 mg/L, S 130 mg/L, S 140 mg/L, S 150 mg/L,
S 160 mg/L, S 170 mg/L, S 180 mg/L, 3 190 mg/L or S 200 mg/L.
In certain embodiments, administration of an antisense compound targeted to an ApoCIII
nucleic acid results in increase in HDL levels by at least about 15, 20, 25, 30, 35, 40, 45, 50, 55,
60, 65, 70, 75, 80, 85, 90, 95 or 99 %, or a range defined by any two ofthese .
In certain ments, stration of an antisense compound targeted to an ApoCIII
nucleic acid results in reduction of TG (postprandial or fasting) levels by at least about 15%,,
%,, 25%,, 30%,, 35%,, 40%,, 45%,, 50%,, 55%,, 60%,, 65%,, 70%,, 75%,, 80%,, 85%,, 90%,,
95%, or 99%, or a range defined by any two of these values. In certain ments, TG
(postprandial or fasting) is reduced to S 100 mg/dL, S 110 mg/dL, S 120 mg/dL, S 130 mg/dL, S
140 mg/dL, S 150 mg/dL, S 160 mg/dL, S 170 mg/dL, S 180 mg/dL, S 190 mg/dL, S 200 mg/dL,
s 210 mg/dL, s 220 mg/dL, s 230 mg/dL, s 240 mg/dL, s 250 mg/dL, s 260 mg/dL, s 270
mg/dL, S 280 mg/dL, S 290 mg/dL, S 300 mg/dL, S 350 mg/dL, S 400 mg/dL, S 450 mg/dL, S
500 mg/dL, S 550 mg/dL, S 600 mg/dL, S 650 mg/dL, S 700 mg/dL, S 750 mg/dL, S 800 mg/dL,
s 850 mg/dL, s 900 mg/dL, s 950 mg/dL, s 1000 mg/dL, s 1100 mg/dL, s 1200 mg/dL, s 1300
mg/dL, : 1400 mg/dL, s 1500 mg/dL, s 1600 mg/dL, s 1700 mg/dL, s 1800 mg/dL or s 1900
mg/dL.
In certain embodiments, ceutical compositions comprising an antisense compound targeted to
ApoCIII are used for the preparation of a medicament for treating a patient suffering or susceptible to a
cardiovascular disease.
Administration
The compounds or pharmaceutical compositions of the present invention can be
administered in a number of ways depending upon whether local or systemic treatment is desired
and upon the area to be treated. Administration can be oral or parenteral.
In certain embodiments, the compounds and compositions as bed herein are
administered parenterally. Parenteral administration includes intravenous, intra-arterial,
aneous, intraperitoneal or intramuscular injection or infusion.
In n embodiments, parenteral administration is by infusion. on can be chronic
or continuous or short or intermittent. In n embodiments, d pharmaceutical agents are
delivered with a pump. In n embodiments, the infusion is intravenous.
In certain embodiments, parenteral stration is by injection. The injection can be
delivered with a syringe or a pump. In certain embodiments, the ion is a bolus injection. In
certain embodiments, the injection is administered directly to a tissue or organ. In certain
embodiments, parenteral administration is subcutaneous.
In certain embodiments, formulations for parenteral administration can include sterile
aqueous solutions which can also contain buffers, diluents and other suitable additives such as,
but not limited to, penetration enhancers, carrier compounds and other pharmaceutically
acceptable carriers or excipients.
In certain embodiments, formulations for oral administration of the compounds or
compositions of the invention can include, but is not limited to, pharmaceutical carriers,
excipients, powders or granules, microparticulates, nanoparticulates, suspensions or ons in
water or non-aqueous media, es, gel capsules, sachets, tablets or minitablets. Thickeners,
flavoring agents, ts, f1ers, dispersing aids or binders can be desirable. In certain
embodiments, oral ations are those in which compounds of the invention are administered
in conjunction with one or more penetration enhancers, surfactants and chelators.
Dosing
In n embodiments, pharmaceutical compositions are administered according to a
dosing regimen (e.g., dose, dose frequency, and duration) wherein the dosing regimen can be
selected to achieve a desired effect. The desired effect can be, for example, reduction of ApoCIII
or the prevention, reduction, amelioration or slowing the progression of a disease or condition
associated with ApoCIII.
In certain embodiments, the variables of the dosing regimen are ed to result in a
desired concentration of pharmaceutical composition in a subject. “Concentration of
pharmaceutical composition” as used with regard to dose regimen can refer to the compound,
oligonucleotide, or active ingredient of the pharmaceutical composition. For example, in certain
embodiments, dose and dose frequency are adjusted to provide a tissue concentration or plasma
concentration of a ceutical composition at an amount sufficient to achieve a desired effect.
Dosing is dependent on severity and responsiveness of the disease state to be treated, with
the course of treatment lasting from several days to several months, or until a cure is effected or a
diminution of the e state is achieved. Dosing is also dependent on drug potency and
metabolism. In certain embodiments, dosage is from 0.01 ug to 100mg per kg of body weight, or
within a range of 0.001mg — lOOOmg dosing, and may be given once or more daily, weekly,
monthly or yearly, or even once every 2 to 20 years. Following successful treatment, it may be
desirable to have the patient o maintenance therapy to prevent the recurrence of the
disease state, n the oligonucleotide is administered in maintenance doses, ranging from
0.01ug to 100mg per kg of body weight, once or more daily, to once every 20 years or ranging
from 0.00lmg to lOOOmg dosing.
Certain Combination Therapies
In certain ments, a first agent comprising the compound described hereinis co-
administered with one or more secondary agents. In certain embodiments, such second agents are
ed to treat the same disease, disorder, or condition as the first agent described herein. In
n embodiments, such second agents are designed to treat a ent disease, disorder, or
condition as the first agent described herein. In certain embodiments, a first agent is designed to
treat an undesired side effect of a second agent. In certain embodiments, second agents are co-
administered with the first agent to treat an undesired effect of the first agent. In n
embodiments, such second agents are designed to treat an undesired side effect of one or more
pharmaceutical compositions as described . In certain ments, second agents are co-
administered with the first agent to produce a ational effect. In certain embodiments,
second agents are co-administered with the first agent to produce a synergistic effect. In certain
embodiments, the co-administration of the first and second agents permits use of lower dosages
than would be required to achieve a therapeutic or lactic effect if the agents were
administered as independent therapy.
In certain embodiments, one or more compositions described herein and one or more
other pharmaceutical agents are administered at the same time. In certain embodiments, one or
more compositions of the ion and one or more other pharmaceutical agents are
stered at ent times. In certain embodiments, one or more itions described
herein and one or more other pharmaceutical agents are prepared together in a single formulation.
In certain embodiments, one or more compositions described herein and one or more other
pharmaceutical agents are prepared separately.
In certain embodiments, second agents include, but are not limited to, ApoCIII lowering
agent, cholesterol lowering agent, non-HDL lipid lowering (e.g., LDL) agent, HDL raising agent,
fish oil, niacin, fibrate, statin, DCCR (salt of diazoxide), glucose-lowering agent and/or anti-
diabetic agents. In certain embodiments, the first agent is stered in ation with the
maximally tolerated dose of the second agent. In certain embodiments, the first agent is
administered to a subject that fails to respond to a maximally tolerated dose of the second agent.
es of ApoCIII ng agents include an ApoCIII antisense oligonucleotide
different from the first agent, niacin or an Apo B antisense oligonucleotide.
Examples of glucose-lowering and/or anti-diabetic agents include, but is not limited to, a
therapeutic lifestyle change, PPAR agonist, a dipeptidyl peptidase (IV) inhibitor, a GLP-l analog,
insulin or an insulin analog, an insulin secretagogue, a SGLT2 inhibitor, a human amylin analog,
a biguanide, an glucosidase inhibitor, metformin, sulfonylurea, itazone, meglitinide,
thiazolidinedione, alpha-glucosidase tor and the like. The sulfonylurea can be
acetohexamide, chlorpropamide, tolbutamide, tolazamide, glimepiride, a glipizide, a glyburide, or
a zide. The meglitinide can be nateglinide or repaglinide. The thiazolidinedione can be
pioglitazone or rosiglitazone. The alpha-glucosidase can be acarbose or miglitol.
The terol or lipid lowering therapy can e, but is not limited to, a therapeutic
lifestyle change, statins, bile acids sequestrants, nicotinic acid and fibrates. The statins can be
atorvastatin, fiuvastatin, loyastatin, praVastatin, rosuVastatin and simVastatin and the like. The
bile acid sequestrants can be coleseVelam, cholestyramine, colestipol and the like. The fibrates
can be gemfibrozil, rate, clofibrate and the like.
HDL increasing agents include cholesteryl ester transfer protein (CETP) inhibiting drugs
(such as Torcetrapib), peroxisome proliferation ted receptor agonists, Apo-Al, Pioglitazone
and the like.
n Treatment Populations
Certain subjects with high TG levels are at a significant risk of cardiovascular and
metabolic disease. In many subjects with high TG (e.g., hypertriglyceridemia), current treatments
cannot reduce their TG levels to safe levels. ApoCIII plays an important role in TG metabolism
and is an independent risk factor for cardiovascular disease. ApoCIII inhibition, as shown ,
significantly decreases TG levels which can ameliorate cardiovascular or metabolic disease, or
the risk thereof.
Borderline high TG levels (150—199 mg/dL) are commonly found in the general
population and are a common component of the metabolic syndrome/insulin resistance states.
High plasma TG level of2 200 mg/dL is a common al trait associated with an increased risk
of cardiovascular disease (Hegele et al., Hum Mol Genet 2009, 18:4189-4194; Hegele and
PolleX, Mol Cell Biochem, 2009, 326:35-43). Very high TG levels (2500 and S2000 mg/dL)
are most often associated with elevated chylomicron levels as well, and are accompanied by
sing risk for acute pancreatitis.
In certain embodiments, the compounds, compositions and methods disclosed herein are
used to treat subjects with a TG level between 100-200 mg/dL, 100-300 mg/dL, 100-400 mg/dL,
lOO-5OO mg/dL, 200-500 mg/dL, 300-500 mg/dL, 400-500 mg/dL, 500-1000 mg/dL, 600-1000
mg/dL, 700-1000 mg/dL, 800-1000 mg/dL, 00 mg/dL, 500-1500 mg/dL, 1000-1500
mg/dL, lOO-2000 mg/dL, l50-2000 mg/dL, 200-2000 mg/dL, 300-2000 mg/dL, 400-2000 mg/dL,
500-2000 mg/dL, 600-2000 mg/dL, 700-2000 mg/dL, 800-2000 mg/dL, 900-2000 mg/dL, 1000-
2000 mg/dL, 1100-2000 mg/dL, 000 mg/dL, 1300-2000 mg/dL, 1400-2000 mg/dL, or
1500-2000 mg/dL. In certain embodiments, treatment with the compounds disclosed herein is
ted for a subject with a TG level of 2 100 mg/dL, 2 110 mg/dL, 2 120 mg/dL, 2 130
mg/dL, Z 140 mg/dL, Z 150 mg/dL, Z 160 mg/dL, Z 170 mg/dL, Z 180 mg/dL, Z 190 mg/dL, Z
200 mg/dL, Z 300 mg/dL, Z 400 mg/dL, Z 500 mg/dL, Z 600 mg/dL, Z 700 mg/dL, Z 800 mg/dL,
2 900 mg/dL, 2 1000 mg/dL, 2 1100 mg/dL, 2 1200 mg/dL, 2 1300 mg/dL, 2 1400 mg/dL, 2
1500 mg/dL, 2 1600 mg/dL, 2 1700 mg/dL, 2 1800 mg/dL, 2 1900 mg/dL, 2 2000 mg/dL, 2
2100 mg/dL, Z 2200 mg/dL, Z 2300 mg/dL, Z 2400 mg/dL or Z 2500 mg/dL.
Some types of hypertriglyceridemia can be terized by the Fredrickson classification
system or by the classification system described by ay (Tremblay et al., J Clin Lipidol,
2011, 5:37-44). In certain ments, the compounds, compositions and s described
herein are useful in treating subjects with, or at risk for, ckson Type II, IV or V
hypertriglyceridemia.
Fredrickson Type IIb (also known as familial combined hyperlipoproteinemia) is a mixed
hyperlipidemia (high terol and TG levels), caused by elevations in LDL-C and in VLDL.
The high VLDL levels are due to overproduction of substrates, including TG, acetyl CoA, and an
se in B-100 sis. They may also be caused by the decreased clearance of LDL.
Prevalence in the population is about 10%.
Fredrickson Type IV (also known as familial hypertriglyceridemia) is an autosomal
dominant condition occurring in approximately 1% of the population. TG levels are elevated as a
result of excess hepatic production of VLDL or heterozygous LPL deficiency, but are almost
always less than 1000 mg/dL. Serum cholesterol levels are usually within normal limits. The
disorder is heterogeneous and the phenotype strongly influenced by environmental factors,
particularly carbohydrate and ethanol consumption. In certain ments, the compounds,
compositions and methods described herein are useful in treating ts with a TG level 2 200
mg/dL and heterozygous LPL deficiency or VLDL oduction. In certain ments, the
compounds, compositions and s described herein are useful in treating subjects with a TG
level 2 500 mg/dL and heterozygous LPL deficiency or VLDL overproduction.
Fredrickson Type V has high VLDL and chylomicrons. It is characterized by carriers of
loss-of-fiinction LPL gene variants associated with LPL activity of at least 20% (i.e. partial LPL
ncy). These subjects present with lactescent plasma and severe hypertriglyceridemia
because of chylomicrons and VLDL. TG levels are invariably greater than 1000 mg/dL and total
cholesterol levels are always elevated. The LDL-C level is usually low. It is also associated with
increased risk for acute pancreatitis, glucose intolerance and hyperuricemia. Symptoms lly
present in adulthood (> 35years) and, although the prevalence is relatively rare, it is much more
common than homozygous or compound heterozygous LPL deficient subjects. In certain
embodiments, the compounds, compositions and methods bed herein are useful in treating
subjects with Z 1000 mg/dL TG. In certain embodiments, the nds, compositions and
methods described herein are useful in treating subjects with, or at risk for, pancreatitis associated
with high TG levels in a t.In certain embodiments, the compounds, compositions and
methods described herein are useful in treating subjects with, or at risk for, vascular or
metabolic disease associated with high TG levels in a subject. In certain embodiments, the
cardiovascular disease is aneurysm, angina, arrhythmia, atherosclerosis, cerebrovascular disease,
coronary heart e, hypertension, dyslipidemia, hyperlipidemia, hypertriglyceridemia,
hypercholesterolemia, stroke and the like. In certain embodiments, the dyslipidemia is
chylomicronemia. In certain embodiments, the metabolic es or disorders include, but are
not limited to, hyperglycemia, prediabetes, diabetes (type I and type II), obesity, insulin
resistance, metabolic syndrome and diabetic dyslipidemia.
In certain embodiments, treatment with the compounds disclosed herein is indicated for a
human animal with a genetic defect that increases I levels and/or triglyceride levels. In
certain embodiments, the genetic defect is an allelic variant or polymorphism that increases
ApoCIII expression. In certain embodiments, the polymorphism are T (at on 74) to A, C (at
position -641) to A, G (at position -630) to A, T (at position -625) to deletion, C (at position -
482) to T, T (at position -455) to C, C (at position 1100) to T, C (at position 3175) to G, T (at
position 3206) to G, C (at position 323 8) to G, and the like. In certain embodiments, the c
defect is a heterozygous LPL deficiency.
In certain embodiments, treatment with the compounds disclosed herein is indicated for a
human animal with ed ApoCIII levels. In certain embodiments, the elevated ApoCIII level
is Z 50 mg/L, 2 60 mg/L, 2 70 mg/L, 2 80 mg/L, 2 90 mg/L, 2 100 mg/L, 2 110 mg/L, 2 120
mg/L, 2 130 mg/L, 2 140 mg/L, 2 150 mg/L, 2 160 mg/L, 2 170 mg/L, 2 180 mg/L, 2 190 mg/L,
2 200 mg/L, 2 300 mg/L, 2 400 mg/L or Z 500 mg/L.
EXAMPLES
Non-limiting disclosure and incorporation by reference
While certain compounds, compositions and methods described herein have been
bed with specificity in ance with certain embodiments, the following examples serve
only to illustrate the compounds described herein and are not intended to limit the same. Each of
the references recited in the present application is incorporated herein by reference in its ty.
Example 1: Effect of in vivo antisense tion of human ApoCIII in huApoCIII
transgenic mice
Transgenic mice with the human ApoCIII ene utilized in the study were the
progeny of huApoCIII transgenic F1 hybrids on Laboratories, CA) and C57BL/6 mice.
ISIS 304801 (previously disclosed in US Patent 7,598,227) with a start site of 508 on SEQ ID
NO: 1 (GENBANK Accession No. NM_000040. 1) and a start site of 3 139 on SEQ ID NO: 2
(GENBANK Accession NT_O33899.8 truncated from nucleotides 20263040 to 20266203), with
the sequence 5’- TTGTCCAGCTTTAT-3’ (SEQ ID NO: 3) and a 55 MOE gapmer
motifwas utilized in this assay. Another ISIS nse oligonucleotide, ‘Compound X’, with a
55 MOE gapmer motif, targeting another region of SEQ ID NO: 1 or SEQ ID NO: 2, was
also ed in this assay. Another ISIS nse oligonucleotide, ‘Compound Y’, with a 55
MOE gapmer motif, targeting a rodent ApoCIII sequence (GenBank Accession No.
NM_023 1 14.3; SEQ ID NO: 5) was also ed in this assay.
Treatment
Human I transgenic mice were maintained on a 12-hour light/dark cycle and fed
ad libitum Teklad lab chow. Animals were acclimated for at least 7 days in the research facility
before initiation of the experiment. Antisense oligonucleotides (ASOs) were prepared in PBS
and sterilized by filtering through a 0.2 micron filter. Oligonucleotides were ved in 0.9%
PBS for ion.
Male and female mice were assayed separately. The male mice were divided into three
treatment groups consisting of 5 mice each. Two such groups received subcutaneous injections of
ISIS 304801 or Compound X at a dose of 37.5 mg/kg twice a week for 2 weeks. One group of
mice received subcutaneous injections ofPBS twice a week for 2 weeks. The female mice were
divided into four treatment groups consisting of 4-5 mice each. Three such groups received
subcutaneous injections of ISIS 304801, Compounds X or Y at a dose of 37.5 mg/kg twice a
week for 2 weeks. One group of mice received subcutaneous injections ofPBS twice a week for
2 weeks. Prior to the treatment as well as after the last dose, blood was withdrawn from each
mouse and plasma samples analyzed. Two days following the final dose, the mice were
euthanized, organs harvested and analyses done.
Cholesterol and ceride Levels
Plasma triglycerides and cholesterol were extracted by the method of Bligh and Dyer
(Bligh, E.G. and Dyer, WJ. Can. J. Biochem. Physiol. 37: 911-917, 1959) and measured with a
commercially ble triglyceride kit (DCL Triglyceride Reagent; Diagnostic Chemicals Ltd.).
The results of the triglyceride analyses in males and females are presented in Tables 1 and
2, and are expressed in mg/dL. As ed, triglyceride levels in all the treatment groups were
significantly lowered compared to that in the control groups.
For measuring the ent fractions of cholesterol (HDL, LDL and VLDL), the plasma
samples from the female groups were analyzed by HPLC and are presented in Table 3. As
observed, nse inhibition of ApoCIII cantly decreased VLDL and also significantly
increased levels of HDL. An increase in HDL and a decrease in VLDL levels is a cardiovascular
beneficial effect of antisense inhibition of ApoCIII and can be beneficial to animals with, or at
risk or, idemic diseases.
Table 1
Effect of antisense ucleotide treatment on triglyceride levels (mg/dL) in female transgenic
mice
Week 0 Week 2
change
PBS 2144 253 3 +21
Compound X 2385 677 -72
Compound Y 2632 1644 -37
ISIS 304801 2390 542 -75
Table 2
Effect of antisense oligonucleotide treatment on triglyceride levels (mg/dL) in male transgenic
mice
Week 0 Week 2
Change
PBS 6191 7073 +14
ISIS 304801 6588 780 -88
Compound X 5464 861 -84
Table 3
Effect of antisense oligonucleotide treatment on plasma cholesterol fractions (% total cholesterol)
in female transgenic mice
VLDL (%) HDL (%)
PBS 77 :: 2.6 4:: 1.0 19:: 1.9
ISIS 304801 41 :: 0.6 7 :: 0.3 52 :: 0.5
CompoundX 46 :: 5.1 7:: 1.0 48 :: 5.8
Example 2: Dose-dependent nse inhibition of human ApoCIII in huApoCIII
transgenic mice
ISIS 304801 and nd X were further studied in a dose-dependent study using
human ApoCIII transgenic mice.
Treatment
Human ApoCIII transgenic mice were maintained on a r light/dark cycle and fed
ad libitum Teklad lab chow. Animals were acclimated for at least 7 days in the ch facility
before initiation of the experiment. Antisense oligonucleotides (ASOs) were prepared in PBS
and ized by filtering through a 0.2 micron filter. Oligonucleotides were dissolved in 0.9%
PBS for injection.
Female mice were d into nine treatment groups consisting of 3 mice each. Eight
such groups received subcutaneous injections of ISIS 304801 or compound X at a dose of 1.5
mg/kg/week, 5 week, 15 mg/kg/week, or 50 mg/kg/week for 2 weeks. One group of mice
received subcutaneous ions ofPBS for 2 weeks. Prior to the treatment as well as after the
last dose, blood was withdrawn from each mouse and plasma samples analyzed. Two days
ing the final dose, the mice were euthanized, organs harvested and analyses done.
Cholesterol and Triglyceride Levels
Plasma triglycerides and cholesterol were ted by the method of Bligh and Dyer
(Bligh, E.G. and Dyer, WJ. Can. J. Biochem. Physiol. 37: 911-917, 1959) and measured with a
commercially available triglyceride kit (DCL Triglyceride Reagent, Diagnostic Chemicals Ltd).
The results of the cholesterol and triglyceride analyses in the mice are presented in Tables
4 and 5, and are expressed in mg/dL. As observed, HDL levels in mice treated with higher doses
of ISIS 304801 were significantly elevated, indicating the beneficial effect of inhibition of
ApoCIII by the oligonucleotides. LDL and triglyceride levels in the high dose treatment groups
were lowered compared to that in the control groups. An increase in HDL and a decrease in LDL
and TG levels is a cardiovascular beneficial effect of antisense inhibition of ApoCIII and can be
beneficial to animals with, or at risk of, dyslipidemic diseases.
WO 49495
Table 4
Effect of antisense oligonucleotide treatment on cholesterol and triglyceride levels (mg/dL) in
transgenic mice
Dose Total
TrlleCerldes. .
(mg/kg/wk) Cholesterol
PBS ' 124 1017
50.0 105 417
ISIS 15.0 116 593
304801 5.0 101 871
1.5 125 1092
50.0 90 496
Compound 15.0 127 1168
X 5.0 166 1506
1.5 168 1518
Table 5
Effect of nse oligonucleotide treatment on HDL and LDL cholesterol levels (mg/dL) in
transgenic mice
Dose
HDL LDL
(mg/kg/Wk)
PBS - 40 :: 8 42 :: 8
50.0 62 :: 19 28 :: 7
ISIS 15.0 60 :: 9 34 :: 7
304801 5.0 44 :3 30:: 13
1.5 39 :: 2 40 :: 2
50.0 46 :: 10 25 :: 3
Compound 15.0 37 :: 40 :: 2
X 5.0 40 :: 10 47 :5
1.5 45 :: 7 44 :: 6
2012/035694
e 3: Effect of antisense tion of ApoCIII in CETP Transgenic LDL receptor
null mice
Compound Y was further studied in a human CETP transgenic LDLr'/' mouse model to
examine the effects of a mouse ApoCIII antisense inhibitor on plasma lipids and lipoprotein
metabolism in hyperlipidemic mice.
Human CETP transgenic LDLr'/' transgenic mice were maintained on a 12-hour
light/dark cycle and fed ad libitum a western diet (42% calories from fat, 0.2% cholesterol).
Animals were acclimated to this diet for 10 days in the research facility before initiation of the
experiment. Antisense oligonucleotides (ASOs) were prepared in PBS and sterilized by filtering
through a 0.2 micron filter. Oligonucleotides were dissolved in 0.9% PBS for injection.
Eight week old male mice were divided into three treatment groups. One such group of
6 mice received subcutaneous ions of compound Y at a dose of 12.5 mg/kg/week for 4
weeks. One group of 4 mice received subcutaneous injections of the l oligonucleotide ISIS
141923 (SEQ ID NO: 4) at a dose of 12.5 mg/kg/week for 4 weeks. One group of 5 mice
received subcutaneous injections ofPBS for 4 weeks. Plasma s were taken at prior to the
start of dosing, and at 2 and 4 weeks of treatment.
Cholesterol and Triglyceride Levels
Plasma triglycerides and cholesterol were extracted by the method of Bligh and Dyer
(Bligh, E.G. and Dyer, WJ. Can. J. Biochem. Physiol. 37: 911-917, 1959) and measured with a
commercially available triglyceride kit (DCL Triglyceride Reagent; Diagnostic Chemicals Ltd).
The results of the cholesterol and triglyceride es in the mice are ted in Tables
6 to 7, and are expressed in mg/dL. Cholesterol and triglyceride levels in the treatment group
were significantly lowered compared to those in the control group. A decrease in terol and
TG levels is a cardiovascular beneficial effect of antisense inhibition of ApoCIII and can be
beneficial to animals with, or at risk of, dyslipidemic diseases.
Table 6
Effect of antisense oligonucleotide treatment on cholesterol levels (mg/dL) in transgenic mice
Compound
Week PBS
0 185 l 1747
2 2035 878
4 2359 686
Table 7
Effect of antisense oligonucleotide treatment on triglyceride levels ) in transgenic mice
Compound
Week PBS
0 297 45 l
2 420 150
4 496 86
tion ofCETP protein levels and activity
Plasma CETP protein levels were measured using a commercial ELISA kit (ALPCO,
Cat# 47-CETHU-E01). CETP protein activity was measured using a etric assay kit (Roar
Biomedical, Inc. Cat# RB-CETP). As presented in Table 8, treatment with antisense
oligonucleotide reduced CETP protein expression and activity. CETP (cholesteryl ester transfer
protein) tates the exchange of triglycerides and cholesterol esters n high density
lipoproteins (HDL) and apoB-containing lipoproteins, such as very low density lipoproteins
(VLDL), LDL and chylomicrons. A decrease in CETP is associated with increased HDL levels
and decreased LDL levels (Barter P.J. et al. Artherioscler. . Vasc. Biol. 23: 160-167,
2003). Therefore, inhibition of CETP protein levels and activity is a cardiovascular beneficial
effect of antisense inhibition of ApoCIII and can be beneficial to animals with, or at risk of,
dyslipidemic diseases. The control oligonucleotide did not have any significant effect on CETP,
as expected.
Table 8
Percent inhibition of CETP protein in enic mice
Level Activity
Compound Y 24 24
ISIS 141923 0 3
Increase ofapoA] Protein levels andparaoxcmase-I (PONI) ly
Plasma ApoAl n levels were measured by ELISA. PONl protein activity was
measured using a EnzChek® Paroxanase etric assay kit (Invitrogen, Cat# E33702). As
presented in Tables 9 and 10, treatment with antisense oligonucleotide ed ApoAl protein
expression and increased PONl protein activity. ApoAl and PONl are major protein
components ofHDL in plasma (Aviram, M and Rosenblat, M. Curr. Opin. Lipidol. 16: 393-399,
2005). Therefore, enhancement of protein level and activity of these two protein components is a
cardiovascular beneficial effect of antisense inhibition of ApoCIII and can be beneficial to
animals with, or at risk of, dyslipidemic diseases. The control oligonucleotide did not have any
effect on either protein, as expected.
Table 9
Percent increase in APOA1 protein levels in transgenic mice
mg/dL
PBS 65
Compound Y 211
ISIS 141923 106
Table 10
Percent se in PONl protein activity in enic mice
. Compound ISIS
M1nutes PBS
Y 141923
0.2 0.5 0.2
0.8 1.1 0.8
60 2.3 3.5 2.3
120 4.9 7.5 4.8
180 7.7 11.6 7.6
Example 4: Effect of antisense inhibition of ApoCIII on HDL cholesterol clearance in
CETP Transgenic LDL receptor null mice
Compound Y was further studied in a human CETP transgenic LDLr'/' mouse model to
examine the effects of an ApoCIII antisense inhibitor on HDL cholesterol clearance and
lism in hyperlipidemic mice.
Treatment
Human CETP transgenic LDLr'/' mice were maintained on a 12-hour light/dark cycle
and fed ad libitum a western diet (42% calories from fat, 0.2% cholesterol). Animals were
acclimated to this diet for 10 days in the research facility before initiation of the ment.
Antisense ucleotides (ASOs) were prepared in PBS and ized by ng through a 0.2
micron filter. ucleotides were dissolved in 0.9% PBS for injection.
Eight week old male mice were divided into three treatment groups. One group of 6 mice
received subcutaneous injections of nd Y at a dose of 15 mg/kg/week for 6 weeks. One
group of 4 mice received subcutaneous injections of the control oligonucleotide ISIS 141923 at a
dose of 15 mg/kg/week for 6 weeks. One group of 5 mice received subcutaneous injections of
PBS for 6 weeks.
2O Cholesterol and Triglyceride Levels
Plasma triglycerides and cholesterol were extracted by the method of Bligh and Dyer
(Bligh, E.G. and Dyer, WJ. Can. J. Biochem. Physiol. 37: 911-917, 1959) and measured with a
commercially available triglyceride kit (DCL Triglyceride Reagent; Diagnostic Chemicals Ltd).
The results of the terol and triglyceride analyses in the mice are presented in Table
11, and are expressed in mg/dL. Cholesterol and triglyceride levels in the treatment group was
significantly lowered compared to that in the l group. A decrease in cholesterol and TG
levels is a cardiovascular beneficial effect of antisense tion of ApoCIII and can be
beneficial to animals with, or at risk of, dyslipidemic diseases.
Table 11
Effect of antisense oligonucleotide treatment on terol and triglyceide levels (mg/dL) in
transgenic mice
Total
T ' -
r1g ycerides1
cholesterol
PBS 2188 641
Compound Y 1402 170
HDL clearance
Mice from all groups were injected via tail vein with 1 X 106 dpm of 3H-cholesteryl ether
th)-labeled HDL. The radiolabeled cholesteryl ether is urally similar to cholesterol
but it will be trapped in tissues that take it up. Therefore, the clearance of the radiolabeled
cholesteryl ether from plasma and it’s accumulation in the liver can be used to evaluate effects on
reverse cholesterol transport. Plasma samples were collected at 5 min, 1.5 hrs, 3 hrs, 6 hrs and 24
hrs post-injection and the radioactivity was d using a liquid scintillation counter. At 24
hours, the mice were sacrificed and liver were harvested. The liver samples were extracted in 2:1
form/Methanol and the t was blown down under nitrogen gas, solubilized in
scintillation cocktail and counted using the same liquid scintillation counter.
The decrease in radiolabel, as presented in Table 12 is associated with the nce of
HDL-Ceth from the plasma. The results indicate that treatment with Compound Y lead to
enhanced rate ofHDL cholesterol clearance from the plasma. This was associated with the
greater accumulation of radiolabeled cholesteryl etherin the liver of Compound Y-treated mice,
as presented in Table 13. Therefore, the data indicates that inhibition of ApoCIII in these
2O transgenic mice improves reverse cholesterol transport and, therefore, would have a cial
effect on patients with cardiovascular e such as patients with a dyslipidemic disease.
Table 12
Effect of antisense oligonucleotide treatment on plasma HDL cholesterol (% of count at 0 hrs) in
trans enic mice
1.5 hr 3hr 6hr 24 hr
PBS 87 79 64 38
ISIS 141923 84 82 69 39
Compound Y 78 71 57 25
Table 13
Effect of antisense oligonucleotide treatment on hepatic uptake of radiolabeled CEth in
transgenic mice
% se
(dpm/g liver
ISIS 141923 0
nd Y 14
Example 5: Comparison of the effect of antisense inhibition of human I in C57BL/6
mice with an ApoCIII ut mouse model
ApoCIII knockout mice were obtained from Jackson Laboratories (stock number 002057)
and were compared to ApoCIII antisense oligonucleotide treated C57BL/6 mice. Compound Z,
with a 55 MOE gapmer motif and targeting a rodent ApoCIII sequence (GenBank Accession
No. NM_023114.3; SEQ ID NO: 5) was used in this study.
Antisense oligonucleotide treatment
C57BL/6 mice were maintained on a 12-hour dark cycle and fed a high fat diet
nd Teklad lab chow #88137) for one week. Antisense oligonucleotides (ASOs) were
prepared in PBS and sterilized by filtering through a 0.2 micron filter. Oligonucleotides were
dissolved in 0.9% PBS for injection. The mice were randomized based on total plasma
cholesterol and triglyceride levels into groups of 6-8 mice each. Three groups of C57BL/6 mice
received weekly intraperitoneal injections of Compound Z at doses of 3.1 mg/kg, 6.3 mg/kg, or
12.5 mg/kg for a period of 6 weeks. A group of C5 7BL/6 mice received weekly intraperitoneal
ions ofPBS for a period of 6 weeks. The PBS group served as a control to which the
oligonucleotide-treated groups and the ApoCIII knockout mice were compared.
Two days after the final dose, the mice were sacrificed and organs harvested. Similar
groups of mice fed a normal murine chow were also tested.
Liver triglycerides
Liver triglycerides were with an Olympus clinical analyzer (Hitachi Olympus AU400e,
Melville, NY). The data is presented in Table 14 and demonstrates that mice treated with an
ApoCIII antisense oligonucleotide have a different phenotype than ApoCIII knockout mice. The
high dose ApoCIII antisense oligonucleotide treated mice had liver triglyceride levels similar to
that of the PBS control. Liver triglyceride levels in the ApoCIII knockout mice were significantly
higher than in C57BL/6 mice treated with an ApoCIII antisense oligonucleotide or the PBS
control. Therefore, antisense inhibition of ApoCIII had the ial effect of lowering the risk
of liver sis compared to the ApoCIII knockout mouse model.
Table 14
Liver triglyceride levels (mg/ liver tissue)
Hi h-
ams) mist
PBS - 33
3.1 44
Compound Z 6.3 47
12.5 33
I KO - 60
Example 6: Effect of in vivo antisense inhibition of ApoCIII in C57BL/6 mice
The effect of antisense inhibition of ApoCIII on plasma lipid levels and fat clearance was
evaluated.
Treatment
Male C57/BL6 mice were maintained on a 12-hour light/dark cycle and fed ad libilum a
western diet (Harland Tekland 88137). Animals were acclimated for at least 7 days in the
research ty before initiation of the experiment. Antisense ucleotides (ASOs) were
prepared in PBS and sterilized by filtering through a 0.2 micron filter. Oligonucleotides were
dissolved in 0.9% PBS for injection.
2O Groups of 7-8 mice each received intraperitoneal injections of Compound Z at a dose of
12.5 mg/kg/wk for 6 weeks. Another group of mice ed intraperitoneal injections of l
oligonucleotide ISIS 141923 at a dose of 12.5 mg/kg/wk for 6 weeks. A third group of mice
received intraperitoneal injections ofPBS for 6 weeks. Two days after the final dose, the mice
were fasted for 4 hours, ced and plasma and tissues were collected.
Inhibition oproClll mRNA
Total RNA was extracted from the liver and small intestine and ApoCIII mRNA was
quantitated by RT-PCR using an ApoCIII primer probe set and normalized to cyclophilin. The
results are presented in Table 15, expressed as percent inhibition of ApoCIII mRNA compared to
the PBS control. ISIS 141923 did not cause any reduction in ApoCIII mRNA levels, as expected.
The data demonstrated the significant tion of ApoCIII mRNA in the liver and small
intestine by Compound Z compared to the PBS l.
Inhibition of intestinal ApoCIII expression could be important in the prevention of
chylomicronemia (Chait et al., 1992, Adv Intern Med. 1992, -73), a dyslipidemic state
caused by improper clearance of chylomicron triglyceride. Severe forms of chylomicronemia can
lead to atitis, a life-threatening condition. By inhibiting intestinal ApoCIII, inhibition of
lipoprotein lipase would be reduced, and icron ceride clearance would be enhanced,
thereby ting pancreatitis. In addition, inhibition of intestinal ApoCIII would enhance
clearance of postprandial triglyceride, thereby lowering post prandial TG a known risk factor for
ry heart disease.
Table 15
Percent inhibition of ApoCIII mR\IA relative to the PBS control
inhibition
Liver 74
Small Intestine 13
Cholesterol and triglyceride levels
2O Plasma cholesterol were extracted by the method of Bligh and Dyer , E.G. and
Dyer, WJ. Can. J. Biochem. Physiol. 37: 911-917, 1959) and measured with an Olympus clinical
analyzer (Hitachi Olympus AU400e, Melville, NY). HDL and non-HDL cholesterol were
dually measured by HPLC. Triglyceride levels were measured with the use of a
commercially available triglyceride kit (DCL ceride Reagent; Diagnostic als Ltd.,
Charlottetown, Canada). The s are presented in Table 16 and are expressed in mg/dL.
Treatment with Compound Z resulted in significant reduction of total cholesterol, non-HDL
cholesterol and plasma triglyceride levels compared to the PBS control. A decrease in total
cholesterol, non-HDL cholesterol and TG levels is a cardiovascular beneficial effect of antisense
inhibition of ApoCIII and can be beneficial to animals with, or at risk of, dyslipidemic diseases.
Table 16
Plasma cholesterol and triglyceride levels (mg/dL) in 6 mice
Dose Total HDL LDL VLDL
Trea ment t Tri 1 cerides
(mg/kg/wk) terol cholesterol cholesterol cholesterol g y
PBS - 93 7O 20 2.9 84
ISIS 141923 12.5 97 78 19 2.1 82
Compound Z 12.5 95 75 17 3.1 70
Fat clearance
Plasma s were collected at 30 min, 1 hr, 2 hrs, 3 hrs, and 4 hrs post-injection and
plasma total lipid content was measured with an Olympus clinical analyzer (Hitachi Olympus
AU400e, Melville, NY). The lipid level in the plasma, as presented in Table 17 was an inverse
indicator of lipid clearance from the . The results indicate that treatment with Compound Z
lead to enhanced rate of fat nce from the plasma.
Therefore, the data indicates that inhibition of ApoCIII in these transgenic mice improves
reverse cholesterol transport and, would have a beneficial effect on patients with cardiovascular
disease.
Table 17
Effect of nse oligonucleotide ent on plasma lipid (mg/dL) in C57BL/6 mice
Area under the
0 hr 0.5 hr 1 hr 2 hr 3 hr 4 hr curve
PBS mm- -m—
ISIS 141923 115 142 124 236 225 150 43677
Compoundz 15-“ 156 101 28371
Example 7: Effect of in vivo antisense inhibition of ApoCIII in C57BL/6 mice
The effect of antisense inhibition of ApoCIII on ApoCIII sion levels and fat
clearance was evaluated.
Treatment
Male C57/BL6 mice were maintained on a 12-hour light/dark cycle and fed ad libilum a
western diet (Harland Tekland 88137). Animals were acclimated for at least 7 days in the
research facility before initiation of the experiment. Antisense oligonucleotides (ASOs) were
prepared in PBS and sterilized by filtering through a 0.2 micron filter. ucleotides were
dissolved in 0.9% PBS for injection.
Groups of 5 mice each received intraperitoneal injections of an I targeting
antisense oligonucleotide, Compound Z, at a dose of 12.5 mg/kg/wk for 6 weeks. Another group
of mice received intraperitoneal injections of control oligonucleotide ISIS 141923 at a dose of
12.5 mg/kg/wk for 6 weeks. Two days after the final dose, the mice were fasted overnight, and a
bolus of 200 uL of olive oil was administered by oral gavage. Following the bolus, plasma
triglyceride levels were measured at regular als for 4 hours. The mice were sacrificed and
plasma and tissues were collected.
Inhibition oproCIH mRNA
Total RNA was extracted from the liver and small intestine and ApoCIII mRNA was
quantitated by RT-PCR using an ApoCIII primer probe set and normalized to cyclophilin. The
results are presented in Table 18, sed as percent inhibition of I mRNA compared to
the oligonucleotide control. The data demonstrated the significant tion of ApoCIII mRNA
in the liver and small intestine by Compound Z compared to the olionucleotide control.
As noted elsewhere herein, inhibition of intestinal ApoCIII expression could be important
in the tion of chylomicronemia (Chait et al., 1992, Adv Intern Med. 1992, 37:249-73), a
idemic state caused by improper clearance of chylomicron triglyceride. Severe forms of
2O icronemia can lead to pancreatitis, a life-threatening condition. By inhibiting intestinal
ApoCIII, inhibition of lipoprotein lipase would be reduced, and chylomicron triglyceride
clearance would be enhanced, thereby ting pancreatitis. In addition, inhibition of intestinal
ApoCIII would enhance clearance of postprandial triglyceride, thereby lowering post prandial TG
a known risk factor for coronary heart disease.
Table 18
Percent inhibition of ApoCIII mRNA relative to the control oligonucleotide treated C57/BL/6
mice
Strain of mice
inhibition
Liver 74
C57BL 6/
Small Intestine 6O
Fat clearance
Plasma samples were ted at 0 min, 30 min, 60 min, 120 min, 180 min, and 240 min
post-injection and plasma triglyceride concentrations was measured with an Olympus clinical
analyzer (Hitachi Olympus AU400e, Melville, NY). The results te that treatment with
Compound Z lead to enhanced rate of triglyceride clearance from the plasma.
This study can be compared to fat bolus clinical studies in which patients sing high
apo-CIII levels showed increased postprandial TG trations sen KF. et al., N Engl J
Med 2010; 362: 1082-1089).
Table 19
Effect of antisense oligonucleotide treatment on postprandial plasma TG (mg/dL) in C57BL/6
mice
—---120 18-0 210
mm mm mm
1923 115 142 124 236 225 150
C57BL/6
Compoundz n-n 156 101
Example 8: Effect of in vivo antisense tion of ApoCIII in C57BL/6 mice
The effect of antisense inhibition of ApoCIII on fat clearance was evaluated.
Treatment
Male C57/BL6 mice were maintained on a 12-hour light/dark cycle and fed ad libilum a
western diet (Harland Tekland 88137). Animals were acclimated for at least 7 days in the
research facility before initiation of the experiment. Antisense oligonucleotides (ASOs) were
2O prepared in PBS and sterilized by filtering through a 0.2 micron filter. Oligonucleotides were
dissolved in 0.9% PBS for injection.
Groups of 6 mice each received intraperitoneal injections of an I targeting
antisense oligonucleotide, Compound Y or nd Z, at a dose of 12.5 wk, 6.3
mg/kg/week or 3.1 mg/kg/week for 6 weeks. Another group of mice received intraperitoneal
injections of control oligonucleotide ISIS 141923 at a dose of 12.5 mg/kg/wk for 6 weeks.
r group of mice received intraperitoneal injections ofPBS for 6 weeks. Two days after the
final dose, the mice were fasted overnight, and a bolus of 200 11L of olive oil was administered by
oral gavage. Following the bolus, plasma triglyceride levels were measured at regular intervals
for 4 hours.
Fat clearance
Plasma samples were collected at 0 min, 30 min, 60 min, 120 min, 180 min, and 240 min
post-injection and plasma triglyceride concentrations were measured with an Olympus clinical
analyzer (Hitachi Olympus , Melville, NY). The results te that treatment with
Compound Y and Compound Z lead to enhanced rate of fat clearance from the plasma. N.d.
indicates that the data set was not calculated.
This study can be compared to fat bolus clinical studies in which patients sing high
apo-CIII levels showed increased postprandial TG concentrations (Petersen KF. et al., N Engl J
Med 2010; 362: 1082-1089)
Table 20
Effect of antisense oligonucleotide treatment on postprandial plasma TG (mg/dL) in C57BL/6
m1ce
Dose 240
0 mm.
60 120 180
(mg/kg/wk) min min min min min
PBS - 79 104 118 126 113 116
ISIS 141923 12.5 75 100 116 150 138 133
12.5 79 74 103 117 120 96
Compound Y 6.3 64 70 81 94 120 112
3.1 91 85 106 139 164 133
12.5 73 65 84 118 94 76
Compound Z 6.3 70 73 89 117 120 89
3.1 86 98 143 137 152 128
Example 9: Effect of ISIS antisense ucleotides targeting human I in monkey
model of hypertriglyceridemia
Rhesus monkeys maintained on a high fructose diet were treated with ISIS 304801.
Antisense oligonucleotide cy and tolerability, as well as the cological effect were
evaluated.
Treatment
The monkeys were 2-4 years old and weighed between 2 and 5 kg. The monkeys were
assigned to six groups of five randomly assigned male rhesus monkeys each. About 60g of diet
fied Primate Diet #5048, PMI Nutrition International, Inc.) was provided to each monkey in
Groups 1-4 twice daily. An appropriate fructose supplement (i.e. approximately 15% Kool Aid®
mixture) was supplied in the morning for 16 weeks prior to antisense oligonucleotide dosing. To
confirm sufficient ceride level elevations, blood samples for serum try were collected
from all animals 1-2 weeks prior to dosing.
The groups of monkeys were injected subcutaneously with ISIS ucleotide or PBS
using a stainless steel dosing needle and syringe of appropriate size into one of 4 sites on the back
of the monkeys; each site being used per dose in a clock-wise manner. Some of the groups were
dosed three times a week for the first week (Days 1, 3, and 5) as loading doses, and subsequently
twice a week for weeks 2-12, with 5 mg/kg, 10 mg/kg, or 20 mg/kg of ISIS 304801. Two control
groups of 5 rhesus monkeys each were injected with PBS subcutaneously three times a week for
the first week (Days 1, 3, and 5), and subsequently twice a week for weeks 2-12. The dosing
chart is shown in Table 21. Monkeys of Groups 1-4 were sacrificed on Day 86.
An additional high fat challenge was administered to monkeys of Groups 5 and 6 in the
form of a whipping cream milk shake. The milk shake was standardized to consist of 782 calories
per m2 of body surface with 77.6% of calories from fat, 19.2% from carbohydrate, and 3.1% from
protein. Monkeys of Groups 5 and 6 were fasted ght and the milk shake was administered
once on day 84 via a gastric tube. Blood was drawn just prior to (time = 0 hours) and 1, 2, 3, 4,
and 6 hours after ingestion of the fat load to assess the triglyceride excursion. The s were
rested and remained otherwise g during the 6 hours post-fat challenge. Monkeys of this
group were sacrificed on Day 87.
Table 21
Groups of rhesus monkeys on a high fructose diet
Weekly Dose
N0. of
Group Test Article (mg/kg/week
Animals
Toxicology groups
1 —-_
2 Male
High Fat Challenge Tesl
groups
—-_ 5
Hepatic Target Reduction
RNA analysis
Approximately 150 mg of liver was collected from Groups 1-4 for ApoCIII mRNA
analysis at sacrifice. The liver was divided into 2 pieces and soaked in two tubes containing RLT
buffer with 1% beta-mercaptoethanol. The tissues were homogenized and ApoCIII expression
was fied by RT-PCR analysis. As shown in Table 22, treatment with ISIS 304801 resulted
in significant reduction of ApoCIII mRNA in comparison to the PBS control. The
Table 22
Percent Inhibition of ApoCIII mRNA in the rhesus monkey liver relative to the PBS control
Groups Dose % inhibition
(mg/kg/week)
2 10 68
3 2O 78
4 40 83
Protein analysis
Approximately 1.5 mL of blood was collected from all study animals in Groups 1-4 and
placed in tubes containing Kz-EDTA and then centrifuged for plasma separation. I protein
levels were fied on a clinical er using a commercially ble turbidometric assay
(Kamiya Biomedical Co., Seattle, WA). As shown in Table 23, treatment with ISIS 304801
resulted in significant reduction of ApoCIII protein levels in comparison to the PBS control. The
kinetics of ApoCIII protein level reduction was also analyzed and is presented in Table 24..
Table 23
Percent Inhibition of I plasma protein levels in the rhesus monkey relative to the PBS
control
Groups Dose % inhibition
(mg/kg/week)
2 10 74
3 2O 72
4 4O 89
Table 24
ApoCIII plasma protein levels (mg/dL) on different days in the rhesus monkey relative to the
PBS control
Dose Da
Grows Day '7
Da30y Da86y
(mg/kg/wk) 16y
1 — 4.0 5.5 3.8 5.7
2 10 4.8 3.2 0.2 1.5
3 20 4.5 3.8 0.9 1.6
4 40 5.2 2.9 0.0 0.6
Lipoprotein particle analysis
To establish the cs of plasma ApoCIII suppression, plasma samples were collected 7
days before the commencement of dosing, as well as on days 16, 30 and 86 of the dosing period.
The samples were subjected to N1\/[R1ipoprotein particle analysis (Liposcience, h, NC).
Since there were no significant differences in ApoCIII lowering between the ent groups
(Groups 2-4), the analyses is ted only of Group 2 (treatment group receiving 10
mg/kg/week). The data is presented in Tables 25 and 26.
tically significant mean changes from the baseline were observed in total plasma
triglycerides (TG) and in VLDL and chylomicron TG of the treatment group at day 30. At the
same time, the control monkeys demonstrated mean increases in the same parameters. Sustained
treatment with ISIS 304801 in these fructose-fed monkeys led to time-dependent increases in
HDL terol particle numbers by approximately 8 umol/L (Tables 27) and did not produce
elevations in LDL cholesterol in these studies (Table 28). There were no significant changes in
LDL cholesterol particle quantity over the 12 week treatment period, ve to the PBS l
group.
2O At the time of sacrifice, livers were extracted using the Bligh and Dyer extraction method
(Bligh EG and Dyer WI. Can J Biochem Physio1 1959; 37: 91 1-917) and quantified using a
Wako co1orimentric TG assay. Antisense inhibition of I did not increase hepatic TG
accumulation in any of the treatment groups relative to the PBS control group (Table 29).
Table 25
Change from baseline plasma TGmg/dL) on different days in the rhesus monkey
Dose Day Day Day
Day '7
(mg/kg/wk) 16 30 86
PBS - O 18 23 27
ISIS 10 0 —22 —32 —27
3 04801
Table 26
Change from baseline VLDL and icron TG (mg/dL) on ent days in the rhesus
monkey
Dose Day Day Day
Day '7
(mg/kg/wk) 16 30 86
PBS - 0 17 22 28
ISIS
0 -22 -31 -26
304801
Table 27
Change from ne HDL cholesterol particles (umol/L) on different days in the rhesus monkey
Dose Day Day Day
Day '7
(mg/kg/wk) 16 30 86
PBS - 0.3 -5.6 -3.5 -8.1
ISIS
0.0 0.5 9.7 8.0
304801
Table 28
Total LDL cholesterol particles (nmol/L) on different days in the rhesus monkey
Dose Day Day Day
Day '7
(mg/kg/wk) 16 30 86
PBS - 982 928 1005 1184
ISIS
1007 938 781 910
304801
Table 29
Hepatic triglyceride content in PBS control and ISIS 304801 cohorts after 12 weeks in HTG
rhesus monkeys
Liver TG
(ug/mg) Average
PBS 9
10mg/kg/wk 16
g/wk 18
40mg/kg/wk 6
Post-prandialplasma TG clearance
At 10 weeks, the post-prandial plasma TG levels in monkeys from the 10 mg/kg/week
group (Group 2) were measured at 0 hr, 1 hr, 2 hr, 3 hr, and 4 hr after providing a meal to the
monkeys. As shown in Tables 30 and 31, post-prandial plasma TG clearance was significantly
WO 49495
increased, as shown by the 38% decrease in post-prandial TG area under the curve (AUC) in
monkeys of the 10 mg/kg/week group.
randial TG clearance was also assessed in Groups 5 and 6 (the PBS control and 40
mg/kg/week group after a fat challenge) at 12 weeks. The data is presented in Table 32, and also
tes a significant decrease in post-prandial TG area under the curve (AUC) in monkeys of
that group ed to the control.
Table 30
Plasma TG (mg/dL) in the rhesus monkey
Dose
0 hr 1 hr 2 hr 3 hr 4 hr
(mg/kg/wk)
PBS - 167 169 146 147 131
ISIS
105 87 95 102 80
304801
Table 31
Post-prandial TG area under the curve (AUC) in the rhesus monkey
PBS 610
ISIS 304801 376
Table 32
Post-prandial TG area under the curve (AUC) in the rhesus monkey after fat nge
PBS 613
ISIS 304801 405
Monkeys in the 10 mg/kg/wk group had lower fasting plasma TG levels than the PBS
group at 10 weeks. Results in non-human primates demonstrate that antisense inhibition of
ApoCIII represent an attractive therapeutic strategy for reducing plasma TG and VLDL in
dyslipidemic individuals, and treatment can concurrently raise HDL-C levels with no adverse
effects on LDL-C.
Example 10: ISIS 304801 Phase I Clinical Trial
In a double-blind, single and multiple ascending-dose (SAD and MAD) Phase 1 study,
healthy subjects, aged 18 to 55 years, were randomly assigned in a 3 :1 ratio to e ISIS
304801 or placebo (normal saline).
SAD subjects were administered a single subcutaneous (SC) injection of 50, 100, 200, or
400 mg (n=4/cohort) at the Study Center. The subjects returned to the Study Center for an
outpatient visit on Days 4 and 8 (:24 hour ) for blood sampling and for clinical
evaluation. The subjects were followed until Day 15 when they were evaluated by a telephone
interview.
MAD subjects were administered multiple SC injections at 50, 100, 200, and 400 mg at
the Study Center. The subjects received a loading regimen of 3 doses the first week (Days 1, 3
and 5) followed by once weekly dosing for 3 weeks (Days 8, 15 and 22). The ts were
followed for 8 weeks after their last dose of study drug. The subjects returned to the Study Center
for an outpatient visit on Days 29, 36 and 50 (:24 hour window) for safety and clinical tory
evaluations and for blood sampling for PK analysis. The subjects were followed until Day 78 (:7
day window) when they were evaluated by a telephone interview.
The MAD subjects stayed at the Study Center from days -1 to 6 and days 22 to 23, where
they were provided the diet shown in Table 33. The subjects fasted for at least 12 hours before
blood s were taken for evaluation at Days 5, 8, 15, 22, 23, 29, 36, 43 and 50 (:24 hour
window).
Table 33
Study Center Patient Diet
Serving
Study Day Food Description
Portion
525 m1. 0 Thai noodles with Beef & mixed vegetable, li, bean sprout, green & red peppers
375 m1. 0 Fresh fruit salad
Day '1 300 m1. 0 Orange juice
[Admit]
1 0 Horse shoe cake
250 ml. 0 2% Milk
1 0 Butter croissant
2 0 Eggs, led
250 m1. 0 Sliced peaches with syrup
300 m1. 0 Orange juice
Day 1 75 g. o Grilled Chicken Breast [Sandwich] on Kaiser bun
1.5 cup 0 Cream of Mushroom Soup
1-pkg. o Crackers
Small 0 Salad
011 side 0 Condiments
355 ml. 0 Ginger Ale
WO 49495
75 g. 0 Roast Beef
250 ml. 0 Mashed Potatoes
375 ml. 0 Mixed Vegetables
On side 0 Gravy
011 side 0 Garlic bread
300 “IL 0 Apple juice
1 0 Carrot muffin
250 ml. o 2% Milk
3 o Pancakes
On side 0 Syrup
1 0 Banana
300 ml. 0 Orange juice
9” o Mesquite Chicken, Chicken, bacon, cheddar, tomato, red omon, & lettuce on whole
wheat bread
On side 0 Ranch dressing
Cup 0 Broccoli & cheese soup
Day 2 l-pkg. o Crackers
355 ml. 0 Ginger ale
375 g. 0 Beef Stir-fry & mixed vegetables, broccoli, carrots, celery, & onions
150 g. o Steamed rice
l-pkg. o Raisin
300 ml. 0 Apple juice
250 ml. 0 Fresh fruit salad
300 ml. 0 Cranberry juice
Med. 0 Cheese & vegetable omelet on whole wheat bagel toasted
300 ml. 0 Grape juice
9” 0 Black Angus Steak, mozzarella, cheddar, d onion & mushrooms on Cheese bread
On side 0 Honey Bourbon Mustard, Zesty Grille Sauce
Cup 0 Chicken noodle soup
l-pkg. o Crackers
355 ml. 0 Ginger ale
Day 3
400 g. 0 BBQ Chicken Breast, Vegetables, cooked mixed, cauliflower, s, red & green
peppers, green beans
1.5 cups 0 Flavored rice
l-pkg. o Grapes
300 ml. 0 Apple juice
1 o Raisin Oatmeal cookie
250 ml. 0 2% milk
1 0 Cheese Croissant
250 ml. 0 Sliced Peaches in syrup
300 ml. 0 Orange juice
Day 4 2 o Flatbread Sammie, with Chicken, bacon, r, tomato & romaine lettuce
On side 0 Buttermilk ranch dressing
Cup 0 li & Cheese soup
l-pkg. o Crackers
355 ml. 0 Ginger ale
425 g. 0 Beef Stew, tender Beef cubes, with carrots, omons, & potatoes
325 g. 0 Thai salad, with romaine lettuce, pasta, & dressings
1 0 Italian bread
250 m1. 0 Sliced Pears in syrup
300 1111. 0 Apple juice
1 o Blueberry muffin
250 ml. o 2% Milk
375 ml. 0 Corn Flakes
Med. 0 Banana
250 ml. o 2% Milk
300 1111. 0 Apple juice
6 pcs. 0 n wings
250 ml. 0 Fried rice
250 ml. . Mixed cooked veggies, green beans, carrots, & red peppers with ed tomato sauce
Day 5 355 ml. . 7.1110
6” Pizza 0 Pepperoni lovers Pizza a double helping of deli style pepperoni & 100% Pizza
Mozzarella
Small 0 Salad
355 ml. 0 Ginger Ale
1 o Almond Croissant
250 ml. o 2% Milk
Day 6 45 g. o Bagel with Cream Cheese
[Discharge] 300 ml. . Orange juice
450 g. 0 ast Omelets Spinach & Feta cheese
2 slices 0 Brown toast
300 ml. 0 Orange juice
9” o Zesty Grille Steak Prime Rib Steak, mozzarella, r, mushroom, sauteed onion, on
Cheese bread
On side 0 Honey Bourbon Mustard, Zesty Grille Sauce
Cup 0 Broccoli & Cheese soup
Day 22 l-pkg. o Crackers
355 ml. 0 Ginger Ale
400 g. 0 Herb Grilled n Breast with Vegetables
1.5 cups 0 Flavored rice
Small 0 Fresh fmit salad
300 1111. 0 Apple juice
1 o Raisin Oatmeal cookie
250 ml. o 2% Milk
Day 23 45 g. o Butter croissant
[Discharge] 300 ml. . Orange juice
Results
Overall, ISIS 304801 demonstrated a good safety profile and was well tolerated in all
subjects with no clinically meaningful elevations of transaminase enzymes and no significant
adverse events.
2012/035694
The baseline characteristics ofMAD cohorts are shown in Table 34. MAD subjects
showed dose-dependent sustained reductions in total apoC-III and TG levels expressed as a
percentage change from baseline in Tables 35-36.
Table 34
Baseline Characteristics ofMAD Cohorts
Placebo 50 mg 100 mg 200 mg 400 mg
(n=4) (n=3) (n=3) (n=3) (n=3)
Gender (MzF) 3:1 3:0 3:0 3:0 3:0
Age (yrs) 43.0 40.0 40.0 43.0 40.0
BMI (kg/m2) 27.7 24.0 27.3 28.0 27.5
Lipids & Lipoproteins, mg/dL
Apo CIII 6.3 10.4 9.5 11.6 8.7
cerides 97 124 94 195 89
Total Cholesterol 195 157 196 185 181
HDL-C 45 42 46 43 62
Non-HDL-C 136 118 150 149 126
LDL-C 112 93 131 95 102
Per-protocol population. Values presented are the median.
Table 35
Dose-Dependent Prolonged Reduction in Serum ApoCIII:
Median % change in I from Baseline
Study Day Placebo 50 mg 100 mg 200 mg 400 mg
Day5 38.6 33.4 -4.5 -10.8 -42.6
Day8 31.9 17.8 -5.2 -36.0 -78.6
Day 15 0.0 -22.1 -24.0 -54.1 -79.8
Day 22 11.7 -20.9 -21.0 -61.7 -86.4
Day 23 15.8 -15.6 -11.9 -58.7 -79.0
Day 29 -11.0 -l9.7 -17.3 -70.5 -77.5
Day 36 1.9 -26.6 -32.1 -57.3 -69.5
Day 50 16.4 21.9 -3.9 -63.0 -78.6
WO 49495
Table 36
Dose-Dependent Reductions in Triglycerides:
Median % Change in Triglycerides from Baseline
Study Day Placebo 50 mg 100 mg 200 mg 400 mg
Day 5 78.5 50.0 15.9 -15.6 -7.7
Day 8 34.9 17.7 -24.5 -31.8 -38.5
Day 15 21.2 -27.4 -12.8 -50.8 -46.2
Day 22 12.2 -18.3 -9.8 -25.1 -53.8
Day 23 51.8 -4.0 1.1 -41.0 -44.2
Day 29 28.5 -19.5 -25.0 -43.1 -43.8
Day 36 15.4 -33.1 -34.8 -17.9 -36.5
Day 50 33.1 48.8 -23.9 -48.2 -48.1
Median percent change from baseline values in the 50, 100, 200 and 400 mg multiple-
dose groups showed reductions of total apoC-III of 20, 17, 71, and 78% and of TG of 20, 25, 43,
and 44%, respectively, one week (Day 29) after the last dose. ions were sustained for at
least four weeks after the last dose in the higher dose groups.
TG levels spiked at Day 5 and 23 for the placebo group, coinciding with the subjects’
ght stays at the Study Center. It is thought that the diet provided by the Study Center led to
the surge in TG levels in the subjects staying overnight at the Study Center. ISIS 304801
decreased the TG spike in a dose-dependent manner. In a manner, the results shown herein,
indicate a andial effect on TG (although TG levels were assessed after a 12 hour fast) by
ISIS 304801 as a diet induced surge in TG was decreased in a dose-dependent manner by ISIS
304801.
LDL-C values did not change (data not shown) while HDL-C values tended to increase in
a treatment-dependent manner as shown in Table 37.
Table 37
No Deleterious Effects on HDL-C
Study Day Placebo 50 mg 100 mg 200 mg 400 mg
Day 5 -5.9 7.7 -3.1 -3.2 -16.1
Day 8 2.1 2.4 0.0 -11.1 -2.9
Day 15 -2.8 4.8 10.9 4.7 -9.7
Day 22 -0.6 4.8 8.7 11.6 -2.0
Day 23 0.7 7.1 12.5 19.4 -1.6
Day 29 2.1 19.0 0.0 13.9 8.0
Day 36 0.0 23.8 8.8 13.9 1.6
Day 50 -4.8 16.7 5.9 25.0 14.5
Example 11: ISIS 304801 Phase II Clinical Trial
A ized, -blind, placebo-controlled, dose response study is planned
to evaluate the dose/response pharmacodynamic effects of ISIS 304801 vs. placebo on fasting
apoC-III associated with VLDL levels. Additional endpoints to evaluate include:
the pharmacodynamic effects of ISIS 304801 vs. o on fasting total apoC-III, TG, apoC-II
(total and associated with VLDL), apolipoprotein B-lOO (apoB-IOO), apolipoprotein A-1 (apoA-
1), apolipoprotein A-2 (apoA-2), apolipoprotein E (apoE), total cholesterol (TC), low-density
lipoprotein-cholesterol (LDL-C), LDL-TG, VLDL-C, G, non-high-density otein-
cholesterol (non-HDL-C), non-HDL-TG, HDL-C, HDL-TG, chylomicron-C (CM-C), CM-TG,
free fatty acids (FFA), and ol levels; the randial lipid, apolipoprotein and lipoprotein
characteristics and kinetics, and glucose levels in a subset of the patients in the study and assess
more extensive PK in another subset of the patients (will not be the same patients as those
undergoing the post-prandial assessment); and, the , tolerability and PK of ISIS 304801.
For each patient, the participation period consists of a 35-week screening period, (which
includes a 4-week tight diet control run-in qualification period), a 1-week study
qualification/baseline assessment period, a 13-week treatment period, and a post-treatment
evaluation period of 13 weeks, for a total of 32 weeks of study participation. Concomitant
tions and adverse events (AEs) will be recorded throughout all periods of the study.
Patients will be at least 18 years of age and have fasting TG ZSOOmg/dL at screening and
fasting TG Z300mg/dL and £2000mg/dL after 4-weeks of tight diet control run-in.
Seventy two (72) ts are planned for this study. There will be 24 patients planned per
dose cohort (100, 200, 300 mg) with 18 ISIS 304801 e) and 6 placebo patients per cohort.
Eligible patients will be enrolled equally (1:1) into a non-extensive -prandial group
(Group 1) or an extensive PIonst-prandial group (Group 2). Patients in Group 2 will be
randomized equally (1:1) to an extensive PK group (Group 2a) or a post-prandial assessment
group (Group 2b). Group 2a patients will be randomized equally (1 : 1 : 1) to 1 of the 3 dose cohorts
(100, 200, 300 mg) and, within each dose cohort, 5:1 to receive active or placebo. Group 2b
ts will be ized equally (1:1) to 1 of 2 dose cohorts (200, 300 mg) and, within each
dose cohort, 2:1 to receive active or placebo. Group 1 patients will be randomized to dose cohort
and treatment in a manner that achieves an overall study randomization of 1 : 1 :1 to dose cohort
(100, 200, 300 mg) and 3:1 to treatment (active, placebo).
Patients will be placed on a tightly controlled diet (after screening procedures are
performed) for the duration of study participation. After 28 days on the controlled diet, patients
will have baseline measurements and be ed for qualification of enrollment into the
treatment phase of the study. Patients who meet the enrollment criteria following diet run-in will
be ed equally (1:1) into a non-extensive PIonst-prandial group (Group 1) or into an
extensive PIonst-prandial group (Group 2) and ized within their Group assignment.
Study Drug and Treatment
A solution of ISIS 304801 (200 mg/mL, 1.0 mL) contained in 2-mL stoppered glass vials
will be provided.
The o for this study will be 0.9% sterile saline.
ISIS 304801 solution and placebo will be prepared by an unblinded pharmacist (or qualified
delegate). Vials are for single-use only. A trained professional, d to the identity of the drug,
will administer the Study Drug. The Study Drug will be administered as a SC injection in the
abdomen, thigh, or outer area of the upper arm on each dosing day. Doses of 100 and 200 mg will
be administered as a single SC injection. Doses of 300 mg will be administered as two equal
volume noncontiguous SC injections.
Patients will e 13 doses of Study Drug stered by SC injection once a week
for 13 weeks (Days 1, 8, 15, 22, 29, 36,43, 50, 57, 64, 71, 78, and 85).
Patients will complete the treatment visits on Day 1 :: 0 days and on Day 8, 15, 22, 29, 36,
43, 50, 57, 64, 71, 78, and 85 within :: 1 day. Patients in the extensive PK group will also visit the
clinic on Day 2 and 86 :: 0 days relative to Day 1 and 85, respectively, for the 24 hour blood
draw. Patients will complete the follow-up visits on Day 92 and 99 within :: 1 day, Day 127
within :: 3 days, and Day 176 within :: 5 days of the scheduled visit date. Patients in the post-
prandial assessment group will also visit the clinic on Day 103 within :: 2 days and on the day
following the Day 103 visit for the 24 hour blood draw.
Preceding each visit that includes a blood draw for pharmacodynamic measurements
(Days 8, 15, 29, 43, 57, 71, and 85), patients will be provided a rdized pre-cooked meal for
the dinner on the evening prior to their visit (to ensure equal moderation of fat intake, per patient
and per time point) after which they will remain fasted. l consumption will not be allowed
for 48 hrs preceding these clinic visits.
Blood will be collected for measurement of VLDL apoC-III and other codynamic
markers on Days 8, 15, 29, 43, 57, 71, and 85 (prior to Study Drug stration).
Patients in the post-prandial assessment group will e standardized pre cooked
meals (lunches and dinners (provided) and instructions for breakfasts and snacks) for the 2 days
prior to the post-prandial evaluations. On each of the randial evaluation days, following the
2O blood draws, patients will consume a standardized liquid meal, which represents about a third of
the daily caloric requirements, with a stable radioisotope tracer, followed by serial blood
sampling. Patients will receive a standardized oked meal 9 hrs after consuming the liquid
meal, after which they will fast until the 24 hour blood draw the following day.
In addition to trough sample collection, patients in the extensive PK assessment group
will undergo serial blood sampling for 24 hrs after their first (Day 1-2) and last (Day 85-86) dose
of Study Drug.
Post-treatment Evaluation Period
Patients will be followed until Study Day 176. During this time, patients will return to the
study center for outpatient clinic visits on Study Days 92, 99, 127, and 176 (and Day 103 for
patients in the post-prandial assessment group) for safety and clinical laboratory evaluations
(blood draws), diet counseling and monitoring, concomitant medication usage recording, and AE
event collection.
Blood samples for PK and PD analysis will be collected periodically hout the post-
treatment evaluation period. Laboratory measurements of serum chemistry, urinalysis,
coagulation, complement, hematology, immune filnction, thyroid function, and filll lipid panel
will be performed at the various times hout the study.
Post-prandial assessments will be done in a subset of ts as described below.
Post-prandial Meal, Sampling Schedule, andAssessment
Post-prandial assessment for lipoproteins metabolism will be performed using a
radiolabelled meal supplemented with a labeled tracer, 3H-palmitate (3 OOuCi, Perkin Elmer Inc.,
Woodbridge, ON, Canada),sonicated into the liquid meal. Palmitate is a fatty acid that is a
common tuent of any diet. The 3H-palmitate tracer emits weak radioactivity, equivalent to
an X-ray. Since dietary palmitate is incorporated into chylomicrons as they are formed in
the enterocytes of the gut, this enables monitoring the appearance and clearance of newly-
formed chylomicrons from circulation. The methodology to be applied for studying post-
prandial kinetics of chylomicrons appearance and clearance is well-established (Mittendorfer et
al. 2003, Diabetes, 52: 1641-1648; Bickerton et al. 2007; Normand-Lauziere et al. 2010, PLoS.
One, 5: ).
A liquid meal (similar to a milkshake) containing a small amount (300uCi)
of radiolabelled fatty acids lmitate) will be provided. The liquid meal will provide about a
third of the daily caloric requirements. From 1 hr prior to 9 hrs after the ingestion of the meal, a
constant infusion of [U-13C]-K palmitate (0.01umol/kg/min in 100 ml 25% human serum
albumin; Cambridge Isotopes Laboratories Inc., Andover, MA) and a primed (1.6 g)
continuous (0.05 g/min) infusion of [1,1,2,3,3-2H]—glycerol idge Isotopes
Laboratories Inc.) will be administered as previously described (Normand-Lauziere et al. 2010,
PLoS. One, 5: ). Plasma palmitate and ol appearance rates will be calculated using
Steele’s non-steady state equation assuming a volume of distribution of 90ml/kg and 23 0ml/kg,
tively (Gastaldelli et al. 1999, J Appl. Physiol, 87: 1813-1822).
Blood samples will be drawn at intervals before and after the ingestion of
the radiolabelled meal on days prior to and after the Treatment phase as noted in the table below.
A standardized meal will be given to the participants after the 9 hr blood draw. Blood will be
collected in tubes containing Na2 EDTA and Orlistat (30 ug/ml, Roche, Mississauga, Canada) to
prevent in vitro triacylglycerol lipolysis and te samples will be collected in NaF tubes for
plasma glucose determination.
The following will be ed at each time-point:
0 Plasma and CM fraction levels for 3H-tracer
0 Plasma [U-l3C]-K palmitate and [1, l, 2, 3, 3-2H]—glycerol appearance rates
0 Plasma and CM fraction levels for TG, TC, and apoB
0 Plasma and VLDL fraction levels for apo CIII, apo C11, and apo E
0 Plasma levels for e
Plasma samples may also be used for profiling of drug binding
proteins, bioanalytical method validation purposes, stability and metabolite assessments, or to
assess other actions of ISIS 304801 with plasma constituents.
Claims (38)
1. Use of a compound targeting ApoCIII in the manufacture of a medicament for a) treating, preventing, delaying or ameliorating pancreatitis; b) increasing HDL levels and/or improving the ratio of TG to HDL in an animal y preventing, delaying or ameliorating a cardiovascular disease, disorder, condition or symptom thereof or onset of a cardiovascular disease, disorder, condition or symptom thereof in an animal; and/or c) increasing HDL levels and/or improving the ratio of TG to HDL in an animal thereby reducing the risk of a cardiovascular disease, disorder, condition or symptom in an animal; and/or d) treating, preventing, delaying or ameliorating icronemia, wherein the compound is capable of inhibiting apolipoprotein C-III.
2. The use of claim 1, wherein the animal has, or is at risk for, riglyceridemia.
3. The use of claim 2, wherein the animal has a triglyceride level between 100-200 mg/dL, 100-300 mg/dL, 100-400 mg/dL, 100-500 mg/dL, 200-500 mg/dL, 300-500 mg/dL, 400-500 mg/dL, 500-1000 mg/dL, 600-1000 mg/dL, 00 mg/dL, 800-1000 mg/dL, 900- 1000 mg/dL, 500-1500 mg/dL, 1000-1500 mg/dL, 100-2000 mg/dL, 150-2000 mg/dL, 200- 2000 mg/dL, 300-2000 mg/dL, 00 mg/dL, 500-2000 mg/dL, 600-2000 mg/dL, 700- 2000 mg/dL, 800-2000 mg/dL, 900-2000 mg/dL, 1000-2000 mg/dL, 1100-2000 mg/dL, 000 mg/dL, 1300-2000 mg/dL, 1400-2000 mg/dL, or 1500-2000 mg/dL.
4. The use of claim 2, wherein the hypertriglyceridemia is ckson Type II, IV or V.
5. The use of any preceding claim, wherein the animal has a genetic defect g to hypertriglyceridemia, wherein the genetic defect is a heterozygous LPL deficiency or an I polymorphism.
6. The use of any preceding claim, wherein the animal has a triglyceride level ≥ 500 mg/dL and/or a heterozygous LPL deficiency.
7. The use of any preceding claim, wherein ApoCIII has a nucleic acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2.
8. The use of any preceding claim, wherein the compound ing ApoCIII comprises a modified oligonucleotide.
9. The use of claim 8, wherein the nucleobase sequence of the modified oligonucleotide is 80%, 90% or 100% complementary to a base sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
10. The use of claim 8 or claim 9, wherein the modified oligonucleotide consists of a single-stranded modified oligonucleotide.
11. The use of any one of claims 8-10, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides.
12. The use of claim 11, wherein the modified oligonucleotide ts of 20 linked nucleosides.
13. The use of any one of claims 8-12, wherein at least one internucleoside linkage of the modified ucleotide is a modified internucleoside linkage, wherein at least one nucleoside of the modified oligonucleotide comprises a modified sugar and/or wherein at least one nucleoside of the modified oligonucleotide comprises a modified nucleobase.
14. The use of claim 13, n each modified internucleoside linkage of the modified oligonucleotide is a phosphorothioate internucleoside linkage.
15. The use of claim 13, wherein at least one ed sugar is a bicyclic sugar.
16. The use of claim 13, n at least one modified sugar comprises a 2’-O- methyoxyethyl.
17. The use of claim 13, wherein the modified nucleobase is a 5-methylcytosine.
18. The use of claim 8, n the modified oligonucleotide comprises: (a) a gap segment ting of linked deoxynucleosides; (b) a 5’ wing segment consisting of linked nucleosides; (c) a 3’ wing segment ting linked nucleosides; wherein the gap segment is positioned immediately adjacent to and between the 5’ wing segment and the 3’ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.
19. The use of claim 8, wherein the modified oligonucleotide comprises: (a) a gap segment consisting of 8-12 linked deoxynucleosides; (b) a 5’ wing segment consisting of 1-5 linked nucleosides; (c) a 3’ wing segment consisting 1-5 linked nucleosides; wherein the gap segment is positioned immediately adjacent to and n the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a 2’-O-methyoxyethyl sugar, wherein each cytosine is a 5’-methylcytosine, and wherein each internucleoside linkage is a phosphorothioate linkage.
20. The use of claim 8, wherein the modified oligonucleotide comprises: (a) a gap segment consisting of 10 linked deoxynucleosides; (b) a 5’ wing segment consisting of 5 linked nucleosides; (c) a 3’ wing segment consisting 5 linked nucleosides; wherein the gap segment is positioned immediately adjacent to and between the 5’ wing segment and the 3’ wing segment and n each nucleoside of each wing t comprises a ethyoxyethyl sugar, wherein each cytosine is a hylcytosine, and wherein each internucleoside linkage is a phosphorothioate linkage.
21. The use of any preceding claim, wherein the animal has ms that may be any one of angina; chest pain; shortness of ; palpitations; weakness; dizziness; nausea; sweating; tachycardia; bradycardia; arrhythmia; atrial fibrillation; swelling in the lower extremities; cyanosis; fatigue; fainting; numbness of the face; numbness of the limbs; claudication or cramping of muscles; ng of the abdomen; or fever.
22. Use of a modified oligonucleotide targeting ApoCIII, wherein the modified ucleotide comprises: (a) a gap segment consisting of 10 linked deoxynucleosides; (b) a 5’ wing segment consisting of 5 linked nucleosides; (c) a 3’ wing segment consisting 5 linked sides; wherein the gap segment is positioned immediately adjacent to and between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a 2’-O-methyoxyethyl sugar, wherein each cytosine is a 5’- methylcytosine, and wherein each internucleoside linkage is a phosphorothioate linkage; and n the modified oligonucleotide is capable of inhibiting the expression of apolipoprotein C-III; in the manufacture of a medicament for: (1) treating, preventing, delaying or ameliorating atitis (2) increasing HDL levels and/or improving the ratio of TG to HDL in an animal y preventing, delaying or ameliorating a cardiovascular disease, er, condition or symptom thereof or onset of a cardiovascular disease, disorder, ion or symptom thereof in an animal; (3) increasing HDL levels and/or improving the ratio of TG to HDL in an animal y reducing the risk of a cardiovascular disease, disorder, condition or symptom in an animal; and/or (4) treating, preventing, delaying or ameliorating chylomicronemia in an animal.
23. The use of any preceding claim, n the animal is human.
24. The use of any ing claim, wherein the cardiovascular disease is aneurysm, angina, arrhythmia, atherosclerosis, cerebrovascular disease, coronary heart e, hypertension, dyslipidemia, hyperlipidemia, hypertriglyceridemia or hypercholesterolemia.
25. The use of claim 24, wherein the dyslipidemia is chylomicronemia.
26. The use of any preceding claim, wherein the animal is at risk for pancreatitis.
27. The use of any preceding claim, wherein reducing ApoCIII levels a) prevents, treats or ameliorates pancreatitis; b) enhances clearance of postprandial cerides; and/or c) lowers andial triglycerides.
28. The use of any preceding claim, wherein the medicament is formulated for parenteral administration.
29. The use of claim 28, wherein the parenteral administration is subcutaneous administration.
30. The use of any preceding claim, wherein the medicament is formulated for use in combination with a second agent.
31. The use of claim 30, wherein the second agent is selected from an ApoCIII lowering agent, cholesterol lowering agent, non-HDL lipid lowering agent, LDL lowering agent, TG ng agent, cholesterol lowering agent, HDL g agent, fish oil, niacin, fibrate, statin, DCCR (salt of diazoxide), glucose-lowering agent or anti-diabetic agents.
32. The use of claim 30, wherein the animal fails to respond to a maximally tolerated dose of the second agent.
33. The use of claim 30, wherein the second agent is formulated for stration concomitantly or sequentially with the compound.
34. The use of any preceding claim, wherein the compound is a salt form.
35. The use of any preceding claim, wherein the medicament is formulated with a pharmaceutically acceptable carrier or diluent.
36. The use of any ing claim, wherein the compound is a conjugated compound.
37. The compound of claim 36, wherein the compound is conjugated with a carbohydrate conjugate group.
38. Use of a compound or use of a modified oligonucleotide according to any one of the preceding claims, substantially as herein sed with reference to any one or more of the examples, excluding comparative examples.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ710192A NZ710192A (en) | 2011-04-27 | 2012-04-27 | Modulation of apolipoprotein ciii (apociii) expression |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161479817P | 2011-04-27 | 2011-04-27 | |
US61/479,817 | 2011-04-27 | ||
US201261595009P | 2012-02-03 | 2012-02-03 | |
US61/595,009 | 2012-02-03 | ||
PCT/US2012/035694 WO2012149495A1 (en) | 2011-04-27 | 2012-04-27 | Modulation of apolipoprotein ciii (apociii) expression |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ616779A NZ616779A (en) | 2015-08-28 |
NZ616779B2 true NZ616779B2 (en) | 2015-12-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017200025B2 (en) | Modulation of apolipoprotein ciii (apociii) expression | |
AU2018211325B2 (en) | Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations | |
US9909124B2 (en) | Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile | |
US20200095581A1 (en) | Modulation of apolipoprotein c-iii (apociii) expression in lipodystrophy populations | |
NZ616779B2 (en) | Modulation of apolipoprotein ciii (apociii) expression |